<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <title>Parkinson's Guide</title>
<meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=3">



<style>
html {
    background-color: light-dark(#710, #F30);
    margin: 0;
    padding: 0;
    font-size: 0;
    height: 100%;
    width: 100%;
    overflow-x: hidden;
}

body {
    background-color: light-dark(#EEEEEED3, #222222cc);
	color: light-dark(#111111cc, #CCCE);

    font-family: georgia, "Open Sans", Helvetica;
    position: relative;
    font-size: calc(10px + 1.5vi);
    margin: 0;
    padding-left: 5vi;
    border-style: solid;
    border-width: 1px;
    border-color: light-dark(#DDDDDDcc, #330500cc);
    min-height: 100%;
    overflow-x: hidden;
    position: relative;
}

abbr[title], dfn[title] {
    position: relative;
    text-decoration: underline;
  	text-decoration-style: dotted;
}

abbr[title]::after, dfn[title]::after {
	opacity: 0.0000000001;
    position: absolute;
    bottom: 100%;
    left: 100%;
    padding: .5em .46em .5em .5em;
    background-color: light-dark(#EEE, #555);
    color: light-dark(#444, #EEE);
    font-size: smaller;
    border-radius: .4em;
    transition: opacity 0.3s ease-in;
    content: attr(title);
    z-index: -1;
}

abbr[title]:hover::after, dfn[title]:hover::after {
    z-index: 1;
	opacity: 0.9999999;
}

a:link, a:visited {
	color: inherit;
	text-decoration: underline;
	font-weight: bold;
}

cite.reflink {
	font-size: 60%;
}
a:visited {
	color: lighten;
	font-style: italic;
}

dl {
	font-family: cormorant, "Latin Modern Roman";
}
dt {
	font-style: italic;
}
.block-image {
    display: block;
    margin: auto;
}

section > figure {
    border-width: 0.1vh;
    border-style: solid;
    border-color: light-dark(#333333, #333333);
    background-color: light-dark(#FFFFFF33, #FFFFFF33);
    padding: 2vi 3vi;
}

ol.reference-list > li[id]::before {
	font-size: 60%;
	font-style: italic;
	margin: .1em;
	content: "[" attr(id) "]"
}

body > section, body > header {
    padding-left: 1.2vw;
    padding-right: 1.2vw;
}

section, header {
    background-color: light-dark(lighten, darken);
    margin: 0;
    border: 2px solid transparent;
}

*:target {
    background-color: light-dark(#FFFFFFCC, #5555);
    animation: highlightFade 4s ease forwards; /* Play the animation */
}
section section {
    background-color: inherit;
}

@scope(.product-list) {
	figure, p {
		margin-bottom: 0;
	}
}
/* Animation for highlighting and fading out on in-page links */
@keyframes highlightFade {
    0% {
        border-color: #e635;
    }
    50% {
        border-color: light-dark(lighten, darken);
    } 
    100% {
        background-color: initial;
    }  
} 

.good-answers, .bad-answers, .baseline-answers {
	list-style: none;
}
.good-answers li::before {
	content: "‚úÖ";
}
.bad-answers li::before {
	content: "‚ùå";
}

.baseline-answers li::before {
	content: "‚úîÔ∏è";
}

.product-list {
    list-style: none;
    display: flex;
    flex-direction: row;
    flex-wrap: wrap;
    align-items: flex-end;
}

.product-list li {
    max-width: 400px;
    height: auto;
    flex-grow: 1;
    flex-shrink: 3; /* default 1 */
}

.product-list img {
    width: auto;
    max-height: 200px;
    max-width: 200px;
    min-width: 0;
    object-fit: cover;
    vertical-align: bottom;
}

#treatment-legend {
    margin-top: 1.2em;
    border: 1px solid #9999;
    position: relative;
}

#treatment-legend > h3:first-child {
    background-color: light-dark(#FFFFFFCC, #401C16EE);
    border-color: #777;
    border-width: 1px;
    border-style: solid;
    position: absolute;
    margin-top: -1em;
    margin-bottom: -1em;
    padding: 0.05em 0.3em;
}

#legend-legend {
    list-style: none;
    font-size: smaller;
}

/** Nav styles */
nav {
    position: fixed;
    left: 0;
    top: 0;
    bottom: 0;
    padding: 0;
    margin: 0;
    transform: translateX(calc(-100% + 3.9vi));
    transition: transform 0.3s ease;
    background-color: #333333FC;
    color: #FFFC;
    height: 100%;
    z-index: 100;
    overflow-x: hidden;
    overflow-y: hidden;
}

nav > ul {
    position: relative;

	opacity: 0.01;
    transition: opacity 0.3s ease;

    list-style: none;
    margin: 2vi 1.4vi;
    padding: 0 0 0 1vw;
    width: 100%;
    height: 10%;
    max-height: 100%;
}

nav > ul > li > a {
    font-weight: bolder;
}

nav > div:first-child {
    border-top: 1vh solid #0000;
	writing-mode: vertical-lr;
	background: transparent;
	position: absolute;
	top: 0;
	right: 0;
	width: 3.8vw;
	z-index: 1000;
	font-size: 2.3vi;
	height: 5.5em; /** accomodate "Menu" */
	display: flex;
	flex-direction: row-reverse;
	justify-content: flex-end;
	align-items: flex-start;
}

nav > div:first-child:hover {
    border-top: 1vh solid #100E;
}

nav.open > div:first-child  {
    border-color: #FFFe;
}
nav h3 {
	writing-mode: vertical-lr;
	display: inline-block;
	position: sticky;
	top: 1vh;
	padding: 1vi 0.3vi;
	margin: 0;
	cursor: pointer;
	z-index: 1000;
	user-select: none;
	font-size: 2.65vw;
	border: 1px solid #0000;
}

nav h3:hover, nav.open h3 {
	background-color: #77110088;
	border: 1px solid #11000033;
	border-bottom-right-radius: 0.4vw;
	border-bottom-left-radius: 0.4vw;
}

nav h3:hover {
	color: #fff;
}

nav > ul {
	position: relative;
	z-index: 1;
}

nav > ul > li:last-child {
	margin-bottom: 4dvh;
}

nav a {
    color: #fff;
  	container: sidebar / normal;
}

nav.open {
    transform: translateX(0);
}

nav.open > ul {
	/* put overflow on UL, not nav, 
	because we must keep the "Menu" tab sticky
	*/
	min-height: 99dvh;
    overflow-y: auto;
    bottom: 0;
    position: relative;
    padding-bottom: 1dvi;
}
nav.open h3{
	right: 0;
}

nav.open > ul {
    opacity: 1;
}

nav a:hover {
	color: #9cf;
}
*/

@container sidebar (min-width: 200px) {
	  h3 {
		writing-mode: unset !important;
		position: static;
		cursor: default;
	}
}
    </style>
    
    <script type="module">
const documentElement = document.documentElement;
const clickHandler = event => {
	const target = event.target;
	if (!target) return;
	const nav = document.getElementById("nav");
	const isNotNav = !nav.contains(target);
	const isNavHeader = target.matches("#nav-heading");
	
	if (isNavHeader) {
		nav.classList.toggle("open");
		return;
	} else if (isNotNav) {
		nav.classList.remove("open");
	}
};
documentElement.addEventListener("click", clickHandler);
documentElement.addEventListener("touchstart", clickHandler);
	</script>
</head>
<body>
    <h1>Parkinson's Disease Guide</h1>
    <p><strong>Working Draft</strong><p>
    <p><strong>Editor:</strong> Garrett Smith</p>
    <nav id="nav">
        <div><h3 tabindex="0" id="nav-heading">Menu</h3></div>
        <ul>
            <li><a href="#purpose">The Purpose of This Guide</a></li>
            <li><a href="#how-to-use-this-guide">How to Use This Guide</a></li>
            <li><a href="#introduction-to-pd">Introduction to Parkinson's Disease</a>
                <ul>
                    <li><a href="#causes-of-pd">Causes and Risk Factors</a></li>
                    <li>
                        <a href="#testing-and-diagnosis">Testing and Diagnosis</a>
                        <ul>
                            <li>
                                <a href="#genetic-testing">Genetic Testing</a>
                            </li>
                        </ul>
                    </li> 
                </ul>           
            </li>
            <li><a href="#introduction-to-health">A Brief Introduction to Health</a></li>
            <li><a href="#care-team">How to Build a Care Team</a>
                <ul>
                    <li><a href="#care-team-introduction">Introduction</a></li>
                    <li><a href="#hypothetical-care-team">Hypothetical Care Team</a></li>
                    <li><a href="#tips-for-selecting-providers">Tips for Selecting Providers</a></li>
                </ul>
            </li>
            <li>
                <a href="#treatment-approaches">Treatment Approaches</a>
                
                <ul>
                    <li><a href="#treatment-approaches-overview">Overview</a></li>
                    <li><a href="#symptomatic-approach">Symptomatic</a></li>
                    <li><a href="#disease-progression-approach">Disease-progression</a></li>
                    <li><a href="#etiological-approach">Etiological</a></li>
                    <li><a href="#holistic-approach">Holistic</a></li>
                </ul>
            </li>
            <li><a href="#etiological-problems">Etiological Problems</a></li>
            <li><a href="#treatment-plan">Treatment Starter Plan</a></li>
            <li> <a href="#treatments">Detailed Treatments</a>
                <ul>
                    <li>
                        <a href="#medications">Medications</a>
                        <ul>
                            <li><a href="#dopamine-agonists">Dopamine Agonists</a></li>
                            <li><a href="#comt-inhibitors">COMT Inhibitors</a></li>
                            <li><a href="#mao-b-inhibitors">MAO-B Inhibitors</a></li>
                            <li><a href="#synuclean-d-and-minzasolmin">SynuClean-D and Minzasolmin</a> üß™</li>
                        </ul>
                    </li>
                    <li>
                        <a href="#hormonal-interventions">Hormonal Interventions</a>
                        <ul>
                            <li><a href="#hrt">HRT &mdash; Testosterone, Estrogen</a></li>
                            <li><a href="#dhea">DHEA</a></li>
                            <li><a href="#pregnenolone">Pregnenolone</a></li>
                        </ul>
                    </li>
                    <li><a href="#dbs">Deep Brain Stimulation (DBS)</a></li>
                    <li><a href="#gene-therapy">Gene Therapy</a></li>
		            <li><a href="#stem-cell">Stem Cells (MSC, iPSC)</a></li>
                    <li><a href="#physical-therapy-exercise"
                        >Physical Therapy / Exercise</a></li>
                    <li><a href="#pbm">Photobiomodulation</a></li>
                </ul>
            </li>
			<li><a href="#how-to-build-a-supplement-plan">How to Build a Supplement Plan</a></li>
            <li>
                <a href="#food-and-supplements">Food &amp; Supplements</a>
                <ul>
                    <li><a href="#glynac">GlyNAC (Glycine n-acetylcysteine)</a></li>
                    <li><a href="#creatine">Creatine Monohydrate</a></li>
                    <li><a href="#cinnamon">Cinnamon</a></li>
                    <li>Cacao</li>
                    <li><a href="#lions-mane">Lion's Mane</a></li>
                    <li><a href="#cordyceps">Cordyceps</a></li>
                    <li>Carvacrol</li>
                    
                    <li class="neuroprotective anti-aggregant"><a href="#turmeric">Turmeric</a></li>
                    <li class="neuroprotective antifibrillogenic"><a href="#saffron">Saffron</a></li>
                    <li><a href="#coconut-oil">Coconut Oil</a></li>
                    <li><a href="#ginger">Ginger</a></li>
                    <li><a href="#egcg">EGCG (Green Tea)</a></li>
                    <li><a href="#ginsenoside">Ginseng</a></li>
                    <li><a href="#acetyl-l-carnitine">Acetyl-L-Carnitine (ALCAR)</a></li>
                    <li><a href="#r-ala">Racemic Alpha-Lipoic Acid (Na-r-ALA)</a></li>
                    <li>
                        <a href="#gaba-5-htp-melatonin">GABA, 5-HTP, and Melatonin</a>
                        <ul>
                            <li><a href="#gaba">GABA</a></li>
                            <li><a href="#5-htp">5-HTP</a></li>
                            <li><a href="#melatonin">Melatonin</a></li>
                        </ul>
                    </li>
                    <li>
                        <a href="#quinones">Mitochondrial Quinones (PQQ, CoQ10, K2)</a>
                        <ul>
                            <li><a href="#pqq">PQQ Pyrroloquinoline Quinone</a></li>
                            <li><a href="#k2">Menaquinone (Vitamin K2)</a></li>
                            <li><a href="#ubiquinol">Ubiquinol (Reduced Coenzyme Q-10)</a></li>
                        </ul>
                    </li>
                    <li><a href="#gg">Geranylgeraniol (GG)</a></li>
                    <li><a href="#nattokinase">Nattokinase</a></li>
                    <li><a href="#dha">Docosahexaenoic Acid (DHA)</a></li>
                    <li><a href="#uridine">Uridine Monophosphate</a></li>
                    <li><a href="#citicoline">Citicoline (CDP Choline)</a></li>
                    <li><a href="#magnesium-threonate">Magnesium Threonate</a></li>
                    <li><a href="#vitamin-d">Vitamin D</a></li>
                    <li><a href="#vitamin-b16">Vitamin B-6</a></li>
                    <li><a href="#vitamin-b12">Vitamin B-12</a></li>
                    <li><a href="#tocotrienols">Tocotrienols + Tocopherols</a></li>
                    <li>
                        <a href="#nicotinamides">NAD+, NMN, Niacin, and NR</a>
                        <ul>
                            <li><a href="#nmn">NMN (Nicotinamide Mononucleotide)</a></li>
                            <li><a href="#nr">NR (Nicotinamide Riboside)</a></li>
                            <li><a href="#niacin">Niacin</a></li>
                            <li><a href="#nad-injection">Injectable NAD+</a></li>
                        </ul>
                    </li>
                    <li>
                        <a href="#senolytics">Senolytics</a>
                        <ul>
                            <li><a href="#urolithin-a">Urolithin-A</a></li>
                            <li><a href="#resveratrol">Resveratrol</a></li>
                            <li><a href="#fisetin">Fisetin</a></li>
                            <li><a href="#quercetin">Quercetin</a></li>
                            <li><a href="#sulforaphane">Sulforaphane</a></li>
                            <li><a href="#piperlongumin">Piperlongumin</a></li>
                            <li><a href="#apigenin">Apigenin</a></li>
                            <li><a href="#theaflavin">Theaflavin</a></li>
                        </ul>
                    </li>
                    <!-- li>
                        <a href="#blueberry"></a>
                    </li -->
                </ul>
            </li>
            <li><a href="#summary">Summary</a></li>
        </ul>
    </nav>
    <header id="purpose">
        <h2>The Purpose of This Guide</h2>

        <p>
            The purpose of the guide is to empower individuals with Parkinson's Disease (PD) with the best possible knowledge to maximize their healthspan based on the latest scientific research.
        </p>
    </header>
    <section id="how-to-use-this-guide">
        <h2>How to Use This Guide</h2>
        <p>
            To make the most of this Parkinson's Disease Guide, <a href="#introduction-to-pd">Educate yourself about Parkinson's Disease</a>, learn about <a href="#food-and-supplements">supplements</a>, and get started with the <a href="#treatment-plan">Treatment Starter Plan</a>.
        </p>
    </section>
    <section id="introduction-to-pd">
        <h2>Introduction to Parkinson's Disease</h2>

        <p>
            Parkinson‚Äôs Disease (PD) is a progressive neurological condition caused by the aggregation of the pre-synaptic peptide Œ±-synuclein. This causes loss of dopaminergic neurons, resulting in motor skill defects and progressive neurodegeneration (PN) characterized by motor and non-motor symptoms.
        </p>

        <!--
        <p>
            Alpha-synuclein aggregates in the midbrain and damages neurons, including the autonomic nuclei, also located also throughout the body, which are responsible for autonomic functions (blood pressure, heart rate, GI system, etc).
        </p>
        <p>
            Progressive neurodegeneration ensues and is exacerbated by unilateral neurological modulation of the dopaminergic pathway (the L-Dopa / DDC inhibitors, aka "standard of care") and is more pronounced in later stages.
        </p>

        <p>
            Parkinson's Disease affects various brain regions, including the substantia nigra, basal ganglia, cerebral cortex, thalamus, hippocampus, cerebellum, and other regions involved in motor control, cognition, movement and the nervous systems.
        </p>
        -->
        <!-- p>
            The nervous system comprises the Central Nervous System (CNS), Peripheral Nervous System (PNS), and autonomic nervous system (ANS). The CNS, consisting of the brain and spinal cord, processes information and coordinates responses. The PNS connects the CNS to the body, relaying sensory input and motor output. The ANS regulates involuntary functions like heart rate and digestion.
        </p -->
        <p>
            In PD, progressive neurodegeneration (PN) primarily affects the Central Nervous System (CNS), particularly dopamine-producing neurons, leading to motor symptoms like tremors and rigidity. However, dysfunction of the autonomic nervous system (ANS) becomes more noticeably pronounced in the later stages, contributing to non-motor symptoms such as <abbr title="Gastrointestinal">GI</abbr> issues, low blood pressure, and urinary dysfunction.
        </p>
        <p>
            PD-related autonomic dysfunction can exacerbate renal issues, leading to a complex interplay of factors that contribute to orthostatic hypotension in PD.
        </p>
        <section id="causes-of-pd">
            <h3>Causes and Risk Factors</h3>
            <p>
                Parkinson's Disease is a neurological condition resulting from pathology of alpha-synuclein (Œ±-synuclein), (Œ±-synucleinopathy). 
                <span class="call-out">Understanding the role and effects of Œ±-synuclein is key to mitigating the disease's progression.</span>
            </p>
            <p>
                Overexpression of &alpha;-synuclein leads to its aggregation and the formation of &alpha;-synuclein structures, either as oligomers (peptides) or fibrils (see image). Oligomers of &alpha;-synuclein can form Lewy bodies, abnormal
                aggregations that develop inside nerve cells.
            </p>
            
            <figure>
                <img src="img/alpha-synuclein.jpeg" alt="Œ±-synuclein monomer, fibril, and oligomer." class="block-image">
            <figcaption>
                <p>
                    Depiction of Œ±-synuclein monomer, fibril, and oligomer. Œ±-Synuclein fibrils are long, insoluble fibers composed of many monomers and oligomers.
                </p>
            </figcaption>
            </figure>
            <p>
                Alpha-synuclein is abundant primarily in the brain, especially in the neocortex, hippocampus, and substantia nigra (SN). Smaller amounts are found in the heart, muscles, and other tissues. It is transported into and out of the
                brain by the blood-brain barrier. <cite class="reflink">[<a href="#yu-ting-sui">yu-ting-sui</a>]</cite>
            </p>
            <p>
                Six mutations of &alpha;-synuclein are currently associated with familial parkinsonism. Mutant &alpha;-synuclein forms aggregates more readily than wild-type (normal) &alpha;-synuclein. <cite class="reflink">[<a href="#v-c-ruf">v-c-ruf</a>]</cite>, <cite class="reflink"><a href="#jie-li">jie-li</a>]</cite>
            </p>
            <p>
                Wild-type &alpha;-synuclein can be removed by lysosomes. Mutant forms of &alpha;-synuclein, however, resist their degradation and inhibit that of other substrates.
            </p>
            <p>
                &alpha;-synuclein oligomers play a central role in the multi-factorial causes of Parkinson&rsquo;s disease. &alpha;-synuclein oligomers, as well as other &alpha;-synuclein variants, actively participate in disrupting
                mitochondrial function, autophagy and lysosomal degradation, membrane homeostasis, Endoplasmic Reticulum (ER) function, and synapses, and can induce inflammation. 
            </p>
        
            <!-- TODO: Where does this go??
            <h4>SNCA Gene Encodes Alpha-synuclein</h4>
            <p>
                The SNCA gene encodes &alpha;-synuclein. In the brain, &alpha;-synuclein is found mainly at the tips of nerve cells (neurons) in specialized structures called presynaptic terminals.
            </p>
            <p>Mutations in the SNCA gene lead to mutant &alpha;-synuclein.</p>
            <h4>
                Autosomal Dominant Parkinson's Disease, PARK1
            </h4>
            <p>
                PARK1 is an inherited, dominant genetic trait (autosomal dominant) in PD that causes heterozygous triplication of the SNCA gene.
            </p>
            <h4>LRRK2</h4>
            <p>
                Leucine-Rich Repeat Kinase 2 (LRRK2) is an enzyme encoded by a gene of the same name (the LRRK2 gene).
            </p>
            <p>
                LRRK2 mutations are implicated in PD pathogenesis and may influence &alpha;-synuclein metabolism and neuronal function.
            </p>
            <h5>LRRK2-G2019S</h5>
            <p>
                LRRK2-G2019S is a mutant form of LRRK2 found in PD. LRRK2-G20195 causes &alpha;-synuclein accumulation in dopaminergic neurons. &alpha;-synuclein accumulation leads to all of the problems previously mentioned,
                including &alpha;-synuclein oligomers and fibrils.
            </p>
            <p>
                LRRK2 mutants in genetic PD cause shortening and simplification of the dendritic tree in vivo and in cultured neurons.
            </p>
            <p>
                LRRK2 inhibitors can improve Parkinson's disease by reducing &alpha;-synuclein.
            </p>
            <h4>PINK1</h4>
            <p>
                PTEN-induced kinase 1 (PINK1) is a kinase produced by the PINK1 gene. Mutations in the PINK1 gene are a rare cause of one form of autosomal recessive early-onset Parkinson's disease that may be more associated with
                mitophagy, a process by which damaged or dysfunctional mitochondria are removed, reducing oxidative stress and inflammation.
            </p>
            <h4>Current Therapies in Clinical Trials of Parkinson‚Äôs Disease: A 2021 Update</h4>
            <p>
                The complex pathology is partially depicted in the figure below
            </p>
            <figure>
                <img src="img/figure-1-pd.png" alt="Parkinson's Disease Pathology Diagram" class="block-image" />
                <figcaption>
                    <p>
                        The pathological hallmarks of PD and the interplay of aging, environmental hazards, and genetics.
                    </p>
                    <p>
                        (A) The pathological hallmarks of Parkinson‚Äôs disease include dopaminergic neuronal death, &alpha;-synuclein aggregates, mitochondrial dysfunction, reactive oxygen species, apoptosis, and neuroinÔ¨Çammation.
                    </p>
                    <p>
                        (B) PD is a multifactorial disorder involving aging, genetics, and environmental factors, associated with dopaminergic neuronal death. Gene mutations associated with PD include DJ-1, PTEN-induced putative kinase-1 (PINK1), parkin, leucine-rich repeat kinase-2 (LRRK2), Synuclein alpha (SNAC), and ubiquitin carboxyl-terminal hydrolase-L1 (UCHL1). 
                    </p>
                    <p>
                        Neurotoxins (e.g., rotenone, paraquat) and gene mutations of DJ-1,  PINK1, parkin, LRRK2, and SNAC, induce mitochondria complex I inhibition, ATP depletion, reactive oxygen species (ROS) accumulation, mitochondria depolarization, and mitochondrial dysfunction in dopaminergic neurons to promote neuronal death in the substantia nigra of PD patients.
                    </p><cite class="reflink">[<a href="[F. Pan-Montojo]">F. Pan-Montojo</a>]</cite>
                    <p>
                        Overexpression of the SNCA gene can lead to the accumulation of  &alpha;-synuclein in the brain, which, if &alpha;-synuclein is of a mutant form can cause problems and contribute to the formation of Lewy bodies. 
                    </p>
                    <p>
                        The UCHL1 gene and the overexpression of the SNCA gene are related in that UCHL1 is involved in the degradation of &alpha;-synuclein, a protein that is overexpressed in PD. 
                    <p>
                        The UCHL1 gene and the SNCA gene are both involved in PD pathogenesis.
                        UCHL1 gene mutations impair ubiquitin-proteasome systems and further induce autophagy lysosomal pathway dysfunction, contributing to Lewy body formation in dopaminergic neurons.
                    </p>
                </figcaption>
            </figure>
            <p>
                The diagram offers some visual depiction of PD, with small mistakes.
            </p>
            <p>The authors miscall the &alpha;-synuclein gene, SNCA, "SNAC". Most of what they categorize as genetic is epigenetic. That is, attributable to a combination of genetic <em>and</em> environmental factors.</p>
            <p>
                Lewy bodies are comprised of &alpha;-synuclein fibrils, the manifestation of which can be partly affected by environmental factors. Lewy bodies appear in the ‚ÄúGenetic factors" group below &alpha;-synuclein.
            </p>
            <p>
                &alpha;-synuclein increase is not solely attributable to genetics but to a variety of epigenetic factors that can be affected.
            </p>
            -->
			<p>
				In PD aging, environmental hazards, and genetics interact pathologically.
			</p>
			<p>
				The pathological hallmarks of PD include dopaminergic neuronal death, &alpha;-synuclein aggregates, mitochondrial dysfunction, reactive oxygen species (ROS), apoptosis, and neuroinÔ¨Çammation.
			</p>

			<p>
				PD's multifactorial effects involve aging, genetics, and environmental factors associated with dopaminergic neuronal death. <cite class="reflink">[<a href="#k-burton">k-burton</a>]</cite>
			</p>
			<p>
				Neurotoxins, such as rotenone and <a href="https://www.syngenta.com/en/paraquat-in-the-media">paraquat</a>, along with gene mutations of <abbr title="Parkinsonism-Associated Deglycase 1 or Park7">DJ-1</abbr>, <abbr title="PTEN-induced Kinase 1">PINK1</abbr>, parkin, <abbr title="Leucine-Rich Repeat Kinase 2 gene">LRRK2</abbr>, and <abbr title="Synuclein Alpha Gene">SNCA</abbr> genes, contribute to several cellular issues. These include mitochondria complex I inhibition, ATP depletion, and <abbr title="Reactive Oxygen Species">ROS</abbr>  accumulation. They also cause mitochondrial depolarization and dysfunction. Together, these factors promote neuronal death in the substantia nigra of PD patients. <cite class="reflink">[<a href="#jae-hyeon-park">jae-hyeon-park</a>]</cite><cite class="reflink">[<a href="f-pan-montojo">F. Pan-Montojo</a>]</cite>
			</p>
			<p>
				This is difficult. Reread that until it makes sense.
			</p>
			
            <p>
                Epigenetic factors can influence mutations in <abbr title="Leucine-Rich Repeat Kinase 2 gene"
                >LRRK2</abbr> (<abbr title="Leucine-Rich Repeat Kinase 2 gene with a Glycine to Serine substitution at position 2019"
                >LRRK2-G2019S</abbr>) and cause encoding mutations in <abbr title="Leucine-Rich Repeat Kinase 2 gene"
                >LRRK2</abbr> and <abbr title="Synuclein Alpha Gene">SNCA</abbr> genes that affect the production and pathogenicity of mutant &alpha;-synuclein. <cite class="reflink">[<a href="#christine-klein">christine-klein</a>]</cite>
            </p>
            <p>
                Vitamin B12, for example, is an external factor that prevents LRRK2-G2019S-potentiated &alpha;-synuclein accumulation in dopaminergic neurons. <cite class="reflink">[<a href="#a-schaffner">a-schaffner</a>]</cite>
            </p>
            
            <h5>The Role of Pesticides</h5>
            <p>
                Pesticide and herbicide exposure causes &alpha;-synuclein overexpression in certain individuals. Herbicide rotenone and pesticide paraquat so reliably induce PD that they are used to induce PD in rodent model experiments. 
            </p>
            <p>
                <abbr title="Special AT-rich sequence-binding protein 1">SATB1</abbr> a cell regulator, represses the expression of p21 in dopaminergic neurons. P21 is a pro-senescence factor that maintains the viability of senescent cells under persistent DNA damage response.  <cite class="reflink">[<a href="#markus-riessland">markus-riessland</a>]</cite>
            </p>
            <p>
                <abbr title="Special AT-rich sequence-binding protein 1">SATB1</abbr> is inhibited in PD. Less SATB1 means more p21, leading to decreased <abbr 
                title="cyclin-dependent kinases">CDKs</abbr>, leading to the accumulation of senescent cells. Senescent dopaminergic neurons contribute to the pathology of PD.
                <cite class="reflink">[<a href="#markus-riessland">markus-riessland</a>]</cite>
            </p>
            <p>
                Senescent cells cease to function and divide, damaging healthy neighboring cells by secreting inflammatory factors and contributing to further tissue dysfunction and senescence.
            </p>

            <h5>
                Alpha-synuclein References:
            </h5>
            <ol class="reference-list">
                <li id="f-nouri-emamzadeh">
                    <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5122110/"
                    title="Alpha-synuclein structure, functions, and interactions"
                    target="_blank"
                    >Alpha-synuclein structure, functions, and interactions</a>
                    <p>
                        Upon clinical diagnosis of PD, serious damage has already been done to nerve cells of the substantia nigra pars compacta. This underscores the importance of early testing and genetic testing. 
                    </p>
                </li>
                <li id="v-c-ruf">
                    <a href="https://pubmed.ncbi.nlm.nih.gov/30605594/"
                    title="Different Effects of Œ±-Synuclein Mutants on Lipid Binding and Aggregation Detected by Single Molecule Fluorescence Spectroscopy and ThT Fluorescence-Based Measurements"
                    target="_blank"
                    >Different Effects of Œ±-Synuclein Mutants on Lipid Binding and Aggregation Detected by Single Molecule Fluorescence Spectroscopy and ThT Fluorescence-Based Measurements</a>, Viktoria C Ruf, et al.
                    <p>
                    This study showed that differential mechanisms of metals, such as iron, in &alpha;-synuclein pathology on the molecular level.
                    </p>
                </li>
                <li id="alpha-synuclein-net">
                    <a href="https://alpha-synuclein.net/mutations/"
                    title="ALPHA SYNUCLEIN: MUTATIONS"
                    target="_blank"
                    >ALPHA SYNUCLEIN: MUTATIONS</a>
                    <p>
                        Individuals who developed a triplication of the <abbr title="Synuclein Alpha Gene">SNCA gene</abbr>, as opposed to a duplication, displayed more severe symptoms including early-onset parkinsonism with dementia. This indicates that there is a ‚Äúdose dependent‚Äù correlation between the progression of PD and <abbr title="Synuclein Alpha">SNCA</abbr> gene dosage. <cite class="reflink">[<a href="#alpha-synuclein-net">alpha-synuclein-net</a>]</cite>
                    </p>
                </li>
                <li id="jie-li">
                    <a href="https://pubs.acs.org/doi/10.1021/bi010616g"
                    title="Effect of Familial Parkinson's Disease Point Mutations A30P and A53T on the Structural Properties, Aggregation, and Fibrillation of Human Œ±-Synuclein"
                    target="_blank"
                    >Effect of Familial Parkinson's Disease Point Mutations A30P and A53T on the Structural Properties, Aggregation, and Fibrillation of Human Œ±-Synuclein</a>, Jie Li, et al.
                    <p>
                        This rodent study showed that the <dfn title="Alpha-53-Thr mutation: point mutation in the human alpha-synuclein (Œ±-synuclein) gene, associated with early-onset familial PD">A53T</dfn> and <dfn title="a point mutation in the alpha-synuclein (SNCA) gene, which is associated with autosomal dominant Parkinson‚Äôs disease">A30P</dfn> genetic mutations in Œ±-synuclein have increased propensity to aggregate compared with the wild-type protein, and this strongly supports the direct and critical role of Œ±-synuclein aggregation in the etiology of Parkinson‚Äôs disease. 
                    </p>
                    <p>
                        They note Œ±-synuclein in PD arose from gene-linkage experiments in familial early-onset Parkinson‚Äôs disease, which revealed the A53T mutation.
                    </p>
                </li>
                <li id="f-pan-montojo">
                    <a href="https://pubmed.ncbi.nlm.nih.gov/23205266/"
                    title="Environmental toxins trigger PD-like progression via increased alpha-synuclein release from enteric neurons in mice"
                    target="_blank"
                    >Environmental toxins trigger PD-like progression via increased alpha-synuclein release from enteric neurons in mice</a>, F. Pan-Montojo, et al.
                    <p>
                        This rodent model showed that pharmacologically increasing SIRT3, as recommended in this article, can counteract Œ±-synuclein-induced mitochondrial dysfunction by reducing Œ±sŒ±-synucleinyn oligomers and normalizing mitochondrial bioenergetics. 
                    </p>
                </li>
                <li id="jae-hyeon-park"> 
                    <a href="https://pubmed.ncbi.nlm.nih.gov/31931835/"
                    title="Alpha-synuclein-induced mitochondrial dysfunction is mediated via a sirtuin 3-dependent pathway"
                    target="_blank"
                    >Alpha-synuclein-induced mitochondrial dysfunction is mediated via a sirtuin 3-dependent pathway</a>, Jae-Hyeon Park, et al.
                    <p>
                    	This rodent model showed that pesticides can initiate the progression of PD pathology and that this progression is based on the transneuronal and <dfn>"retrograde axonal transport"</dfn> (that &alpha;-synuclein goes back into the cell) of alpha-synuclein. If confirmed in patients, this study would have crucial implications in the strategies used to prevent and treat PD.
                    </p>
                </li>
                <li id="christine-klein"> 
                    <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3253033/"
                    title="Genetics of Parkinson‚Äôs Disease"
                    target="_blank"
                    >Genetics of Parkinson‚Äôs Disease</a>
                    <p>
                        This 2014 paper provides compelling arguments that identification of PD gene mutations, especially in patients with early-onset PD, can provide information on prognosis and will affect treatment choices in cases of PD that were initially suspected to be psychogenic. <em>Why is this 10-year old paper not the standard of care!?</em>
                    </p>
                </li>
                <li id="yu-ting-sui"> 
                    <a href="https://pubmed.ncbi.nlm.nih.gov/25278492/"
                    title="Alpha synuclein is transported into and out of the brain by the blood-brain barrier"
                    target="_blank"
                    >Alpha synuclein is transported into and out of the brain by the blood-brain barrier</a>, Yu-Ting Sui, et al.
                    <p>
                        This rodent model study showed Œ±-synuclein is transported across the BBB bidirectionally, in both the brain-to-blood and blood-to-brain directions.
                    </p>
                </li>
                <li id="adam-schaffner"> 
                    <a href="https://pubmed.ncbi.nlm.nih.gov/30858560/"
                    title="Vitamin B12 modulates Parkinson's disease LRRK2 kinase activity through allosteric regulation and confers neuroprotection"
                    target="_blank"
                    >Vitamin B12 modulates Parkinson's disease LRRK2 kinase activity through allosteric regulation and confers neuroprotection</a>, Schaffner, et al
                    <p>
                        This rodent model study showed Œ±-synuclein is transported across the BBB bidirectionally, in both the brain-to-blood and blood-to-brain directions.
                    </p>
                </li>
                
                <li id="markus-riessland"> 
                    <a href="https://pubmed.ncbi.nlm.nih.gov/30858560/"
                    title="Loss of SATB1 Induces p21-Dependent Cellular Senescence in Post-mitotic Dopaminergic Neurons"
                    target="_blank"
                    >Loss of SATB1 Induces p21-Dependent Cellular Senescence in Post-mitotic Dopaminergic Neurons</a>, Riessland, et al.
                    <p>
                        Moreover, we found that SATB1 directly represses expression of the pro-senescence factor p21 in dopaminergic neurons. Our data implicate senescence of dopamine neurons as a contributing factor in the pathology of Parkinson's disease.
                    </p>
                </li>
                                

            </ol>
        </section>
        <section id="testing-and-diagnosis">
            <h3>Testing and Diagnosis</h3>
            
            <p>
            Upon clinical diagnosis of PD, serious damage has already been done to nerve cells of the substantia nigra. This underscores the importance of early testing and genetic testing. 
			</p>

            <p>
                Alpha-synuclein oligomers are higher in PD patients than in healthy subjects. This can be tested with AlphaSyn-SAA salivary test or Syn-One skin biopsy.
            </p>
            <h3>Early Testing and Diagnosis with AlphaSyn-SAA</h3>
            <p>
                The AlphaSyn-SAA salivary test measures the levels of alpha-amylase in saliva. The results are used to assess autonomic nervous system activity, particularly sympathetic nervous system activation. This test can, with some margin of error, identify people at risk of developing Parkinson‚Äôs disease <em>up to ten years</em> before symptoms appear. 
            </p>
            <h3>Syn-One</h3>
            <p>
                The Syn-One skin biopsy detects the presence of phosphorylated alpha-synuclein in the skin. This is a much more accurate test than the AlphaSyn-SAA, and is usually used as confirmation, rather than a preventive diagnostic.
            </p>
            <section id="genetic-testing">
                <h4>Genetic Testing</h4>
                <p>
                    Most cases of Parkinson's Disease are not classified as genetic. Genetic testing for PD is not routinely performed. The lack of testing is due to the fact that only about 15% of cases are determined to be genetic. It's a classic <dfn>absence of evidence</dfn> fallacy.
                </p>
                <p>
                    Genetic testing for PD can help better inform and guide its treatment.
                    Genes associated with PD may have varying effects on disease progression. (See also: <a href="https://www.michaeljfox.org/what-know-about-f-testing"
                    target="_blank"
                    >What to Know about Genetic Testing</a>)
                </p>
        
                <p>
                    None of the genetic types should be excluded from the proposed treatments in the problems list, but the specific focus and approach would differ based on the genetic mutation and its associated molecular pathway. Familiarize yourself with your genetic type, the associated treatments for it included herein and elsewhere, and communicate this with your care team.
                </p>
                <h5>Test Your Children</h5>
                <p>
                    Children of PD patients should be tested <em>before</em> they exhibit symptoms similar to those of PD. Symptoms may take up to 10 years to present. 
                </p>
                
                <h5>Testing Locations</h5>
        
                <p>
                Genetic testing for these mutations can be done at specialized medical centers and genetic testing companies. Some notable places include:
                </p>
                <ul>
                    <li>
                        <a href="https://www.mayo.edu/research/labs/parkinsons-disease/overview" target="_blank">Mayo Clinic</a>
                    </li>
                    <li>
                        <a href="https://www.hopkinsmedicine.org/health/conditions-and-diseases/parkinsons-disease/the-genetic-link-to-parkinsons-disease" target="_blank">Johns Hopkins Medicine</a>
                    </li>
                    <li>
                        <a href="https://www.23andme.com/topics/health-predispositions/parkinsons-disease/" target="_blank">23andMe</a>
                    </li>
                    <li>
                        <a href="https://www.invitae.com/us/providers/test-catalog/gene-21080" target="_blank">Invitae</a>
                    </li>
                    <li>
                        <a href="https://providers.genedx.com/tests/detail/parkinson-disease-panel-1005" target="_blank">GeneDx</a>
                    </li>
                </ul>
                <h4>Genetic Forms of PD and Corresponding Treatments</h4>
                <dl id="genetic-forms-treatments">
                    <dt><abbr title="Synuclein Alpha Gene">SNCA gene</abbr></dt>
                    <dd>Anti-aggregant, antifibrillogenic, antioxidant, neuroprotective.</dd>

                    <dt><abbr title="Leucine Rich Repeat Kinase 2">LRRK2</abbr></dt>
                    <dd>LRRK2 inhibitors, anti-inflammatory, neuroprotective, dbs, b-12.</dd>

                    <dt><abbr title="PTEN-induced Kinase 1">PINK1</abbr> &amp; Parkin</dt>
                    <dd>Mitochondrial, mitophagy, antioxidant.</dd>

                    <dt><abbr title="Parkinsonism-Associated Deglycase 1 or Park7">DJ-1</abbr></dt>
                    <dd>Antioxidant, mitochondrial.</dd>

                    <dt><abbr title="Ubiquitin C-Terminal Hydrolase L1">UCHL1</abbr></dt>
                    <dd>Ubiquitin-proteasome, anti-aggregant.</dd>
                </dl>

                <h4>Genetic Treatment Approaches</h4>

                <p>
                    A custom-tailored care plan based on the genetic type of PD will predict the best outcomes.
                </p>
                <p>
                    Effective treatment must approach PD from multiple angles. The review <cite>"Current Therapies in Clinical Trials of Parkinson‚Äôs Disease: A 2021 Update"</cite>, provides a fair overview of PD.
                </p>
        
                <ol class="reference-list">
                    <li id="k-burton"> 
                        <a href="https://www.medscape.com/viewarticle/994849"
                        title="Why Genetic Testing May Be Our Best Shot at Progress in PD"
                        target="_blank"
                        >Why Genetic Testing May Be Our Best Shot at Progress in PD</a>, Kelli Whitlock Burton
                        <p>
                            Previous studies have shown that some genetic variants increase the risk for PD after exposure to environmental factors such as pesticides. Research has also shown that patient genotype can indicate survival time and treatment approaches.
                        </p>
                    </li>
                    <li id="l-cook"> 
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8101316/"
							title="Genetic Testing for Parkinson Disease"
							target="_blank"
                        >Genetic Testing for Parkinson Disease</a>, Lola Cook, et al.
                        <p>
                            In some cases, identification of PD variants may aid in diagnosis and management and prediction of disease course.
                        </p>
                    </li>
                </ol>
            </section>
        </section>
    </section>
    <section id="introduction-to-health">
        <h2>A Brief Introduction to Health</h2>

        <p>
            Knowledge is crucial to achieving predictable success, as the predictability of solving problems that are not well understood is low.
        </p>
    
        <p>
            Optimal health describes a state of physical and mental functioning, not merely absence of disease. Healthcare professionals often describe optimal health from a very high-level with with crude descriptors. We could do better.
        </p>
        <p>
            The first step to optimizing one's health is understanding his general condition and some basic understanding of cellular health, neurology, and the human organism (we've barely scratched the surface). 
        </p>        
    
        <ol>
            <li>Balanced hormone levels
            <li>Efficient metabolism (basic <abbr title="Basic Metabolic Panel">BMP</abbr>)
            <li>Healthy blood pressure and cholesterol levels
            <li>Strong immune system
            <li>Health Blood markers (<abbr title="Complete Blood Count">CBC</abbr>)
        </ol>
    
        But we could go deeper:
        <ol>
            <li>Resting heart rate below 60 beats per minute
            <li>Well-functioning organs and systems, including cardiovascular, respiratory, digestive systems (<abbr title="Comprehensive Metabolic Panel">CMP</abbr>)
            <li>Normal blood pressure (around 120/80 mmHg)
            <li><del>crude lipid profile with low LDL and high HDL cholesterol</del>
            <li>More useful lipid profile <em>high</em> <abbr title="Large, Buoyant Low-Density Lipoprotein">lbLDL</abbr> and <abbr title="Large, Buoyant Low-Density Lipoprotein">lbHDL</abbr>, low <abbr title="Small, Dense Low-Density Lipoprotein">sdLDL</abbr> and <abbr title="Small, Dense High-Density Lipoprotein">sdHDL</abbr>, and high ratio of <abbr title="Large, Buoyant High-Density Lipoprotein">lbHDL</abbr> to <abbr title="Large, Buoyant Low-Density Lipoprotein">lbLDL</abbr>
            <li>Healthy body composition; low visceral fat (<abbr title="dual-energy X-ray absorptiometry">DEXA</abbr>)
            <li>Optimal levels of inflammation and oxidative stress (Cytokine Markers and Inflammatory Markers tests).
        </ol>
        Deeper yet:
        <ol>
        	<li>Genetic testing for personal health (<a href="https://www.innerbody.com/dna-testing/dna-health-testing"
        	>Finding the Best DNA Health Test</a>).
        	<li>Advanced hormone tests (<a href="https://dutchtest.com/info-dutch-complete/">Dutch Complete</a>).
            <li>Healthy immune system (dendritic cells (DCs)) (detailed lymphocytes subsets, activation, and tracking) (COSTIM bioassay to test potency of <abbr title="dendritic cells">DCs</abbr>) by measuring their co-stimulatory activity.) (antibody response exam).
            <li>Stable blood glucose levels maintained by insulin sensitivity (<abbr 
            title="Oral Glucose Tolerance Test">OGTT</abbr>).
            <li>Adequate cellular repair mechanisms ensuring tissue integrity and longevity.
            <li>Optimal mitochondrial function providing energy for cellular activities.
            (<a href="https://aonm.org/mitochondrial-testing/">mitochondrial testing</a>).
            <li>Healthy methylation (Genova Diagnostics Methylation Panel).
		</ol>
            Focusing on the brain:
        <ol>
            <li>Precise and sensitive regulation of neurotransmitter synthesis via enzyme pathways and receptor feedback mechanisms.
            <li>Low neuroinflammation through balanced cytokine production and microglial modulation (Cytokine Panel, Multiplex ELISA)
            <li>Synaptic plasticity for quick learning and memory formation.
            <li>Minimal neuroinflammation and neuronal damage.
            <li>Efficient energy metabolism through optimal mitochondrial function and glucose utilization.
        </ol>
    
        Monitoring and testing those brain health parameters involves:
        <ol>
            <li>Neuroimaging techniques like MRI, <abbr title="Positron Emission Tomography">PET</abbr>, or Brain <abbr title="Single Photon Emission Computed Tomography">SPECT</abbr> scans to visualize brain structures.
            <li>Measurement of neurotransmitter levels in bodily fluids with chromatography.
            <li>PET imaging with specific radiotracers to assess microglial activation and neuroinflammation.
            <li>Analysis of cytokine levels in blood or cerebrospinal fluid through <abbr title="Enzyme-Linked ImmunoSorbent Assay">ELISA</abbr> or <abbr title="Polymerase Chain Reaction">PCR methods</abbr>.
            <li>Evaluation of mitochondrial function through assays measuring ATP production, membrane potential, and oxidative stress levels.
        </ol>
        
        <p>
            Monitoring and testing brain health involves specialized assessments that require a deeper understanding of neurobiology and physiology. Understanding the interplay between that and some of the recommendations in this guide (<abbr title="Levodopa / Dopa-decarboxylase inhibitors">LD/DDC inhibitors</abbr>, melatonin, <abbr title="Photobiomodulation">PBM</abbr>, mitochondrial quinones), requires an extraordinary mind. Developing a care plan around that is monumentally difficult, not just for the complexity of the problem, but for the dearth of professionals up to the task.
        </p>
        <p>
            Those who take their condition seriously and employ the best strategies to mitigate the progression of the disease will enjoy greater quality of life and longevity. The tired "ask to your doctor" mantra does not lead greater self-empowerment through understanding and does not apply here. Learn, you must.
        </p>
    </section>
    <section id="care-team">
        <h2>
            How to Build a Care Team
        </h2>
        <section id="care-team-introduction">
            <h3>Introduction</h3>

            <p>
                The complexities of human health optimization demand self-education. You need to do the work. But first, you need to learn. 
            </p>
            <p>
            	Following are some example questions that strip away all assumptions you may have to address the complexities of becoming an <em>active participant</em> in your health. Don't take them at face value; question the question. Derive better questions.
            </p>
        </section>

		<!-- section id="how-to-interview-neurologist">
			<h3>Questions to Ask a Potential Neurologist</h3>
				How can I test my mitochondrial function?
				
		</section -->
        <section id="hypothetical-care-team">
            <h3>
                Hypothetical Care Team
            </h3>
            <p>
                This is a structured, customizable framework for self-directed management of Parkinson's Disease with a focus on health optimization.
            </p>

            <ol>
                <li>Neurologist for planning, diagnosis and oversight.
                <li>Functional and Integrative Medicine Specialist, for planning, diagnosis and oversight.
                <li>Movement Specialist.
                <li>Physical Therapist.
                <li>Research involvement for cutting-edge options.
                <li>Biomarker Testing Laboratory for personalized biomarker testing for monitoring disease progression, treatment response, and personalized treatment optimization.
            </ol>
            
            <h3>How to Interview Your Neurologist</h3>
            <p>
             Some doctors are constrained by institutional protocols. Expectations and requirements imposed by their healthcare employers may dissuade them from self-questioning and information-seeking extrinsic to the institution's protocols or professionally ordained purview. 
             </p>
             <p>
             	Assessing provider competence requires more than just checking credentials, years of experience, or conference attendance; it demands a nuanced and thorough approach.
			</p>
			<p>
				To effectively assess someone's competence, approach the interview from a position of informed knowledge.
             </p>
             
             <p>
            	Inquiring openly and observing without revealing your own level of understanding is a strategic approach to competence assessment. When given the opportunity to speak freely, how do they err?
			</p>
			
			<p>
That strategy can work, provided you have the depth and breadth of understanding to evaluate and scrutinize the veracity of the information your interlocutor emits.
            </p>
            
            <p>
Prepare detailed questions that delve into the neurologist's expertise in your specific area of concern. 
			</p>
			<h4>"In your initial assessment of a patient suspected to have Parkinson's Disease, what tests and evaluations do you conduct?"</h4>

			<h4>
			‚úÖ Good answers must include:
			</h4>
			<ul class="good-answers">
				<li> Diagnostic Imaging (MRI or CT scan to rule out other conditions that may mimic Parkinson's Disease (e.g., stroke, tumor).)
				<li> Syn-One skin biopsy
				<li> DaTscan (Dopamine Transporter Scan)
			</ul>
			<p>
				&mdash; and that is beyond the very basic fundamentals of:&mdash;
			</p>

			<ul class="baseline-answers">
				<li> Detailed medical history and symptom review.
				<li> Thorough motor symptoms exam 
				<li> Non-motor symptoms (sleep disturbances, autonomic dysfunction, mood disorders).
			</ul>

			<h4>
			‚ùå Bad Answers:
			</h4>
			<ul class="bad-answers">
				<li> Omitting the genetic testing aspect entirely without context or justification.
				<li> Failing to mention the importance of ruling out other conditions via imaging and blood tests.
				<li> Lack of mention of the dopaminergic medication trial as a diagnostic tool.
				<li> Generalization without specifying the detailed steps of the neurological examination and symptom review.
			</ul>

			<h4>"Why do you include or exclude genetic testing in your initial assessment for Parkinson's Disease?"</h4>

			<h4>‚úÖ Good answers:</h4>
			<p>
				Genetic testing. A good response <em>must</em> acknowledge the importance of genetic factors in creating custom-tailored solutions and for testing one's offspring for inherited traits. 
			</p>

			<h4>"How do you address non-motor symptoms in the management of Parkinson's Disease?"</h4>
			<p>
			Ask about a few treatments that you're familiar with (photobiomodulation, turmeric, etc), and their mechanism of action.
			</p>

			<h4>‚ùå Bad answers:</h4>
			<ul class="bad-answers">
				<li>
					 Not accurately explaining mechanisms of action in simple terms. If you can't explain it in simple terms, he likely doesn't understand it very well himself.
				</li>
				<li>
 					 Dismissive statements; generalizations about "alterative" or "complementary" treatments. Such statements betray ignorance about treatments with proven efficacy and known mechanisms of action.
				</li>
			</ul>

			<h4>"Can you provide an example of how you adapted a treatment plan based on new research findings in Parkinson's Disease?"</h4>

			<p>
				‚úÖ A good response <em>must</em> show a clear and recent example of a new treatment the provider employed for a patient, with clearly articulated evidence and rationale, and the results of having done that. 
			</p>
			
			<h4>Summary</h4>
				<p>
			These questions and expected answers help ensure that the doctor not only follows a comprehensive and current approach to diagnosing Parkinson‚Äôs Disease but also demonstrates critical thinking and a nuanced understanding of the disease. Doctors are people and are not immune to the irrational trappings of common mental errors.
				</p>
	
				<p>
						Seek a neurologist with the autonomy and openness to exploring novel, evidence-based treatments beyond the standard of care.
				</p>      
        </section>
        <section id="tips-for-selecting-providers">
                <h3>Tips for Selecting Providers</h3>
                <p>
                    Referrals can begin with your PCP, a neurologist, or functional medicine specialist. Where you start doesn't matter; the goal is to build a complete care team. 
                </p>
                <p>
                    Some doctors are subject to protocols or guidelines established by their institution's medical board or regulatory bodies, and this can influence their treatment decisions. Seek a neurologist with the autonomy and openness to exploring novel, evidence-based treatments beyond the standard of care.
                </p>
                <p>
                    Patient-centered care that is complete, addresses the root cause, is individualized, and evidence-based can predict the best results. Starting with a Functional and Integrative Medicine Specialist can be great. However, to avoid unqualified practitioners, it's essential to be well-informed.
                </p>
                <p>
                    During your initial consultation with the neurologist, clearly communicate your interest with optimizing total health to keep dopamine replacement to a minimum. Discuss specific treatments such as <a href="#hrt" title="hormone replacement therapy">HRT</a>, <a title="Photobiomodulation" href="#pbm">PBM</a>, and <a href="#5-htp">5-HTP</a>, and how they might interact with dopamine replacement. If the doctor cannot explain their benefits or potential interactions, consider finding another doctor.
                </p>
        
        
                <blockquote>
                    <p>
                        &ldquo;It is better to know some of the questions than all of the answers.&rdquo;
                    </p>
                    <cite>James Thurber</cite>
                </blockquote>
        
                <p>
                    Creating a care plan for Parkinson's requires specialized expertise. Those who approach this with seriousness and understanding can expect to achieve better quality of life and longevity.
                </p>
            </section>

    </section>
    <section id="treatment-approaches">
        <h2>Treatment Approaches</h2>
        <section id="treatment-approaches-overview">
            <h3>Overview</h3>
            <!-- p>
                This section lists treatments for which strategies can be developed by one's care team.
            </p -->
        
            <!-- p>
                The approach recommended herein is not the tired "listen to your doctor," but to get informed and build a team of healthcare professionals with multiple specialties with whom to collaborate on an individualized treatment plan. 
            </p -->
        
            <p>
                Treatment strategies can be grouped into <dfn>symptomatic</dfn>, <dfn>disease progression</dfn>, and <dfn>etiological</dfn>, and <dfn>holistic</dfn> categories, with some overlap.
            </p>
            <dl>
                <dt>Symptomatic Approach
                <dd>addresses symptoms rather than slowing or stopping their progression.
                
                <dt>Disease-Progression Approach
                <dd>manages progression of the disease once it has already developed
                
                <dt>Etiological Approach
                <dd>targets the underlying causes of disease with thorough investigation and research
                <dt>Holistic Approach
                <dd>patient-centered care that targets underlying causes and addresses them more comprehensively
                </dl>
        </section>
        <section id="symptomatic-approach">
            <h3>Symptomatic Approach</h3>
            <h5>Gold Standard: Dopamine Agonism</h5>
            <p class="call-out">
                The gold standard for managing PD is symptomatic management via dopamine agonism (<abbr title="Levodopa / Dopa-decarboxylase inhibitors">LD/DDC inhibitors</abbr>, MAO-B inhibitors, and <dfn title="catechol-O-methyltransferase">COMT</dfn> inhibitors). Unfortunately, that leads to other neurological imbalances, causes other nutrient deficiencies, and leads to PN.
            </p>
            <p>
                Maintaining dopamine levels in the brain helps alleviate motor problems and can reduce fibrillization. However, unilateral dopamine replacement therapy has has some problems.
            </p>
            <p>
                Some doctors may attempt to enhance dopamine function by suppressing the cholinergic system using anticholinergics, but this approach leads to adverse effects.
            </p>        
        </section>
        
        <section id="disease-progression-approach">
            <h4>Disease-Progression Approach</h4>
            <p>
                Doctors tend to discount the idea of slowing the progression of the disease. Some will off-handedly discount supplements and nutrition into "complementary" care without examination. Many of these same doctors once prescribed anticholinergics. (If your doctor is one of those, get a new doctor.)
            </p>
        </section>
        <section id="etiological-approach">
         <h3>Etiological Approach</h3>
         
        <p>
            Etiological treatments target the underlying causes of disease. These providers address the root causes with scientific rigor however, some may rely on conventional medicine and focus on the disease itself, rather than individual factors and health optimization.
        </p> 
        </section>
        
        <section id="holistic-approach">
            <h3>Holistic Approach</h3>
            
            <p>
                The holistic approach is patient-centered care that aims to address the underlying causes of disease and promote overall health. However, some holistic providers use implausible or disproven strategies (e.g. homeopathy, reiki, "mind, body, spirit", etc). 
            </p>
        </section>
    <!-- TODO: Move where??
            <h4>The Role of Nutrition</h4>
            <p>
                Nutritional deficiencies can exacerbate symptoms in individuals with PD and may sometimes be mistaken for progressive neurodegeneration. This misinterpretation can lead to inappropriate management strategies if the underlying nutritional issues are not addressed.
            </p>
            <p>
                Furthermore, certain nutrient deficiencies can trigger cascading effects, exacerbating PD symptoms or hasten the decline of the condition. For example, deficiencies in vitamins B12, folate, and vitamin D have been implicated in PD and can affect neurological function and overall health. Inadequate intake of essential nutrients can also impair mitochondrial function, increase oxidative stress, and compromise neurotransmitter synthesis and signaling, all of which are implicated in PD pathophysiology.
            </p>
            <p>
                Additionally, levodopa/carbidopa therapy can reduce vitamin B6 levels, which is essential for the synthesis of neurotransmitters.
            </p>
            <p>
                It's crucial to build a comprehensive plan that strikes a balance between supplementation, nutrition, lifestyle, and regular monitoring to slow disease progression.
            </p>
            <p>
                Don't just "talk to your doctor", collaborate with a team of healthcare professionals with multiple specialties to create individualized treatment plans that include nutrition, lifestyle, supplementation, and medication. Regularly test and monitor status with symptoms and biochemical markers to assess the effectiveness of interventions and make adjustments as needed.
            </p>
            <p>
                <dfn>Antifibrillogenics</dfn> mitigate formation of Œ±-synuclein fibrils. Anti-aggregants aim to prevent the accumulation of fibrils and other misfolded proteins into lewy bodies. By preventing the formation of Œ±-synuclein fibrils and aggregates, these compounds address the underlying pathology of Parkinson's disease at a more fundamental level, potentially offering therapeutic benefits in managing the condition.
            </p>
            <p>
                Preventing fibril aggregation (<dfn>anti-aggregant</dfn>): These treatments focus on inhibiting the aggregation of Œ±-synuclein fibrils into Lewy bodies, potentially slowing the spread of pathology and neurodegeneration.
            </p>
            <p>
                It is necessary to work with doctors who focus on what works. Focus on the facts and evidence, consider risk/reward, and work on total health. Avoid doctors who won't look at the evidence you present them.
            </p>
            
            <h4>What Do Doctors Miss?</h4>
            <p>
                Doctors typically prioritize symptoms over addressing the underlying causes. Specifically, they tend to focus on the dopamine pathway with medications like levodopa/carbidopa, to enhance dopamine levels in the brain, and COMT inhibitors, to inhibit its breakdown by catechol-O-methyltransferase (COMT).
            </p>
            <p>
                Approaches to mitigating the underlying cause can extend longevity, improve quality of life, and reduce the dependence on medication which is not without side effects. Address these key areas for a more comprehensive approach to managing PD. (For solutions, see: <a href="#problem-list">Problem List</a>)
            </p>
            <ul>
                <li class="senolytic">Senescence: Senolytics</li>
                <li class="mitochondrial">Mitochondrial health: Mitophagy and mitogenesis</li>
                <li class="neuroprotective">Neuroprotective measures</li>
                <li class="neuroinflammation">Anti-inflammatory: Reducing neuroinflammation</li>
                <li class="cytotoxicity">Reducing cytotoxicity</li>
                <li class="multiple-pathways">Addressing Dopaminergic, serotonergic, and GABAergic systems</li>
                <li class="fibrils">Preventing fibril formation and aggregation</li>
                <li class="sleep">Sleep management</li>
                <li class="total-health">
                    Overall health promotion
                </li>
            </ul>

            <p>
                Many approaches overlap more than one problem area and have synergistic benefits. For example, 5-HTP is converted into serotonin in the brain. It inhibits the release of glutamate, mitigates oxidation modulates dopamine
                release, improves mitochondrial function, and improves sleep, which improves overall health, leading to a better sense of well-being and better exercise capacity and recovery.
            </p>
            -->
		</section>

		<section id="etiological-problems">
            <h3>The Best Approach</h3>
            <p>
                The best possible individual results can be predicted by a comprehensive, evidence-based approach. Seek care that is etiologically-sound, evidence-based, patient-centered, integrated, and comprehensive. Exercise measured skepticism and examine the veracity of claims made by all healthcare providers.
            </p>

            <!-- TODO: Move to new peptides section? p>
                Peptide therapy, by practitioner in-home visits, can be used (SS-31, AICAR, Epitalon, Pinealon).
            </p -->
            
            <p>
                Here are some approaches to target underlying problem areas:
            </p>
            <dl id="problems-list">
                <dt class="antifibrillogenic">Antifibrillogenic</dt>
                <dd>Preventing fibril formation of Œ±-synuclein</dd>

                <dt class="anti-aggregant">Anti-aggregant</dt>
                <dd>Preventing aggregation of fibril and other junk</dd>

                <dt class="anti-ischemic">Anti-ischemic</dt>
                <dd>Promoting blood flow deep within the brain</dd>

                <dt class="senolytic">Senolytic</dt>
                <dd>Targeting senescent cells</dd>

                <dt class="mitochondrial">Mitochondrial</dt>
                <dd>Promoting mitochondrial health (mitogeneic, mitophagic)</dd>

                <dt class="sleep">Sleep</dt>
                <dd>Addressing insomnia</dd>

                <dt class="dopaminergic">Dopaminergic side-effects</dt>
                <dd>Mitigating side effects of dopaminergic treatments (e.g., dyskinesia, impulse control disorders)</dd>

                <dt class="neuroprotective">Neuroprotective</dt>
                <dd>Protecting neuronal structure and function</dd>

                <dt class="antioxidant">Antioxidant</dt>
                <dd>Reducing oxidative stress</dd>

                <dt class="anti-inflammatory">Anti-inflammatory</dt>
                <dd>Reducing inflammation</dd>

                <dt class="neurorestorative">Neurorestorative</dt>
                <dd>Promoting recovery and regeneration of neural tissue</dd>
            </dl>
            <!-- p>
                Supplements, peptides, therapies, drugs, and stem cells can mitigate &alpha;-synuclein overexpression, reduce mutant &alpha;-synuclein, strengthen the mitochondria, reduce the side effects of LD/dopa decarboxylase (DDC), decrease the need for LD/dopa decarboxylase, reduce ROS, improve mood, improve sleep, improve recovery.
            </p -->

        </section>
    <section id="treatment-plan">
        <h2>
           Treatment Starter Plan
        </h2>
        <p>
            The Treatment Starter Plan is a structured, customizable framework for self-directed management of Parkinson's Disease with a health-optimization mindset. 
        </p>
        <ol>
            <li>Adopt a mindset to maximize health.
            <li>Get <a href="#genetic-testing">genetic testing</a>.
            <li>Learn health (<a href="#introduction-to-health">basic overview</a>).
            <li>Learn <a href="#introduction-to-pd">Parkinson's Disease.</a>.
            <li>Learn about <a href="#food-and-supplements">supplements</a> and get started with the <a href="#how-to-build-a-supplement-plan">Supplement Starter Plan</a>.
            <li>Get a <a href="#pbm">Red Light Therapy</a> device and learn how to use it.
            <li>Look into <a href="#hormonal-interventions">Hormonal Interventions</a>.
            <li>Build a <a href="#care-team">Care Team</a>.
            <li>Develop an <a href="#physical-therapy-exercise">exercise</a> plan.
            <li>Consider early <a href="#dbs">Deep Brain Stimulation (DBS)</a> for longevity.
            <li>Look into cutting edge treatments like <a href="#gene-therapy">Gene Therapy</a>, <a href="#nad-injection">NAD+ Injections</a>, and <a href="#msc">Mesenchymal Stem Cells</a>. 
            <li>Rinse and repeat.
        </ol>
 
        <p>
            Your <a href="#care-team">care team</a> should be working for you and your care plan, not themselves. For this to be effective, you <em>must understand</em> your condition and the treatments <em><strong>very</strong> well</em>. 
        </p>
        <h4>Question assumptions</h4>
        <p>
            Don't trust experts or take things at face value. Question the methods used to reach conclusions, learn the underlying principles, and employ critical thinking to make informed decisions based on merit.
        </p>
        
        <p>
            Examine the framing or assumptions inherent in any question before attempting to answer it. Evaluating the underlying assumptions, biases, and implications embedded within the question itself. Question the question.
        </p>

        <p>
            Start by questioning the question. Carefully evaluate the risks and benefits of each step outlined above. What is missing, misleading, or wrong?
        </p>
    </section>
        
    <section id="treatments">
        <h2>Detailed Treatments</h2>
        <section id="medications">
            <h3>Medications</h3>
            
            <p class="call-out">
                Parkinson's disease is generally treated with symptomatic management. That includes:&mdash;
            </p>
            
            <ul>
                <li>Levodopa/Carbidopa (Dopamine Agonists)</li>
                <li>COMT Inhibitors</li>
                <li>MAO-B Inhibitors</li>
                <li>Anticholinergics ‚ùå WARNING: Take these only if you want cognitive impairment.</li>
            </ul>
            <p>
                Levodopa/Carbidopa are dopamine agonists. COMT inhibitors prevent the breakdown of dopamine. Both classes of drugs exhibit dopaminergic side-effects.
            </p>
            
            <section id="dopamine-agonists">
                <h4>Dopamine Replacement Therapy &mdash; Overview</h4>
            
                <p>
                    Dopamine replacement therapy (DRT) for PD commonly includes levodopa/carbidopa (LD/DDC) and MAO-B inhibitors. 
                </p>
                
                <p>
                    Replenishing dopamine levels in the brain helps alleviate motor symptoms such as tremors, rigidity, and bradykinesia (slowness, freezing), improving patients' quality of life. However, dopamine replacement therapy has other effects, good and bad.
                </p>
            
                <h4>Impact of Dopamine Agonists</h4>

                <h5>Fibrillization Inhibition</h5>
                <p>
                    Dopamine agonists inhibit fibrillization by reacting with the Œ±-synuclein. This is an advantage, as fibrils contribute to cellular damage, senescent cells, and neurodegeneration. 
                </p>

                <h5>Problems</h5>
                <p>
                    Dopamine's antifibrillogenic effects are good but its interaction with Œ±-synuclein also contributes to cellular damage and neurodegeneration.
                </p>
                <p>
                   Dopaminergic modulation must therefore be carefully balanced to achieve optimal neuroprotection. Better neuroprotection and healthspan can be achieved through the multi-faceted approach described in the <a href="#treatment-plan">Treatment Starter Plan</a>. 
                </p>

                <h5>Neurochemical and Vitamin Imbalances</h5>
                <p>
                    Dopamine agonists also deplete active vitamin B6 levels in the body. They do this by irreversibly binding to and permanently deactivating pyridoxal 5‚Äô-phosphate (P5P), the active form of vitamin B6. This leads to various side effects and exacerbates the progression of the disease, as B6 is essential for dopamine synthesis and is involved in other metabolic pathways.
                </p>

                <h5>Progressive Neurodegeneration</h5>
                <p>
                    Dopamine is but one of many neurochemical systems in the midbrain. Focusing solely on the dopaminergic system without considering other neurotransmitter systems leads to progressive neurodegeneration (PN) exacerbating motor and non-motor symptoms.
                </p>
                        
                <h4>Dopamine Replacement Therapy &mdash; Summary</h4>
                <p>
                    Therefore, while dopamine replacement is beneficial, its use can be minimized to the least effective dose with a multi-faceted approach that addresses neuroprotection, neurorestoration, antioxidation, and mitochondrial health.
                </p>
            </section>           
            <section id="comt-inhibitors">   
                <h4>COMT Inhibitors</h4>
                
                <p>
                	COMT inhibitors are a class of medications that prolong the effect of levodopa by inhibiting the breakdown of dopamine in the brain. They work by blocking the action of the enzyme catechol-O-methyltransferase (COMT), which breaks down catecholamines, including dopamine, norepinephrine, and epinephrine, resulting in sustained levels of these catecholamines.
                </p>
                <p>
                    Tolcapone, a COMT inhibitor, has been associated with a higher risk of liver damage, which can be severe in some cases.
                </p>
                <p>
                    Entacapone, another COMT inhibitor, has been linked to an increased risk of dyskinesias and other dopaminergic side effects.
                </p>
            </section>
            <section id="mao-b-inhibitors">
                 <h4>MAO-B Inhibitors</h4>
                 <p>
                    Problems with MAO-B Inhibitors, such as side effects, dietary restrictions, and potential interactions with other medications, have contributed to a decline in their use.
                 </p>
            </section>

            <section id="synuclean-d-and-minzasolmin">
                <h4>SynuClean-D and Minzasolmin üß™</h4>
                <p>
                SynuClean-D and Minzasolmin are in the research phase. There are outlets for research chemicals, and there are ongoing clinical trials.
                <p>
                    https://sciencebeta.com/synuclean-d-parkinsons/
                </p>
                <ol>
                    <li>
                        <h4>SynuClean-D Can Revert Neurodegeneration Caused By Parkinson's</h4>
                        <p>
                            SynuClean-D inhibits &alpha;-synuclein aggregation, disrupts amyloid fibrillization, prevents degeneration of dopaminergic neurons (<a href="https://pubmed.ncbi.nlm.nih.gov/30249646/"><abbr title="Proceedings of the National Academy of Sciences">reference</abbr></a>) and inhibits &alpha;-synuclein aggregation.
                        </p>
                        <p>
                            SynuClean-D is available as a research chemical. It is being studied in a Phase 2 clinical trial of 450 early-stage PD patients with an expected completion date in mid-2024.
                        </p>
                    </li>
                    <li>
                        <h4>Minzasolmin</h4>
                        <p>
                            Minzasolmin is a misfolding inhibitor, whereas SynuClean-D is an aggregation inhibitor. While Minzasolmin is in clinical development for Parkinson‚Äôs disease, SynuClean-D is primarily mentioned as a research compound.
                        </p>
                        <p>
                           Patients with Parkinson‚Äôs disease can apply to participate in clinical trials for Minzasolmin. The clinical trial information is available on ClinicalTrials.gov (ID: NCT04658186; EudraCT Number 2020-003265).
                        </p>
                    </li>
                </ol>
                <h4>Summary</h4>
                <p>
                    Minzasolmin and SynuClean-D both seem promising in inhibiting the misfolding and aggregation of &alpha;-synuclein aggregation respectively. Ask your team about clinical trials or apply to participate directly with those trials' clinicians.
                </p>
            </section>
        </section>
        <section id="hormonal-interventions">
            <h3>Hormonal Interventions</h3>
            <section id="hrt">
                <h4 class="neuroprotective">HRT &mdash; Estrogen and Testosterone</h4>
            
                <p>
                    Estrogen is neuroprotective and has had positive effects in animal models of PD, reducing dopaminergic neuron loss and improving motor function.
                </p>

                <p>
                    Estrogen can be used in women. Testosterone is also neuroprotective and converts partially to estradiol, so can be used in men.
                </p>
                <h4>HRT References</h4>
                <ol>
                    <li><a href="https://www.alzforum.org/news/research-news/estrogen-and-neuroprotection-matter-time"
                    >Estrogen and Neuroprotection: A Matter of Time?</a>
                    </li>
                    <li>
                        <a href="https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2011.00035/full">Male/female differences in neuroprotection and neuromodulation of brain dopamine</a>
                        </li>
                </ol>
            </section>
            <section id="pregnenolone">
                <h4>Pregnenolone</h4>
                <p>
                    Pregnenolone is a neurosteroid and precursor to various hormones, including cortisol, DHEA, and progesterone. Pregenolone reduces levodopa-induced dyskinesias (LIDs) without compromising L-DOPA's motor benefits.
                </p>
                <h5>Pregnenolone Dosage</h5>
                <p>
                    Pregnenolone is available as a dietary supplement and typically safe in doses ranging from 10 to 50 mg per day.
                </p>
                <p>
                    Pregnenolone is fat-soluble and crosses the BBB. Once in the brain, pregnenolone can be converted into other neurosteroids, such as allopregnanolone, which have various effects on neuronal function and behavior.
                </p>                
                <p>
                    Several clinical studies have investigated pregnenolone as a treatment for Parkinson‚Äôs disease. One study found that pregnenolone dose-dependently countered L-DOPA-induced dyskinesias (LIDs) without affecting L-DOPA-induced motor improvements. 
                </p>
                <ol>
                    <li>
                        <p>
                            A study found that DHEA administration alone improved the mean parkinsonian score in moderately and severely impaired MPTP monkeys, a model of Parkinson‚Äôs disease. 
                            <a href="https://www.sciencedirect.com/science/article/pii/S0014488623000547"
                            >Pregnenolone for the treatment of L-DOPA-induced dyskinesia in Parkinson's disease</a>
                        </p>
                    </li>
                </ol>
            </section>
            <section id="dhea">
                <h5 class="neuroprotective">Dehydroepiandrosterone (DHEA)</h5>
                <p>
                    Dehydroepiandrosterone (DHEA) is a hormone produced by the adrenal glands, the ovaries, and the brain. It is a precursor to both estrogen and testosterone and is converted into estrogen and testosterone in peripheral tissues.
                </p>
                <p>
                    DHEA is also involved in the regulation of sleep, memory, and cholesterol levels.
                </p>
                <p>
                    DHEA is neuroprotective effects, which may help protect against the progression of PD. This is due to its ability to modulate memory formation, regulate neuronal activity, and enhance or restore memory and learning processes.
                </p>
                <p>Like pregnenolone, DHEA is lipid-soluble, which allows it to cross the BBB relatively easily, and is available as a dietary supplement. Recommended dosage is 100mg ED.
                </p>
                <ol>
                    <li>
                        <p>
                            A study found that DHEA administration alone improved the mean parkinsonian score in moderately and severely impaired MPTP monkeys, a model of Parkinson‚Äôs disease. 
                            <a href="https://www.sciencedirect.com/science/article/abs/pii/S0197458005003003"
                            >DHEA improves symptomatic treatment of moderately and severely impaired MPTP monkeys</a>
                        </p>
                    </li>
                </ol>
            </section>
        </section>
        <section id="dbs" class="neuroprotective">
            <h3>Deep Brain Stimulation (DBS)</h3>
            <p>
                Deep Brain Stimulation (DBS) uses electrodes implanted in the brain to deliver electrical impulses to the globus pallidus internus (GPi). This helps to regulate brain activity.
            </p>
            
            <h4>LRRK2-G2019S and DBS</h4>
            <p>
                LRRK2-G2019S mutations, especially, tend to have relatively good outcomes with DBS compared to other genetic types. 
            </p>
            
            <p>
                DBS of the (GPi) primarily targets the GABAergic output neurons of the basal ganglia, influencing motor output and reducing motor symptoms in PD. However, the therapeutic effects of GPi stimulation in PD extend beyond
                modulating GABAergic transmission within the basal ganglia circuitry and can indirectly impact cortical glutamatergic input to the basal ganglia.
            </p>
            <p>
                While GPi stimulation primarily targets the GABAergic output of the basal ganglia, the dopaminergic system remains crucial in PD pathology and treatment. Dopamine depletion in the basal ganglia is a hallmark feature of
                PD and leads to motor symptoms such as bradykinesia, tremors, and rigidity, and DBS helps treat these problems.
            </p>
            <p>
                Other neurotransmitter systems affected by DBS include the serotonergic, cholinergic, noradrenergic, and glutamatergic systems. Due to the delicate balance between all these systems stimulation of the entire GPi can more
                easily achieve a positive, balanced effect, compared to medication and supplementation with l-dopa/carbidopa and supplements like 5-HTP and GABA.
            </p>
            <p>
                This normalizes basal ganglion activity resulting in reduced excitotoxicity, better neuronal function, and greater cell longevity.
            </p>
            <p>
                Medication alone leads to PN. DBS reduces the need for medication, thus mitigating PN. Supplementation further reduces the need for medication, and thus PN. A team of specialists to craft a program with DBS, medication,
                and supplementation may offer the best possible outcome with the least PN and greater longevity.
            </p>
            <p>
                Crafting a personalized treatment program that incorporates DBS, medication, and supplementation requires the expertise of a multidisciplinary team of specialists, including neurologists, movement disorder specialists,
                neurosurgeons, pharmacists, dietitians, and other healthcare professionals. This team can collaborate to tailor treatment to the individual patient's needs, optimize therapy, and minimize PN.
            </p>
        </section>
        
        <section id="gene-therapy">
            <h3>Gene Therapy</h3>

            
            <p>
                Gene therapy is designed to repair the dopamine system. The procedure involves injecting a gene into the brain.
            </p>
            
            <h3>Cell Therapies</h3>
            <p>
                <dfn>Cell replacement</dfn> is injection of dopamine cells into the brain to replace those that are lost or dying. 
            </p>
            <ol class="reference-list">
                    <li>
                        <a href="https://www.parkinson.org/blog/research/gene-cell-based-therapies"
                        title="Exploring the Potential of Gene and Cell-Based Therapies in Parkinson‚Äôs"
                        target="_blank"
                        >Exploring the Potential of Gene and Cell-Based Therapies in Parkinson‚Äôs
</a>
                        <p>
                        
                        </p>
                    </li>
                </ol>
        </section>
            <section id="stem-cell">
                <h4 class="neuroprotective neurorestorative">Stem Cells (MSC, iPSC)</h4>
                <h5>Mesenchymal Stem Cells (MSCs)</h5>
                <p>
                    Systemic injection of mesenchymal stem cells therapy helps restore dopaminergic neurons. <cite class="reflink">[<a 
             href="#h-j-park">h-j-park</a>]</cite>
                </p>
                
                <p>
                	The concomitant use of cell therapy and photobiomodulation therapy can improve the symptoms of PD. <cite class="reflink">[<a 
             href="#b-ahrabi">b-ahrabi</a>]</cite>
                </p>
                
                <h5>Induced pluripotent stem cell (iPSCs)</h5>
                <p>
                	Induced pluripotent stem cells (iPSCs) are generated by reprogramming adult somatic cells, such as skin or blood cells, to express the same genes as embryonic stem cells in a process is called <dfn>induced pluripotency</dfn>.
               </p>
               <p> 	
                	 iPSCs have the ability to differentiate into any cell type in the body, similar to embryonic stem cells, but they are generated from adult cells, which makes them a promising source for regenerative medicine and tissue engineering. intracerebrally injected to the striatum and substantia nigra of PD patients.
                	
                </p>
                <h5>Mesenchymal Stem Cells References:</h5>
                <ol class="reference-list">
                    <li id="w-chen">
                    	 <a href="https://pubmed.ncbi.nlm.nih.gov/30346716/"
                    	 title="Progress in Dopaminergic Cell Replacement and Regenerative Strategies for Parkinson's Disease"
                    	 target="_blank">Progress in Dopaminergic Cell Replacement and Regenerative Strategies for Parkinson's Disease</a>
                        <p>
                        	"Stable cell sources, such as Embryonic stem cells (ESCs) and induced pluripotent stem cell (iPSCs), are far more suitable for clinical application than hfVM- and embryonic or fetal brain-derived NSCs."
                        </p>
                    </li>
                    <li id="h-j-park">
    Mesenchymal stem cells therapy exerts neuroprotection in a progressive animal model of Parkinson's disease
                     <a href="https://pubmed.ncbi.nlm.nih.gov/18665911/"
                     title="Mesenchymal Stem Cells as a Source of Dopaminergic Neurons: A Potential Cell Based Therapy for Parkinson's Disease"
                     >Mesenchymal Stem Cells as a Source of Dopaminergic Neurons: A Potential Cell Based Therapy for Parkinson's Disease</a>, Hyun Jung Park, et al.
                     </li>
                     
                    <li id="b-ahrabi">
						<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9841383/"
						title="Photobiomodulation Therapy and Cell Therapy Improved Parkinson‚Äôs Diseases by Neuro-regeneration and Tremor Inhibition"
						target="_blank"
						>Photobiomodulation Therapy and Cell Therapy Improved Parkinson‚Äôs Diseases by Neuro-regeneration and Tremor Inhibition</a>, Behnaz Ahrabi, et al.
						<p>
							This review study showed concomitant use of cell therapy and photobiomodulation therapy can improve the symptoms of PD.
						</p>
                	</li>
                 </ol>
                <!-- p>
                    Senolytics can be used to induce the death of senescent cells.
                </p -->
            </section>
        <section id="physical-therapy-exercise">
            <h3>
                Physical Therapy / Exercise
            </h3>
            <p>
                Exercise has many positive impacts on general health. In PD, exercise improves motor and non-motor symptoms.
            </p>
            <p>
                Exercise increases brain-derived neurotrophic factor (BDNF) and autophagy (recycling of senescent cells), downregulates proinflammatory cytokines, and lowers blood sugar.
            </p>
            
            <h4>Mitochondrial Benefits</h4>
            <p>
                Regular, frequent exercise has been shown to upregulate NAD+ biosynthesis pathways and increase cellular NAD+ levels. Exercise-induced activation of cellular signaling pathways, such as AMP-activated protein kinase (AMPK) and sirtuins, stimulates mitochondrial biogenesis and enhances mitochondrial function in neuronal cells. Additionally, exercise promotes mitochondrial turnover and quality control mechanisms, such as mitophagy, which help maintain a healthy mitochondrial pool.
            </p>
        </section>
        <section id="pbm">
            <h3 class="neuroprotective">Photobiomodulation (PBM)</h3>
            <p>
                Photobiomodulation (PBM) is a non-invasive, low-risk treatment for PD.
            </p>
            <ul>
                <li>Enhances mitochondrial function and ATP production</li>
                <li>Increases expression of neurotrophic factors, such as brain-derived neurotrophic factor (BDNF)</li>
                <li>Reduces oxidative stress and inflammation</li>
                <li>Promotes neuroprotection and neuroregeneration</li>
                <li>Improves cognitive function in PD patients 
                <cite class="reflink">[<a href="#amir-nizamutdinov">amir-nizamutdinov</a>]</cite></li>
                <li>Improves sleep <cite class="reflink">[<a href="#jiexiu-zhao">jiexiu-zhao</a>]</cite></li>

            </ul>
            
            <h4>Oxidative Stress and Inflammation</h4>
            <p>
                PBM has anti-inflammatory effects, which can help mitigate the inflammatory response associated with ischemic injury, reducing tissue damage and promoting healing.
            </p>
            
            <h4>Ischemia and Blood Flow</h4>
            <p>
                PBM has been shown to increase local blood flow and oxygenation in ischemic tissues, which can help alleviate hypoxia (low oxygen levels) and promote tissue recovery.
            </p>
            
            <p>
                Ischemia can affect the delivery of therapeutic agents to the desired target in the midbrain. During ischemic events, blood flow to affected brain regions can be significantly compromised, limiting the delivery of oxygen and nutrients, and therapeutic compounds like melatonin.
            </p>
                
            <h4>Timing</h4>
            <p>
                The timing of PBM, in conjunction with the administration of substances like melatonin, can play a role in potentially mitigating the effects of ischemic inhibition on nutrient delivery to the midbrain.
            </p>
            
            <p>
            	Whole body irradiation with red light improves sleep quality. Used before sleep may offer better sleep effects. <cite class="reflink">[<a href="#jiexiu-zhao">jiexiu-zhao</a>]</cite>
            </p>

            <p>
            	Red light reaches the motor cortex, influences stem cell function, offers neuroprotection, restores functional activity, improves motor behaviours and reduces clinical signs, reduces gliosis and induces expression of trophic growth factors. 
            	<cite class="reflink">[<a href="#c-hamilton">c-hamilton</a>]</cite>
            </p>
            
            <h4>Red Light on the Body</h4>
            <p>
                Parkinson‚Äôs disease kidney impairment happens from the start but becomes more of a problem during later stages of the disease. Start early; don't wait.
            </p>
			<p>
				Red light improves renal function by improving renal blood flow and improving cell signalling in that area. PD impairs kidney function through &alpha;-synuclein aggregation accumulation and inflammation, autonomic nervous system (ANS) dysfunction, and dopamine depletion (dopamine influences renal blood flow, blood pressure, and kidney function.)
			</p>
			
            <h4>Near-Infrared (NIR) vs Red Light Therapy</h4>

            <p>
                Near-infrared (NIR) light has a deeper penetration depth than red light, allowing it to reach deeper tissues and organs, including the brain, without overstimulating the skin. <cite class="reflink">[<a href="#t-a-henderson">t-a-henderson</a>]</cite>
            </p>

            <p>
                Red light can be effective, too, but the longer duration and stronger intensity required for efficacy may overstimulate skin. Homme LED devices that allow blending NIR and red frequencies should use lower intensity for the red frequencies to avoid burning or overstimulating the skin. This strategy can take advantage of their dermal benefits without damaging the skin while getting more intense NIR for the deep regions of the brain.
            </p>
            <p>
             Despite the large body of experimental and early clinical evidence, there is still much resistance to the use of photobiomodulation by patients and health professionals.
            </p>
            
            <h4>Photobiomodulation References</h4>
            <ol class="reference-list">
                
                <li id="jiexiu-zhao">
                    <a href="https://pubmed.ncbi.nlm.nih.gov/23182016/"
                    title="Red light and the sleep quality and endurance performance of Chinese female basketball players
"
                    target="_blank"
                    >Red light and the sleep quality and endurance performance of Chinese female basketball players</a>, Jiexiu Zhao 
                    <p>
                        Our study confirmed the effectiveness of body irradiation with red light in improving the quality of sleep of elite female basketball players and offered a nonpharmacologic and noninvasive therapy to prevent sleep disorders after training.
                    </p>
                </li>
                
                <li id="michael-r-hamblin"> 
                    <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10581558/"
                    title="Transcranial photobiomodulation for the brain: a wide range of clinical applications"
                    target="_blank"
                    >Transcranial photobiomodulation for the brain: a wide range of clinical applications</a>, Michael R. Hamblin.
                    <p>
                        This review discussed the highly effective use of PBMT in treating Alzheimer‚Äôs and Parkinson‚Äôs disease models as well as the mechanisms that affect the mitochondria.
                    </p>
                </li>
                
                <li id="damir-nizamutdinov"> 
                    <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8219492/"
                    title="Transcranial Near Infrared Light Stimulations Improve Cognition in Patients with Dementia"
                    target="_blank"
                    >Transcranial Near Infrared Light Stimulations Improve Cognition in Patients with Dementia</a>, Damir Nizamutdinov, et al.
                    <p>
                        This placebo controlled, randomized, double-blinded human study examined 6 min, twice daily eight weeks transcranial near-infrared (tNIR) light NIR light with wavelength of 1060-1080nm and 15,000mW, irradiance or power density= 23.1mW/cm2, ~650cm2 per treatment area compared with a sham placebo.
                    </p>

                    <p>
                        The study group showed significant improvements of cognitive functions in several tests and showed less anxiety, improved mood, energy, and positive daily routine after ~14-21 days of treatment. 
                    </p>
                    <p>
                        Patients with sham treatment did not demonstrate significant changes
                    </p>
                </li>
                
                <li id="t-a-henderson"> 
					<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4552256/"
					title="Near-infrared photonic energy penetration: can infrared phototherapy effectively reach the human brain?"
					target="_blank"
					>Near-infrared photonic energy penetration: can infrared phototherapy effectively reach the human brain?</a>, Theodore A Henderson, Larry D Morries
					<p>
						Showed that higher wattage NIR lasers can deliver therapeutic effects to greater depths of the brain without tissue heating or damage. 
					</p>
				</li>
                    
                <li id="c-hamilton">
                    <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128061/"
                    title="Exploring the use of transcranial photobiomodulation in Parkinson's disease patients"
                    target="_blank"
                    >Exploring the use of transcranial photobiomodulation in Parkinson's disease patients</a>, Catherine Hamilton, et al.
                    <p>
                        This study found photobiomodulation reaches the motor cortex, influences stem cell function, offers neuroprotection, restores functional activity, improves motor behaviours and reduces clinical signs, reduces gliosis and induces expression of trophic growth factors.
                    </p>
                </li>

                <li id="a-liebert">
                    <a href="https://pubmed.ncbi.nlm.nih.gov/34215216/">Improvements in clinical signs of Parkinson's disease using photobiomodulation: a prospective proof-of-concept study</a>, Ann Liebert, et al.
                    
                    <p>
                    	This small study showed <abbr title="photobiomodulation">PBM</abbr> was safe and effective for symptoms of PD including mobility, cognition, dynamic balance and fine motor skill. Improvements were maintained for as long as treatment continued, for up to one year
                    </p>
                </li>
            </ol>
        </section>
        
		<section id="how-to-build-a-supplement-plan">
			<h3>How to Build a Supplement Plan</h3>
		
			<p>
				This general-purpose solution serves as a customizable starting point to address health with PD from multiple angles, targeting each of the underlying <a href="#etiological-problems">Etiological Problems</a>.
			</p>
			
			<h4>Mixing and Storing Powders</h4>
			
			<p>The mixed powders "Mitochondrial Mix", "Cacao Mix", and "Post-Workout" powders must be made in batches and should be stored in a cool, dry place with a desiccant pack (like silica gel) inside the powder to prevent clumping and contamination (mold). Silica packs are commonly shipped with the raw powders and supplements and can be reused.
			</p>
			
			<h4>Weighing and Mixing Powders</h4>
			<p>
				A sturdy gram scale or reliable, accurate food scale that measures to the nearest 0.01g (10mg) is necessary to ensure accuracy. To help ensure proper ingredient dispersal, mix the smaller ingredients first and blend in the larger ingredients.
			</p>
			
			
			<h4>Daily Supplements (3x daily)</h4>
			<ol>
				 <li>Ubiquinol &mdash; 300mg 
				 <li>PQQ &mdash; 30mg
				 <li>CDP Choline &mdash; 1000mg 
				 <li>Active B Complex (Integrative Therapeutics)
				 <li>Nattokinase &mdash; 100mg
				 <li>Vitamin K2 &mdash; 500mcg
			</ol>

			<h4 id="mitochondrial-powder">Mitochondrial Mix Powder &mdash; 10 Days</h4>
			<p>
				This 10-day serving can be taken 2x daily; once with the morning supplements; once later.
			</p>
			<ol>
				<li>Uridine Monophosphate &mdash; 5g
				<li>Coffeeberry extract &mdash; 2.5g
				<li>NMN &mdash; 10g
				<li>NR &mdash; 5g
				<li>Niacin &mdash; 2g
				<li>Lion's Mane &mdash; 10g
				<li>Cordyceps &mdash; 10g
				<li>Matcha (ceremonial grade) &mdash; 7g
				<li>Micronized Creatine Monohydrate (CreaPure¬Æ) &mdash; 30g
				<li>Inulin &mdash; &mdash; 30g
				<li>Base: Organic Greens Powder &mdash; 50g
				<li>Base: Organic Fruits Powder &mdash; 50g (e.g. "Navitas Superfood+ Immunity Blend")
			</ol>

			<h4>Cacao Mix Powder &mdash; 10 Days</h4>
			<p>
				This ~10-day serving can be taken in hot water 1-2x daily, earlier in the day. Add coconut oil and organic ginger juice</p>
			
			<p>Do not cook it; add to below-boiling temperature water.
			</p>
			<ol>
				<li>Niacin &mdash; 1g
				<li>Turmeric &mdash; 5g
				<li>Matcha &mdash; 7g
				<li>Lion's Mane &mdash;10g
				<li>Cordyceps &mdash; 10g
				<li>Ceylon cinnamon &mdash; 12g
				<li>Raw Cacao &mdash; 100g
			</ol>

			<h4>Post-Workout Mixed Powder &mdash; 10 Days</h4>
			<p>This can be pre-mixed and stored in the refrigerator</p>
			<p>Mix in water with Organic Ginger Juice before drinking.</p>
			<ol>
				<li>NMN &mdash; 5g
				<li>NR &mdash; 2.5g
				<li>Niacin &mdash; 1g
				<li>Beta Alanine &mdash; 10g
				<li>HMB &mdash; 10g
				<li>Rhodiola Rosea &mdash; 2.5g
				<li>Sodium Bicarbonate &mdash; 5g
				<li>Turmeric &mdash; 7g
				<li>TMG (Betaine) &mdash; 10g
				<li>Natto powder &mdash; 5g
				<li>Lion's Mane &mdash; 10g
				<li>Inulin &mdash; 30g
				<li>Ceylon cinnamon &mdash; 12g
				<li>Micronized Creatine Monohydrate (CreaPure¬Æ) &mdash; 30g
				<li>BCAA 4:1:1 &mdash; 40g
				<li>L-Glutamine &mdash; 50g
				<li>Base: Organic Greens Powder &mdash; 50g
				<li>Organic Fruits Powder &mdash; 50g (e.g. "Navitas Superfood+ Immunity Blend")
				<li>Collagen peptides &mdash; 50g
				<li>Whey protein isolate &mdash; 300g
			</ol>

			<h4>Dinner Supplements üçΩÔ∏è</h4>
			<p>
			Fat-soluble substances are better absorbed when taken with dietary fats.
			</p>
			<ol>
				 <li>Mixed Tocopherols/Tocotrienols
				 <li>K2 &mdash; 500mcg
				 <li>D3 &mdash; 4000 IU
				 <li>Urolithin-A 1000mg
				 <li>Resveratrol &mdash; 500mg
				 <li>Fisetin &mdash;¬†500mg
				 <li>Sulforaphane &mdash; 50mg
				 <li>Quercetin &mdash; 500mg
				 <li>NAC &mdash; 100mg üí§
				 <li>Geranyl geraniol &mdash; 500mg
			</ol>

			<h4>Dinner Foods</h4>
			<ol>
				<li>Natto powder &mdash; 2g
				<li>Turmeric &mdash; 1.5g
				<li>Saffron &mdash; 30mg
				<li>DHA:EPA 2:1 &mdash; 5000mg (Nordic Naturals Children's DHA)
				<li>Free Range Eggs &mdash; ~2-5
			</ol>

			<h4>Sleep Supplements (7:00pm - 9:00pm) üí§</h4>
			<ol>
				 <li>Melatonin (Sleep3) &mdash; 10mg
				 <li>5-HTP &mdash; 100mg
				 <li>GABA &mdash; 1000mg &mdash; 2000mg
				 <li>Magnesium Threonate &mdash; 300mg
				 <li>Chelated Magnesium &mdash; 300mg
			</ol>
			
		</section>
        <section id="food-and-supplements">
            <h3>
                Foods and Supplements
            </h3>
			<p>
				Supplements can fight the progression of PD by addressing the <a href="#problems-list">mechanisms of various problems</a>.
			</p>
			<p>
				I have first-hand experience taking most of these supplements.
			</p>
			<p>
				The supplements are presented with an overview following the legend below.
			</p>

            <h4>The Role of Nutrition</h4>
            <p>
                Nutritional deficiencies can exacerbate symptoms in individuals with PD and may sometimes be mistaken for progressive neurodegeneration. This misinterpretation can lead to inappropriate management strategies if the underlying nutritional issues are not addressed.
            </p>
            <p>
                Furthermore, certain nutrient deficiencies can trigger cascading effects, exacerbating PD symptoms or hastening PN. For example, deficiencies in vitamins B12, folate, and vitamin D have been implicated in PD and can affect neurological function and overall health. Inadequate intake of essential nutrients can also impair mitochondrial function, increase oxidative stress, and compromise neurotransmitter synthesis and signaling, all of which are implicated in PD pathophysiology.
            </p>
            
            <p>
                Additionally, LD/DDC therapy can reduce vitamin B6 levels, which is essential for the synthesis of neurotransmitters.
            </p>

            <p>
                Don't just "talk to your doctor", your <a href="#care-team">multi-specialist team</a> must all work together on your individualized treatment plan that includes nutrition, lifestyle, supplementation, and medication. Regularly test and monitor status with symptoms and biochemical markers to assess the effectiveness of interventions and make adjustments as needed.
            </p>
            
            <p>
                <dfn>Antifibrillogenics</dfn> mitigate formation of Œ±-synuclein fibrils. Anti-aggregants aim to prevent the accumulation of fibrils and other misfolded proteins into lewy bodies. By preventing the formation of Œ±-synuclein fibrils and aggregates, these compounds address the underlying pathology of Parkinson's disease at a more fundamental level, potentially offering therapeutic benefits in managing the condition.
            </p>
            <p>
                Preventing fibril aggregation (<dfn>anti-aggregant</dfn>): These treatments focus on inhibiting the aggregation of Œ±-synuclein fibrils into Lewy bodies, potentially slowing the spread of pathology and neurodegeneration.
            </p>
            <p>
                It is necessary to work with doctors who focus on what works. Focus on the facts and evidence, consider risk/reward, and work on total health. Avoid doctors who won't look at the evidence you present them.
            </p>
			
            <section id="treatment-legend">
                <h3>Treatment Legend:</h3>
                <h3>Supplement Name</h3>
                <ul class="treatment-rating">
                    <li>Mechanisms: See <a href="#problems-list">"mechanisms"</a> list.
                    <li>Dose: [dose]  (üçΩÔ∏è &mdash; with food;&emsp;üí§ &mdash; at night)
                    <li>Fat-soluble: [‚úÖ | ‚ùå]
                    <li>ü©∏üß†BBB: Crosses blood-brain barrier [‚úÖ | ‚ùå]
                    <li>Safety: [1-10]/10 ([safety confidence]% œÉ)
                    <li>Efficacy: [1-10]/10 ([efficacy confidence ]% œÉ)
                </ul>
                <ul id="legend-legend">
                    <li>ED &mdash; Daily
                    <li>BID &mdash; Twice Daily
                    <li>œÉ &mdash; confidence level, 0&ndash;100%
                </ul>
            </section>
            <p>
                Eggs are a source of omega-3 fatty acids, choline, lutein, zeaxanthin, vitamin E, beta carotene, vitamin A, and selenium. Pasture-raised eggs contain more bioactive compounds and less saturated fat and cholesterol.
            </p>
            <p>
                Many plants contain phytochemicals that can improve conditions and inhibit the progression of PD.
            </p>
            <p>
                <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6433754/">
                    Plant Extracts and Phytochemicals Targeting &alpha;-Synuclein Aggregation in Parkinson's Disease Models
                </a>
            </p>
            <section id="glynac">
                <h4>GlyNAC (Glycine-N-Acetyl Cysteine)</h4>
                <ul>
                    <li>Mechanisms: Antioxidant, Anti-inflammatory, Mitochondrial
                    <li>Dose: 3g per day üí§
                    <li>Fat-soluble: ‚ùå
                    <li>ü©∏üß† BBB: ‚úÖ
                    <li>Safety: 9/10 (90% œÉ)
                    <li>Efficacy rating: 5/10 (70% œÉ)
                </ul>
                <p>
                    GlyNAC improves glutathione levels, improves mitochondrial function, reduces inflammation, supports neurotrophic factor expression, and improves cognitive function.
                </p>

                <h4>Supplementation</h4>
                <p>
                     GlyNAC supplementation up to 7.2g per day is safe and well tolerated in older adults. GlyNAC is best taken at night.
                </p>
                
                <p>
                    GlyNAC improves sleep quality. The half-life of NAC in the body is about 6 hours, and the half-life of glycine is anywhere from 25-250 minutes, so taking it at night allows for optimal utilization of the amino acids.
                </p>
                
                <h4>Side Effects</h4>
                <p>
                    N-Acetyl Cysteine (NAC) can cause next-day lethargy. If you experience this, reduce the dose, take it earlier in the evening, and sleep earlier.
                </p>
                <h4>References</h4>
                <ol>
                
                <li>
                      <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9261343/"
                      title="A Randomized Controlled Clinical Trial in Healthy Older Adults to Determine Efficacy of Glycine and N-Acetylcysteine Supplementation on Glutathione Redox Status and Oxidative Damage"
                        target="_blank"></a>
                        <p>
                            This double-blind RCT investigated supplementation with glycine and n-acetylcysteine (GlyNAC) at three different daily doses for 2 weeks (low dose: 2.4 g, medium dose: 4.8 g, or high dose: 7.2 g/day, 1:1 ratio) in a randomized, controlled clinical trial in 114 healthy volunteers.
                        </p>
                    </li>
                    
                    <li>
                        <a href="https://pubmed.ncbi.nlm.nih.gov/33783984/"
                          title="Glycine and N-acetylcysteine (GlyNAC) supplementation in older adults improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, insulin resistance, endothelial dysfunction, genotoxicity, muscle strength, and cognition: Results of a pilot clinical trial"
                          target="_blank"
                          >Glycine and N-Acetylcysteine in Older Adults</a>
                          <p>
                              This clinical trial showed GlyNAC improves glutathione levels, mitochondrial function, and insulin sensitivity while reducing oxidative stress and inflammation.
                          </p>
                      </li>
                  
                      <li>
                          <a href="https://www.mdpi.com/2076-3921/12/5/1042"
                          title="GlyNAC (Glycine and N-Acetylcysteine) Supplementation in Old Mice Improves Brain Glutathione Deficiency, Oxidative Stress, Glucose Uptake, Mitochondrial Dysfunction, Genomic Damage, Inflammation and Neurotrophic Factors to Reverse Age-Associated Cognitive Decline: Implications for Improving Brain Health in Aging"
                          target="_blank">GlyNAC: a simple and effective nutritional supplement for brain health and cognitive function</a>
                      <p>
                        This placebo-controlled rodent study showed that <q>GlyNAC supplementation improves age-associated cognitive decline and supports brain health in aging by improving/correcting brain GSH deficiency, elevated OxS, mitochondrial dysfunction, abnormal mitophagy and autophagy, inflammation, impaired glucose transport/uptake, elevated genomic damage, and reversing the decline in brain neurotrophic growth factors.</q>
                      </p>
                      </li>
                  <li>
                      <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10215265/">GlyNAC (Glycine and N-Acetylcysteine) Supplementation in Old Mice Improves Brain Glutathione Deficiency, Oxidative Stress, Glucose Uptake, Mitochondrial Dysfunction, Genomic Damage, Inflammation and Neurotrophic Factors to Reverse Age-Associated Cognitive Decline: Implications for Improving Brain Health in Aging</a>
                      <p>
                          This rodent study demonstrated improved age-associated cognitive decline (ACD) with GlyNAC.
                      </p>
                  </li>
                </ol>
            </section>
            <section id="creatine">
                <h4>Creatine Monohydrate</h4>
                <ul>
                    <li>Mechanisms: Neuroprotective, Antioxidant
                    <li>Dose: 5g ED
                    <li>Fat-soluble: ‚ùå
                    <li>ü©∏üß† BBB: ‚úÖ
                    <li>Safety: 9/10 (90% œÉ)
                    <li>Efficacy: 5/10 (50% œÉ)
                </ul>
                <p>
                    Creatine has been studied extensively in PD and shown to not slow the disease. So why is it recommended here? 
                </p>
                
                <p>
                	Neuroprotective impacts of creatine and of creatine + CoQ10 were decreased in PD patients with cognitive decline. <cite class="reflink">[<a href="#hyukki-chang">hyukki-chang</a>]</cite>
                </p>
                <h4>Creatine + Exercise</h4>
                <p>
                    Creatine is recommended as an adjuvant therapy with an exercise program to maximize overall effectiveness. Creatine has well-established benefits on muscular strength, exercise recovery, mitochondrial function, and anti-oxidant effects. Exercise plays a fundamental role in health optimization. <cite class="reflink">[<a href="#hyukki-chang">hyukki-chang</a>]</cite>
                </p>

                <p>
                    Creatine increases mitochondrial ATP production, provides antioxidant effects, and reduces oxidative stress and mitochondrial damage. Its neuroprotective properties have been demonstrated to protect against neuronal damage and prevent cell death. <cite class="reflink">[<a href="#c-rae">c-rae</a></cite>, <cite class="reflink"><a href="#a-c-passaquin">a-c-passaquin</a></cite>,  <cite class="reflink"><a href="#hamid-arazi">hamid-arazi</a>]</cite>
                </p>
                
                <h4>Supplementation</h4>
                
                <p>
                Taking creatine with food improves absorption. Eating increases the production of insulin-like growth factor-1 (IGF-1), which helps facilitate creatine uptake.
                </p>
                 
                <h4>Safety and Efficacy</h4>
                <p>
                    Creatine is commonly used with minimal adverse effects reported in clinical studies.
                </p>
                <p>
                    Creatine supplementation alone may not significantly slow the progression of Parkinson's disease, especially not in the later stages. But its neuroprotective and antioxidant effects contribute to overall disease management when used as part of a comprehensive treatment approach, particularly in combination with exercise, to stave off disease progression in the early stages of the disease. Because creatine helps with exercise recovery, its use allows for more frequent training to enjoy the benefits of exercise.
                </p>
                <ol class="reference-list">
                    <li id="c-rae">
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1691485/"  title="Oral creatine monohydrate supplementation improves brain performance: a double-blind, placebo-controlled, cross-over trial."
                        target="_blank"
                        >Oral creatine monohydrate supplementation improves brain performance: a double-blind, placebo-controlled, cross-over trial</a>, Caroline Rae, et al
                        <p>
                            Creatine supplementation had a significant positive effect on both working memory (backward digit span) and intelligence (Raven's Advanced Progressive Matrices), both tasks that require speed of processing. 
                        </p>
                    </li>

                    <li id="hyukki-chang">
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10844727/" title="The potential role of creatine supplementation in neurodegenerative diseases"
                        target="_blank"
                        >The potential role of creatine supplementation in neurodegenerative diseases</a>, Hyukki Chang, et al.
                        <p>
                            This review study concluded creatine supplementation had neuroprotective effects in animal models and in vitro studies of certain neurodegenerative diseases, but that clinical trials failed to reproduce favorable outcomes.
                        </p>
                    </li>
                    <li id="a-c-passaquin">
                        <a href="https://www.sciencedirect.com/science/article/abs/pii/S0960896601002735" title="Creatine supplementation reduces skeletal muscle degeneration and enhances mitochondrial function in mdx mice"
                        target="_blank"
                        >Creatine supplementation reduces skeletal muscle degeneration and enhances mitochondrial function in mdx mice</a>, Anne-Catherine Passaquin , et al.
                        <p>
                            This study found creatine supplementation in mice improves muscle health and may provide a scientific basis for its use as adjuvant therapy in Duchenne muscular dystrophy.
                        </p>
                    </li>
                    
                    <li id="hamid-arazi">
                        <a href="https://www.mdpi.com/2072-6643/13/3/869" 
                        title="Creatine Supplementation, Physical Exercise and Oxidative Stress Markers: A Review of the Mechanisms and Effectiveness"
                        target="_blank"
                        >Creatine Supplementation, Physical Exercise and Oxidative Stress Markers</a>
                        <p>
                            This review study concluded creatine's antioxidant mechanisms include reduced <abbr title="Reactive Oxygen Species">ROS</abbr> and <abbr title="Reactive Nitrogen Species">RNS</abbr> leading, and that creatine can maintain mitochondrial integrity, increase creatine phosphate (CP) resources, act as a cellular energy buffer, and protect two important cellular targets, mtDNA and RNA, from oxidative damage. 
                        </p>
                    </li>
                </ol>
            </section>
            
            <section id="cacao">
                <h4>Cacao</h4>
                <!--
                <h4>Antifibrillogenic and Anti-aggregant</h4>
            Compounds in cacao may help prevent the formation and aggregation of Œ±-synuclein fibrils. These include epicatechin, catechin, procyanidins, theobromine
            
            Theobromine (dimethylxanthine) is the primary methylxanthine in cacao, contributing to the overall pharmacological profile of cacao to a greater extend than the other methylxanthines theophylline and caffeine (trimethylxanthine).
            
            Theobromine chelate metal ions and inhibit enzymes involved in ROS generation, rather than directly scavenging ROS and RNS.
            
             has but its mechanism of action in reducing Œ±-synuclein fibril aggregation is not primarily dopaminergic.
             
             Theobromine inhibits NADPH Oxidase. NADPH oxidizes NADP responsible for generating reactive oxygen species (ROS) in various cells. NADPH oxidase is implicated in the pathogenesis of neurodegenerative diseases, such as Alzheimer‚Äôs and Parkinson‚Äôs diseases.


Neuroprotective and Antioxidant: Cacao's flavonoids possess antioxidant properties, potentially protecting neuronal structures from oxidative stress, which is implicated in PD progression.

Anti-inflammatory: Some components of cacao may have anti-inflammatory effects, which could help reduce neuroinflammation associated with PD.

Neurorestorative: By promoting mitochondrial health and possibly enhancing cellular processes like mitophagy, cacao might facilitate the recovery and regeneration of neural tissue in PD.


Sleep: Cacao contains compounds like theobromine, which may have stimulant effects, but individual responses to cacao consumption can vary regarding its impact on sleep. Moderate consumption may not significantly affect sleep patterns for most individuals.

Senolytic: While cacao has not been directly studied as a senolytic agent, its antioxidant and anti-inflammatory properties may indirectly contribute to cellular health and potentially impact senescent cells.


References:

"Cocoa procyanidins inhibit amyloid Œ≤-protein oligomerization and fibril formation" - published in the journal "Biochemistry" in 2012, investigated the inhibitory effects of cocoa procyanidins on the formation of amyloid fibrils, including those formed by Œ±-synuclein. The researchers found cocoa procyanidins effectively inhibited fibril formation of amyloid Œ≤ (AŒ≤) peptides, which are associated with Alzheimer's disease, and Œ±-synuclein, suggesting a potential role in preventing protein aggregation in neurodegenerative diseases like Parkinson's



"Inhibition of Œ±-synuclein fibrillization by dopamine analogs via reaction with the amino groups of Œ±-synuclein and formation of dopamine adducts" - This study was published in the "Journal of Agricultural and Food Chemistry" in 2015, published in the "Journal of Agricultural and Food Chemistry" in 2015, evaluated the inhibitory effects of cocoa polyphenolic extract on the aggregation of Œ±-synuclein. The researchers observed that cocoa polyphenols significantly inhibited the formation of Œ±-synuclein aggregates and destabilized preformed fibrils, indicating a potential therapeutic strategy for Parkinson's disease and other synucleinopathies.
https://febs.onlinelibrary.wiley.com/doi/abs/10.1111/j.1742-4658.2005.04792.x

Cocoa Extract Provides Protection against 6-OHDA Toxicity in SH-SY5Y Dopaminergic Neurons by Targeting PERK
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405838/

Dietary Cocoa Flavanols Enhance Mitochondrial Function in Skeletal Muscle and Modify Whole-Body Metabolism in Healthy Mice
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8538722/
-->
            </section>
            
            <section id="cinnamon">
				<h4>Cinnamon</h4>
				<ul class="treatment-rating">
					<li>Mechanisms: Neuroprotective, Antidiabetic
					<li>Dose: 4g ED
					<li>Fat-soluble: ‚úÖ
					<li>ü©∏üß†BBB: ‚úÖ
					<li>Safety: 9/10 (90% œÉ)
					<li>Efficacy: 3/10 (50% œÉ)
				</ul>
				
				<h5>Antidiabetic Effects</h5>
				<p>
					Cinnamon exhibits anti-hyperglycemic properties, with the most significant effects observed in Ceylon cinnamon. These effects are species-specific.  <cite class="reflink">[<a href="#n-j-hayward">n-j-hayward</a>]</cite>
				</p>
				
				<p>
					It does this by mimicking insulin receptor kinase, increasing glucose uptake, and glycogen synthase activity and increasing GLP-1 concentrations. <cite class="reflink">[<a href="#n-kizilaslan">n-kizilaslan</a></cite>, <cite class="reflink"><a href="#j-hlebowicz">j-hlebowicz</a>]</cite>
				</p>
						
				<h5>Neuroprotective Effects</h5>
				
				<p>
					Glucose metabolism is impaired in Parkinson's Disease (PD). Improved glucose response and blood glucose levels from cinnamon's antidiabetic effects may benefit PD patients. <cite class="reflink">[<a href="#a-marques">a-marques</a>]</cite>
				</p>
				<p>
					Ingested cinnamon metabolizes to sodium benzoate (NaB). Both cinnamon and NaB upregulate neuroprotective molecules (Parkin and DJ-1) and protect the nigrostriatum in a mouse model.  <cite class="reflink">[<a href="#e-angelopoulou">e-angelopoulou</a>]</cite>
				</p>
				<p>
					However, translating the mouse dosage to humans, 100 mg/kg to a 12x k-factor results in 1.2 g/kg. For a 50 lb human, this equates to 60 grams of cinnamon daily, an impractical amount. Consuming 3g daily is only 5% of the suggested dose, offering minimal neuroprotection.  <cite class="reflink">[<a href="#e-angelopoulou">e-angelopoulou</a>]</cite>
				</p>
				
                <ol class="reference-list">
                    <li id="n-j-hayward">
                    	<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900266/"
                    	title="Cinnamon Shows Antidiabetic Properties that Are Species-Specific: Effects on Enzyme Activity Inhibition and Starch Digestion"
                    	target="_blank"
                    	>Cinnamon Shows Antidiabetic Properties that Are Species-Specific: Effects on Enzyme Activity Inhibition and Starch Digestion</a>, Nicholas J. Hayward, et al.
                    </li>
                    
                    <li id="n-kizilaslan">
                    	<a href="https://pubmed.ncbi.nlm.nih.gov/31372918/"
                    	title="Cinnamon Shows Antidiabetic Properties that Are Species-Specific: Effects on Enzyme Activity Inhibition and Starch Digestion"
                    	target="_blank"
                    	>The Effect of Different Amounts of Cinnamon Consumption on Blood Glucose in Healthy Adult Individuals</a>, Nildem Kizilaslan
                    	<p>
                    		3‚Äì6‚Äâg of cinnamon consumption was found to affect certain blood parameters of individuals positively. 
                    	</p>
                    </li>
                    <li id="j-hlebowicz">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/19158209/"
                        title="Effects of 1 and 3 g cinnamon on gastric emptying, satiety, and postprandial blood glucose, insulin, glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and ghrelin concentrations in healthy subjects"
                        target="_blank"
                        >Effects of 1 and 3 g cinnamon on gastric emptying, satiety, and postprandial blood glucose, insulin, glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and ghrelin concentrations in healthy subjects]</a>
                        <p>
							Ingestion of 3 g cinnamon reduced postprandial serum insulin and increased GLP-1 concentrations without significantly affecting blood glucose, GIP, the ghrelin concentration, satiety, or GER in healthy subjects. The results indicate a relation between the amount of cinnamon consumed and the decrease in insulin concentration.
                        </p>
                        
                        <p>
                        	(<dfn>GIP</dfn>, is <dfn>glucose-dependent insulinotropic polypeptide</dfn>, an <dfn>incretin</dfn> hormone secreted by <dfn title="K Cells or GIP cells are enteroendocrine cells found in the small intestine">K cells</dfn> in the upper small intestine in response to nutrient ingestion, particularly glucose.)
                    </li>
                    
                    <li id="a-marques">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/29866628/"
                        title="Glucose dysregulation in Parkinson's disease: Too much glucose or not enough insulin?"
                        target="_blank"
                        >Glucose dysregulation in Parkinson's disease: Too much glucose or not enough insulin?</a>
                        <p>
                        	Glucose control is impaired in moderate to advanced non-diabetic PD patients, due to impaired adaptive insulin response which may be a novel non-motor consequence of PD associated dysautonomia.
                        </p>
                    </li>
                    
                    <li id="e-angelopoulou">
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6708487/"
                        title="Cinnamon and its metabolite protect the nigrostriatum in a mouse model of Parkinson‚Äôs disease via astrocytic GDNF"
                        target="_blank"
                        >Cinnamon and its Metabolite Protect the Nigrostriatum in a Mouse
Model of Parkinson‚Äôs Disease Via Astrocytic GDNF</a>

						<p>
							A mouse model induced PD with MPTP, mice were treated with either cinnamon or NaB dissolved in 0.5% methylcellulose at individual doses (100 mg/kg, orally) once daily for 7 days and following behavior analysis the mice were sacrificed for biochemical studies.
						</p>
                    </li>

                </ol>
            </section>
            <section id="cavracrol">
                <h4>Cavracrol</h4>
                <p>
                </p>
                
                <ol>
                    <li>
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681233/#B67-biomolecules-09-00271
                        ">Role of Dietary Supplements in the Management of Parkinson‚Äôs Disease
</a>
                    </li>
                </ol>
                <p>
                    Established that carvacrol is also able to inhibit the acetylcholinesterase activity, with positive effects on memory and cognitive performance in PD.
                </p>
            </section>
            <section id="lions-mane">
                <h3>Lion's Mane</h3>
                <ul class="treatment-rating">
                    <li>Mechanisms: Neurorestorative
                    <li>Dose: 1000mg ED
                    <li>Fat-soluble: ‚úÖ
                    <li>ü©∏üß†BBB: ‚úÖ
                    <li>Safety: 9/10 (90% œÉ)
                    <li>Efficacy: 7/10 (80% œÉ)
                </ul>
                
                <p>
                    Lion‚Äôs Mane contains fat-soluble bioactive compounds hericenones and erinacines that have been shown to stimulate the growth of brain cells, improve memory, and boost cognitive function. <cite class="reflink">[<a href="#koichiro-mori">koichiro-mori</a>]</cite><cite class="reflink">[<a href="#i-chen-li">i-chen-li</a>]</cite><cite class="reflink">[<a href="#sarah-docherty">sarah-docherty</a>]</cite>
                </p>
                
                <h4>Lion's Mane in PD</h4>
                <p>
                    Lion‚Äôs mane stimulates neurite outgrowth, promotes neurogenesis, and improves cognitive function in individuals with Parkinson‚Äôs disease. <cite class="reflink">[<a href="#koichiro-mori">koichiro-mori</a>]</cite><cite class="reflink">[<a href="#i-chen-li">i-chen-li</a>]</cite><cite class="reflink">[<a href="#sarah-docherty">sarah-docherty</a>]</cite><cite class="reflink">[<a href="#puei-lene-lai">puei-lene-lai</a>]</cite>
                </p>
            
                <h4>Supplementation</h4>
                <p>
                    Lion's mane is safe and well-tolerated. The compounds Hericenones and erinacines, which are the compounds identified as being active in promoting Nerve Growth Factor (NGF) and are primarily alcohol soluble.
Sterols, which are also fat-soluble compounds.
                </p>
                <ol class="reference-list">
                    <li id="koichiro-mori">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/18844328/"
                        title="Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial"
                        target="_blank"
                        >Improvement of Cognitive Functions by Oral Intake of Hericium erinaceus</a>, Koichiro Mori, et al.
                        <p>
                            This double-blind, parallel-group, placebo-controlled RCT found that elderly men and women with mild cognitive impairment who took Lion's mane mushroom extract for 16 weeks showed significant improvements in cognitive function compared to the placebo group.
                        </p>
                    </li>
                    <li id="i-chen-li">
                        [i-chen-li] <a href="https://pubmed.ncbi.nlm.nih.gov/32581767/"
                        title="Prevention of Early Alzheimer's Disease by Erinacine A-Enriched Hericium erinaceus Mycelia Pilot Double-Blind Placebo-Controlled Study"
                        target="_blank"
                        >Prevention of Early Alzheimer's Disease by Erinacine A-Enriched Hericium erinaceus Mycelia Pilot Double-Blind Placebo-Controlled Study</a>, I Chen Li, et al.
                        <p>
                            This double-blind RCT found that elderly men and women who took a daily 350mg capsule containing 5 mg/g erinacine A (active ingredient) demonstrated better cognitive performance and functioning.
                        </p>
                    </li>
					<li id="sarah-docherty">[sarah-docherty]
                        <a href="https://www.mdpi.com/2072-6643/15/22/4842"
                        title="The Acute and Chronic Effects of Lion‚Äôs Mane Mushroom Supplementation on Cognitive Function, Stress and Mood in Young Adults: A Double-Blind, Parallel Groups, Pilot Study">Lion‚Äôs Mane Supplementation on Cognitive Function, Stress, and Mood in Young Adults</a>, Sarah Docherty, et al.
                        
                        <p>
                            The findings tentatively suggest that Hericium erinaceus may improve speed of performance and reduce subjective stress in healthy, young adults.
                        </p>
                    </li>
                    
                    <li id="puei-lene-lai">[puei-lene-lai]
                    	<a href="https://www.mdpi.com/2072-6643/15/22/4842"
                        title="Neurotrophic Properties of the Lion‚Äôs Mane
Medicinal Mushroom, Hericium erinaceus (Higher
Basidiomycetes) from Malaysia">Neurotrophic Properties of the Lion‚Äôs Mane
Medicinal Mushroom, Hericium erinaceus (Higher Basidiomycetes) from Malaysia</a>, Puei-Lene Lai, et al
                        
                        <p>
                            The extract contained neuroactive
compounds that induced the secretion of extracellular NGF in NG108-15 cells, thereby promoting neurite outgrowth activity.
                        </p>
                    
                    </li>
                </ol>
            </section>
            
            <section id="cordyceps" class="neuroprotective anti-inflammatory">
                <h3>Cordyceps</h3>
                <ul class="treatment-rating">
                    <li>Mechanisms: Neuroprotective, Anti-inflammatory, Mitochondrial, Antioxidant</li>
                    <li>Dose: ~3g EDÔ∏è</li>
                    <li>ü©∏üß†BBB: ‚úÖ</li>
                    <li>Safety: 7/10 (90% œÉ)</li>
                    <li>Efficacy: 5/10 (80% œÉ)</li>
                </ul>                
                <p>
                    Cordycepin, a bioactive component of Cordyceps militaris, reduces neuroinflammation by regulating cytokine production. <cite class="reflink">[<a href="#y-sun">y-sun</a>]</cite>
                </p>
                
                <h4>BBB</h4>
                <p>
	                Cordycepin of (2‚Ä≤-Deoxyadenosine) is a small molecule (<abbr title="molecular weight">MW</abbr> ~251 <abbr title="Daltons &ndash; unit of molecular mass">Da</abbr>) that can cross the BBB and improve its tight junction. <cite class="reflink">[<a href="#j-yuan">j-yuan</a>]</cite>
    			</p>
    			
    			<h4>Immunomodulation</h4>
    			<p>
    				Beta-glucans, a type of polysaccharide found in the cell walls of many mushrooms including Cordyceps, are potent immunomodulators. <cite class="reflink">[<a href="#c-cerletti">c-cerletti</a>]</cite>
    			</p>
    			
    			<p>
    				Both cordycepin and adenosine can be used to mitigate excessive inflammation. <cite class="reflink">[<a href="#s-shin">s-shin</a>]</cite> <cite class="reflink">[<a href="#s-j-jung">s-j-jung</a>]</cite>
    			</p>
                <ol class="reference-list">
                    <li id="y-sun">
                        <a 
                        title="Neuroprotective effects of natural cordycepin on LPS-induced Parkinson‚Äôs disease through suppressing TLR4/NF-Œ∫B/NLRP3-mediated pyroptosis"
                        target="_blank"
href="https://www.sciencedirect.com/science/article/pii/S1756464620304989"
                        >Neuroprotective effects of natural cordycepin on LPS-induced Parkinson‚Äôs disease through suppressing TLR4/NF-Œ∫B/NLRP3-mediated pyroptosis</a>, Ying Sun, et al.
                        <p>
                            Found cordycepin exerts neuroprotective effects via an anti-apoptotic mechanism based on the mitochondrial pathway in a rotenone-induced PD rat model. It suppresses inflammatory cytokines that lead to <dfn>pyroptosis</dfn>, or <dfn>"fiery falling"</dfn>, which describes the bursting of pro-inflammatory chemical signals from the dying cell.
                        </p>
                        <p>
                        	Toll-like receptor 4 (TLR4) is a receptor involved in the innate immune response and inflammation. Activation of TLR4 triggers downstream signaling pathways, including <abbr title="Nuclear factor kappa-light-chain-enhancer of activated B cells ">NF-Œ∫B</abbr> activation. Cordycepin inhibits TLR4 activation, reducing initiation of inflammatory responses in the brain.
                        </p>
                        <p>
                        	Cordycepin inhibits the activation of the <abbr title="NOD-, LRR- and pyrin domain-containing protein 3) &mdash; immune system protein">NLRP3</abbr> inflammasome. This inhibition reduces the production and release of IL-1Œ≤ and IL-18, which are potent mediators of inflammation-induced neurotoxicity.
                        </p>
                    </li>
                    
                    <li id="j-yuan">
						<a 
							title="Cordycepin attenuates traumatic brain injury-induced impairments of blood-brain barrier integrity in rats"
							target="_blank"
	href="https://pubmed.ncbi.nlm.nih.gov/27646481/"
							>Cordycepin attenuates traumatic brain injury-induced impairments of blood-brain barrier integrity in rats</a>, Jing Yuan, et al.
							
						<p>
							Cordycepin has protective effects against brain damage induced by <abbr title="Traumatic Brain Injury">TBI</abbr>. Its protection of BBB integrity is likely achieved through the recovery of tight junction proteins, inhibition of local inflammation, and prevention of <abbr title="NADPH oxidase, an enzyme that reduces NADPH, increasing inflammation">NOX</abbr> activity.
						</p>
                    </li>
                    
                     <li id="s-shin">
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2816959/"
                        title="Role of Cordycepin and Adenosine on the Phenotypic Switch of Macrophages via Induced Anti-inflammatory Cytokines"
                        target="_blank"
                        >Role of Cordycepin and Adenosine on the Phenotypic Switch of Macrophages via Induced Anti-inflammatory Cytokines</a>, Seulmee Shin, et al.
                        
                        <p>
                        	This in-vitro study found cordycepin and adenosine regulated the phenotypic switch on macrophages and suggested that cordycepin and adenosine may potentially be used as immunomodulatory agents in the treatment of inflammatory disease.
                        </p>
                        <p>
                        	By interacting with immune cells such as macrophages and dendritic cells, cordycepin and adenosine promote <dfn title="A process by which a cell engulfs a particle, such as a bacterium, dead cell, or foreign substance, and digests it">phagocytosis</dfn> and enhance immune responses against pathogens.
                        </p>
                    </li>
                    
                    <li id="c-cerletti">
                    	<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8308413/"
                    	title="Edible Mushrooms and Beta-Glucans: Impact on Human Health"
                    	target="_blank">Edible Mushrooms and Beta-Glucans: Impact on Human Health</a>, Chiara Cerletti, et al.
                    </li>
                    
                    <li id="s-j-jung">
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6441223/"
                        title="Immunomodulatory effects of a mycelium extract of Cordyceps (Paecilomyces hepiali; CBG-CS-2): a randomized and double-blind clinical trial"
                        target="_blank"
                        >Immunomodulatory effects of a mycelium extract of Cordyceps (Paecilomyces hepiali; CBG-CS-2): a randomized and double-blind clinical trial</a>, Su-Jin Jung, et al.
                        <p>
                        	The results of this randomized and double-blind clinical trial suggest that CBG-CS-2, a strain of Cordyceps (Paecilomyces hepiali), is safe and effective for enhancing cell-mediated immunity in healthy adults.
                        </p>
                    </li>
                </ol>
            </section>
            
            <section id="turmeric" class="neuroprotective antifibrillogenic">
                <h3>
                    Turmeric 
                </h3>
                <ul class="treatment-rating">
                    <li>Mechanisms: Neuroprotection, Anti-inflammatory, Antifibrillogenic, Anti-aggregation
                    <li>Dose: 1-3g daily üçΩÔ∏èüí§
                    <li>ü©∏üß†BBB: TBD
                    <li>Safety: 8/10 (80% œÉ)
                    <li>Efficacy: 6/10 (70% œÉ)
                </ul>
                
                    <h5>Introduction to Turmeric and Curcuminoids</h5>
                    <p>
                        Turmeric is a rhizome of the Curcuma longa plant.
                    </p>

                    <p>
                        Curcumin is the most well-known and studied curcuminoind found in turmeric. Other curcuminoids contribute to turmeric's health benefits. Herein, the terms are used interchangeably.
                    </p>
                    
                    <p>
                        Curcumin crosses the blood-brain barrier to reach deep brain structures, including the midbrain, where it directly exerts its beneficial effects. 
                    </p>

                    <h4>How Turmeric Helps PD</h4>
                    <p>
                        Several studies in different experimental models of PD strongly support the use of curcumin in PD. Specifically, with neuroprotection, neurogenesis, antifibrillogenic, and anti-aggregation. These actions contribute to a healthier brain, improved cognitive function, and a staving off of progressive neurodegeneration (PN).
                    </p>

                    <h4>Supplementation (Eating Turmeric)</h4>

                    <p>
                        Turmeric is very safe at 1-3g daily. Excessively high doses may cause stomach upset or strain the kidneys.
                    </p>

                    <h4>Challenges with Curcumin Absorption</h4>
                    <p>
                        Although curcumin pills are convenient, orally-ingested curcumin is very poorly absorbed. What is absorbed is quickly metabolized.
                    </p>
                
                    <h4>Self-Emulsifying Drug Delivery Systems SEDDS</h4>
                    <p> 
                        Self-Emulsifying Drug Delivery Systems (SEDDS) are lipid-based formulations that create an emulsion to improve the oral bioavailability of lipophilic substances, like curcumin.
                    </p>
                
                    <h4>Enhancing Absorption with Food</h4>
                    <p>                         
                        Turmeric is good in curries, with vegetables and coconut oil, offering both flavor and health benefits. This formulation with food offers much better absorption as a SEDDS. Turmeric can also be blended into warm milk with other spices, as <dfn>"golden milk"</dfn>.
                    </p>
                    
                    <h4>Safety Concerns</h4>
                    
                    <p>
                        Turmeric thins the blood, which may increase the risk of bleeding, especially in individuals taking blood-thinning medications or those with bleeding disorders or are planning surgery. It may interact with blood-thinners, diabetes medications, and medications that reduce stomach acid production.
                    </p>
                    <p>
                        Consuming excessively high amounts of turmeric (over 5g ED) may lead to gastrointestinal issues or increase the risk of kidney stone formation, particularly in individuals prone to kidney stones or with a history of kidney problems.
                    </p>

                    <h4>
                        Curcumin References:
                    </h4>
                    <ol>
                        <li>
                            <a href="https://pubmed.ncbi.nlm.nih.gov/29027056/" 
                            title="Curcumin affords neuroprotection and inhibits Œ±-synuclein aggregation in lipopolysaccharide-induced Parkinson's disease model"
                            target="_blank">Curcumin neuroprotection and anti- Œ±-synuclein aggregation rodent PD model</a>
                            <p>
                               This rodent study found curcumin significantly improved inflammation, improved the glutathione system (GSH, GSSG and redox ratio), and prevented iron deposition in the dopaminergic neuronsprevented Œ±-synuclein aggregates in the dopaminergic neurons
                            </p>
                        </li>
                        
                        <li>
                            <a href="https://www.frontiersin.org/articles/10.3389/fnagi.2022.984895/full" 
                            title="A novel curcumin oil solution can better alleviate the motor activity defects and neuropathological damage of a Parkinson‚Äôs disease mouse model"
                            target="_blank">Curcumin oil solution on the prevention of movement disorders</a>
                            
                            <p>
                                This rodent study provided comprehensive strong evidence regarding the effect of a novel curcumin oil solution on the prevention of movement disorders. 
                            </p>
                            <p>
                                <dfn>In vivo</dfn> confirmed that the curcumin oil solution has higher bioavailability than curcumin alone.
                            </p>
                            <p>
                                Curcumin had a greater protective effect on dopaminergic neurons in the compact part of the substantia nigra along with the PD process according to pathological evaluation
                            </p>
                        </li>
                        
                        <li>
                            <a href="https://pubmed.ncbi.nlm.nih.gov/22267729/" 
                            title="Curcumin prevents aggregation in &alpha;-synuclein by increasing the reconfiguration rate"
                            target="_blank">Curcumin prevents aggregation</a>
                            <p>
                                This rodent study found curcumin rescues the protein from aggregation by increasing the reconfiguration rate into a faster regime.
                            </p>
                        </li>
                        <li>
                            <a href="https://www.sciencedirect.com/science/article/abs/pii/S0303846722001810?via%3Dihub" 
                            title="Evaluation of curcumin as add-on therapy in patients with Parkinson's disease: A pilot randomized, triple-blind, placebo-controlled trial"
                            target="_blank">Nanomicelle curcumin as an add-on therapy in patients with PD</a>
                            
                            <p>
                                This human study tested the effects of a novel <dfn>nanomicelle</dfn> curcumin preparation. Although it was well-tolerated, it was not successful in improving quality of life and clinical symptoms of PD patients.
                            </p>
                            
                            <p>
                                The problem with this study is they did not test the absorption of their novel <dfn>nanomicelle</dfn> curcumin. They did not prove that curcumin doesn't work, only that their <dfn>nanomicelle</dfn> preparation failed for unknown reasons.
                            </p>
                        </li>
                    </ol>
                    <h4>Turmeric Products</h4>
                    
                    <ul class="product-list">
                        <li>
                            <figure>
                                <img alt="Fronteirs Bulk Turmeric" src="img/frontiers_turmeric-sm.png">
                                <figcaption>
                                    <p>
                                        <a href="https://www.amazon.com/Frontier-Bulk-Turmeric-Powder-Trade/dp/B006K0C1RE">Frontier Co-op Organic Fair Trade Ground Turmeric Root 1lb</a>
                                    </p>
                                </figcaption>
                            </figure>
                        </li>
                        <li>
                            <figure>
                                <img src="img/turmeric-mykind.jpeg" alt="MyKind Turmeric">
                                <figcaption>
                                     <p>
                                        <a
                                        href="https://www.amazon.com/gp/product/B07NXQHXV3/ref=as_li_tl?ie=UTF8&amp;camp=1789&amp;creative=9325&amp;creativeASIN=B07NXQHXV3&amp;linkCode=as2&amp;tag=garrettsmit02-20&amp;linkId=143e5904cc8bab43c355acfc7eed8bc2"
                                    >Garden of Life, MyKind Organics, Extra Strength Turmeric
                                        </a>
                                    </p>
                                </figcaption>
                            </figure>
                        </li>
                        <li>
                            <figure>
                                <img src="img/curcumin.jpeg" alt="CurcuGreen Curcumin">
                                <figcaption>
                                    <p>
                                        <a href="https://www.amazon.com/gp/product/B01ELXB3MA/ref=as_li_tl?ie=UTF8&tag=garrettsmit02-20&camp=1789&creative=9325&linkCode=as2&creativeASIN=B01ELXB3MA&linkId=ab05fa8195a7a04384554288ef47d9bd">Curcumin as BCM-95&reg; (CURCUGREEN&reg;)</a>
                                    </p>
                                </figcaption>
                            </figure>
                        </li>
                    </ul>
            </section>
            <section id="saffron">
                <h3>
                    Saffron (TODO)
                </h3>
                <ul class="treatment-rating">
                    <li>Mechanisms: Neuroprotective, Antioxidant, Sleep</li>
                    <li>Dose: ~30mg of Saffron (8-10 threads) üçΩÔ∏èüí§</li>
                    <li>ü©∏üß†BBB: ‚úÖ</li>
                    <li>Safety: 9/10 (95% œÉ)</li>
                    <li>Efficacy: 7/10 (80% œÉ)</li>
                </ul>
                <p>
                    Saffron, like turmeric, is a fat-soluble neuroprotective food that can help with sleep.
                </p>
                
                <h4>Saffron in Neurodegenerative Disease</h4>
                <p>
                     Glial cells, and specifically astrocytes, support the function and survival of neurons. Astrocytes can release neurotransmitters, such as glutamate and ATP, which can influence neuronal activity.
                </p>
                <p>
                    Glial scar formation is a common pathological feature in various central nervous system (CNS) diseases, including Parkinson‚Äôs disease (PD). In PD, the glial scars form around damaged dopaminergic neurons, blocking their repair.
                </p>
                <p>
                    Saffron inhibits damage and inflammation to astrocytes (glia) through multiple pathways.
                </p>
                <h5>Supplementation</h5>
                <p>
                    Because saffron is fat-soluble, it's best taken with food. (It's also delicious.) Saffron can be drunk with turmeric and cinnamon in golden milk. Excessive amounts may cause bloating and gas. 
                </p>
                <!--
                
                <h4>
                        Saffron Productss
                </h4>
                <ul class="product-list">
                    <li>
                        <a href=""></a>
                    </li>
                    <li>
                        <figure>
                            <img src="" alt="">          
                            <figcaption>
                                <p>
                                    <a href=""
                                    target="_blank"></a>
                                </p>
                            </figcaption>
                        </figure>
                    </li>
                </ul>
                
                    <a    href="https://www.amazon.com/gp/product/B07Q23DCZC/ref=as_li_tl?ie=UTF8&amp;tag=garrettsmit02-20&amp;camp=1789&amp;creative=9325&amp;linkCode=as2&amp;creativeASIN=B07Q23DCZC&amp;linkId=a89eecbeabe1c12666d9093201834fce"
                    title=""
                    >Saffron Extract Supplements
                    </a>
                </div>
                <p>
                    <img src="img/saffron.jpeg" title="saffron">
                </p>
                <div>
                    Turmeric and Saffron can also be prepared together as a warm night drink of golden milk with a calming effect. Both can be purchased online.
                </div>
                <div>
                    <strong>
                        Turmeric and Saffron Product:
                    </strong>
                    <a
                        href="https://www.amazon.com/gp/product/B07BH6KBN4/ref=as_li_tl?ie=UTF8&amp;tag=garrettsmit02-20&amp;camp=1789&amp;creative=9325&amp;linkCode=as2&amp;creativeASIN=B07BH6KBN4&amp;linkId=5726ef5550d5890bb7fd0e237f6a7791"
                    >
                        Turmeric Latte with Saffron
                    </a>
                </div>
                <p>
                    <img src="img/turmeric-latte.jpeg" alt="turmeric latte" />
                </p>
            -->
                <h5>
                        Saffron References:
                </h5>
                <ol class="reference-list">
                    <li>
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7573929/"
                        title="Neuroprotective Potency of Saffron Against Neuropsychiatric Diseases, Neurodegenerative Diseases, and Other Brain Disorders: From Bench to Bedside
"
                        target="_blank"
                        >Neuroprotective Potency of Saffron Against Neuropsychiatric Diseases&hellip;</a>
                        <p>
                            This review study discussed the neuroprotective effects of crocin and crocetin, and that both could provide neuroprotection by reducing AŒ≤ aggregation.
                        </p>
                    </li>
                    <li>
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5361500/"
                        title="Neuroprotective properties of dietary saffron: more than just a chemical scavenger?"
                        target="_blank"
                        >Neuroprotective properties of dietary saffron&hellip;</a>
                        <p>
                            This review study discussed the mechanism of actions of saffron to induce dose-dependent neuroprotective response.
                        </p>
                    </li>
                    <li>
                        <a href="https://pubmed.ncbi.nlm.nih.gov/30573341/"
                        target="_blank"
                        title="Crocus sativus restores dopaminergic and noradrenergic damages induced by lead in Meriones shawi: A possible link with Parkinson's disease"
                        >Crocus sativus restores dopaminergic and noradrenergic damages&hellip;</a>
                        <p>
                            This rodent study showed that movement disorder caused by Pd (lead)-induced damage to dopaminergic and noradrenergic systems in the midbrain was reversed by saffron (crocus sativus).
                        </p>
                    </li>
                    <li>
                        <a href="https://pubmed.ncbi.nlm.nih.gov/32056539/"
                        title="Effects of saffron on sleep quality in healthy adults with self-reported poor sleep: a randomized, double-blind, placebo-controlled trial"
                        target="_blank"
                        >Effects of saffron on sleep quality in healthy adults with self-reported poor sleep: a randomized, double-blind, placebo-controlled trial
</a>
                        <p>
                            This 28-day, parallel-group, double-blind, randomized controlled trial included sixty-three healthy adults aged 18-70 with self-reported sleep problems. Subjects were randomized to receive either saffron extract (saffron; 14 mg twice daily) or a placebo.
                        </p>
                        <p>
                            Conclusions: Saffron intake was associated with improvements in sleep quality in adults with self-reported sleep complaints.
                        </p>
                    </li>
                    <li>
                        <a href="https://pubmed.ncbi.nlm.nih.gov/26705857/"
                        target="_blank"
                        title="Evidence of neuroprotective effects of saffron and crocin in a Drosophila model of parkinsonism"
                        >Evidence of neuroprotective effects of saffron and crocin in a Drosophila model of parkinsonism</a>
                        <p>
                            This drosophila model of parkinsonism study showed the neuroprotective effects of saffron and crocin. It concluded that these effects may be largely attributable to its antioxidant action and recommended saffron be exploited as a supplementary therapeutic agent in PD and other oxidative stress mediated neurodegenerative conditions.
                        </p>
                    </li>
                </ol>
            </section>
            <section id="coconut-oil">
                <h4>
                    Coconut Oil
                </h4>
                Coconut oil helps neural function and mitigates the effects of L-dopa supplementation.
                <strong>
                    Coconut Oil Product:
                </strong>
                <a href="https://www.amazon.com/gp/product/B00CQ7TNDK/ref=as_li_tl?ie=UTF8&amp;tag=garrettsmit02-20&amp;camp=1789&amp;creative=9325&amp;linkCode=as2&amp;creativeASIN=B00CQ7TNDK&amp;linkId=f32fa29138420ac8f79b25b5f9f8849f"
                >
                    Dr. Bronner's - Organic Virgin Coconut Oil
                </a>
                <p>
                    <img src="img/coconut-oil.jpeg" alt="coconut oil" />
                </p>
                <h5>Coconut Oil References:</h5>
                <ol>
                    <li>
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5610862/"
                        >Role of Diet and Nutritional Supplements in Parkinson's Disease Progression</a>
                    </li>

                    <li>
                        <a href="https://pubmed.ncbi.nlm.nih.gov/32707436/"
                        >Neurochemical, neurobehavioral and histochemical effects of therapeutic dose of l-dopa on striatal neurons in rats: Protective effect of virgin coconut oil</a>
                    </li>
                </ol>
            </section>
            <section id="ginger">
                <h4>
                    Ginger
                </h4>
                <div>
                    Ginger, a member of the same family of rhizomes as turmeric, contains several phenolic compounds, including shogaol. Gingerol and shogaol protect dopamanergic neurons.
                </div>
                <div>
                    <strong>
                        Ginger References:
                    </strong>
                </div>
                <ol>
                    <li>
                        <a href="https://pubmed.ncbi.nlm.nih.gov/23811724/"
                        >6-Shogaol, an active compound of ginger, protects dopaminergic neurons in Parkinson's disease models via anti-neuroinflammation.</a>
                        <p>

                        </p>
                    </li>
                    <li>
                        2)
                        <a href="https://nhsjs.com/2021/extractions-of-6-shogaol-and-6-gingerol-from-ginger-zingiber-officinale-on-the-protection-of-dopaminergic-neurons-in-a-parkinsons-disease-model/">
                            Extractions of 6-Shogaol and 6-Gingerol from Ginger (Zingiber officinale) on the Protection of Dopaminergic Neurons in a Parkinson's Disease Model
                        </a>
                    </li>
                </ol>
            </section>
            <section id="egcg">
                <h3>
                    EGCG (from Green Tea)
                </h3>
                <p>
                    EGCG (epigallocatechin gallate), a component in Green Tea, inhibits the ability of preformed oligomers, such as oligomers of &alpha;-synuclein, to permeabilize vesicles and induce cytotoxicity in rat brain cells.
                </p>
                <p>
                    <em>
                        Warning:
                    </em>
                    Green tea contains moderate levels of fluoride, a neurotoxin. Matcha, a Japanese powdered green tea, which contains high levels of EGCG also, unfortunately, has slightly high levels of oxalates. Oxalates contribute to
                    inflammation and damage kidneys. Supplemental ECCG can provide the desired dose without the fluoride oxalate concentrations found in green tea.
                </p>
                <h4>
                    Product:
                </h4>
                <img src="img/cytokine-suppress.png" alt="cytokine suppress" />
                <h4>
                    <a
                        href="https://www.amazon.com/gp/product/B00FPOF0ME/ref=as_li_tl?ie=UTF8&amp;tag=garrettsmit02-20&amp;camp=1789&amp;creative=9325&amp;linkCode=as2&amp;creativeASIN=B00FPOF0ME&amp;linkId=ed2f547390cfaadd1c5ca40695bf1d3a"
                    >
                        Life Extension Cytokine Suppress
                    </a>
                </h4>
                <strong>
                    EGCG References:
                </strong>
                <ol>

                    <li>
                        <a href="https://pubmed.ncbi.nlm.nih.gov/24907278/">
                            How epigallocatechin gallate can inhibit &alpha;-synuclein oligomer toxicity in vitro
                        </a>
                    </li>

                    <li>
                        <a href="https://link.springer.com/article/10.1007/s11064-016-1995-9">
                            https://link.springer.com/article/10.1007/s11064-016-1995-9
                        </a>
                    </li>

                    <li>
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2867908/">
                            EGCG remodels mature &alpha;-synuclein and amyloid-&beta; fibrils and reduces cellular toxicity
                        </a>
                    </li>
                    <li>
                        <a href="https://pubmed.ncbi.nlm.nih.gov/27364962/">
                            Epigallocatechin Gallate (EGCG) Inhibits Alpha-Synuclein Aggregation: A Potential Agent for Parkinson's Disease</a>
                            
                        <p>
                            This study found EGCG reduced cerebral amyloidosis, in mice.
                        </p>                           
                    </li>
                </ol>
            </section>
            <section id="ginsenoside">
                <h3>
                    Ginseng (Ginsenoside Rb1)
                </h3>
                <p>
                    Ginsenoside Rb1 inhibits fibrillation and toxicity of &alpha;-synuclein and disaggregates preformed fibrils.
                </p>
                <p>
                    Oral absorption of non-fermented ginsenosides is roughly 0.1 &mdash; 3.7%. Fermented ginseng has higher ginsenoside concentration and better absorption.
                </p>
                <h5>
                    Products:
                </h5>
                <p>
                    <a href="https://www.amazon.com/Fermented-Korean-Ginseng-Liquid-Extract/dp/B01MQP1DGE/ref=sr_1_7?s=hpc&sr=1-7">ILHWA Fermented Panax Korean Ginseng Liquid 4 Pack of 1</a>
                </p>
                <p>
                    <img src="img/ginseng.jpeg" alt="ginseng" />
                </p>
                <div>
                    <a
                        href="https://www.amazon.com/gp/product/B00KDSZ6XU/ref=as_li_tl?ie=UTF8&amp;tag=garrettsmit02-20&amp;camp=1789&amp;creative=9325&amp;linkCode=as2&amp;creativeASIN=B00KDSZ6XU&amp;linkId=d82ad47963e6dede78ec44e2184a1d36"
                    >
                        https://www.amazon.com/ILHWA- ILHWA 3.5oz(100g) Korean Ginseng Concentrated Pure Extract
                    </a>
                </div>
                <h5>
                    Ginsenoside Rb1 References:
                </h5>
                <ol>
                    <li>
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4882765/"
                        >Ginsenoside Rb1 inhibits fibrillation and toxicity of &alpha;-synuclein and disaggregates preformed fibrils.</a>
                    </li>

                    <li>
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3659629/"
                        >The bioavailability of red ginseng extract fermented by Phellinus linteus</a>
                    </li>
                </ol>
            </section>
            <section id="acetyl-l-carnitine">
                <h3>Acetyl-L-Carnitine (ALCAR)</h3>
                <ul class="treatment-rating">
                    <li>Mechanisms: Neuroprotective, Antioxidant, Mitochondrial</li>
                    <li>Dose: 1-2g</li>
                    <li>ü©∏üß†BBB: ‚úÖ</li>
                    <li>Safety: 8/10 (85% œÉ)</li>
                    <li>Efficacy: 9/10 (80% œÉ)</li>
                </ul>
                                
                <h4>How ALCAR Works</h4>
                <p>
                    ALCAR directly affects mitochondrial respiration.
                </p>
                <p>
                    ALCAR protects dopaminergic neurons by reducing neuroinflammation, apoptosis, astrogliosis (damage to  astrocytes (glial cells)), and oxidative stress. For PD, ALCAR protects cells against the accumulation of alpha-synuclein. <cite class="reflink">[<a href="#s-a-majd">s-a-majd</a>]</cite>
                </p>

                <p>
                    A 1990 Italian study on a small group of patients, published in the International Journal of Pharmacology research, titled &ldquo;
                    <a href="https://pubmed.ncbi.nlm.nih.gov/2387661/"
                    >Clinical pharmacodynamics of acetyl-L-carnitine in patients with Parkinson's disease</a>
                    &rdquo;, found 1&ndash;2g of ALCAR improved the H response, sleep stages and spindling in test (non-placebo) subjects. The H-response, also known as the Hoffmann reflex or H-reflex, is a type of reflexive muscle response triggered by a specific type of nerve stimulation applied to a muscle characterized by a specific latency and amplitude (size) of the muscle response.
                </p>
                <p>
                    A later 2018, &ldquo;
                    <a href="https://pubmed.ncbi.nlm.nih.gov/30906386/"
                    >multicenter, randomized double-blind, placebo-controlled clinical trial for efficacy of acetyl-L-carnitine in patients with dementia-associated with cerebrovascular disease</a>.
                    &rdquo;, found 1.5g of ALCAR significantly improved cognitive assessment.
                </p>
                
                <h4>Products</h4>
                <ul class="product-list">
                    <li>
                        <figure>
                            <img src="img/acetyl-l-carnitine.jpeg" alt="">
                        
                            <figcaption>
                                <p>
                                    <a href="https://www.amazon.com/gp/product/B07BLMSWGN/ref=as_li_tl?ie=UTF8&amp;tag=garrettsmit02-20&amp;camp=1789&amp;creative=9325&amp;linkCode=as2&amp;creativeASIN=B07BLMSWGN&amp;linkId=d5ce891282e299fedbd0358e75eafd91">Superior Labs | Acetyl L-Carnitine 1000mg</a>
                                </p>
                            </figcaption>
                        </figure>
                    </li>
                </ul>

                <h5>References</h5>
                <ol class="reference-list">
                    <li id="akihiro-inano">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/14595704/"
                        target="_blank"
                        >Acetyl-L-carnitine permeability across the blood-brain barrier and involvement of carnitine transporter OCTN2</a>, Akihiro Inano, et al.
                    </li>

                    <li id="s-a-majd">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/28199883/"
                        target="_blank"
                        >Acetyl-l-carnitine protects dopaminergic nigrostriatal pathway in 6-hydroxydopamine-induced model of Parkinson's disease in the rat</a>, Siamak Afshin-Majd, et al.
                    </li>
               </ol>
            </section>
            
            <section id="r-ala">
                <h3>R-ALA &mdash; r-Alpha-Lipoic Acid</h3>
                <ul class="treatment-rating">
                    <li>Mechanisms: Neuroprotective, Antioxidant, Mitochondrial</li>
                    <li>Dose:  250-500 mg ED ‚òÄÔ∏è</li>
                    <li>ü©∏üß†BBB: ‚úÖ <cite class="reflink">[<a href="#akihiro-inano">akihiro-inano</a>]</cite></li>
                    <li>Safety: 7/10 (75% œÉ)</li>
                    <li>Efficacy: 6-7/10 (70% œÉ)</li>
                </ul>

                <p>
                    R-Alpha-Lipoic Acid (r-ALA) reduces mitochondrial dysfunction and oxidative damage, thereby protecting dopaminergic neurons in Parkinson's disease.
                </p>
                
                <h4>Supplement Forms: s- and r-Enantiomers, and Binding</h4>

                <p>
                    Most research on ALA uses both s- and r-isoforms. The synthetically produced s-form inhibits the absorption of the naturally occurring r-isomer, which has better bioavailability. <cite class="reflink">[<a href="#b-salehi">b-salehi</a>]</cite>
                </p>
                
                <p>
                    Na-r-ALA (sodium-bound r-ALA) has better absorption and stability. <cite class="reflink">[<a href="#d-a-carlson">d-a-carlson</a>]</cite>
                </p>

                <h4>How r-ALA Works</h4>
                
                <p>
                    R-ALA activates <abbr title="AMP-activated protein kinase">AMPK</abbr>, which stimulates mitophagy. This leads to mitochondrial biogenesis and improved mitochondrial function. It increases glucose uptake and decreases glucose production in the liver, resulting in enhanced insulin sensitivity and reduced oxidative stress. <cite class="reflink">[<a 
             href="#w-j-lee">w-j-lee</a></cite>]
                </p>
                
                <h4>R-ALA in Parkinson's Disease</h4>
                <p>
                     Insulin resistance (IR) is commonly associated with an increased risk of developing Parkinson‚Äôs disease. IR leads to elevated brain glucose, which damages brain cells and accelerates neurodegeneration. <cite class="reflink">[<a 
             href="#HOMA-IR">HOMA-IR</a></cite>]
                </p>
                
                <h5>Iron in Parkinson's Disease</h5>
                <p>
                	Alpha-synuclein pathology disrupts iron homeostasis in PD. High iron levels harm dopaminergic neurons, inducing cell death and leading to more severe motor deficits with mutant Œ±-synuclein. <cite class="reflink">[<a 
             href="#f-jia">f-jia</a>, <a 
             href="#p-lingor">p-lingor</a></cite>
                </p>
                <p>
                    R-ALA decreases intracellular <abbr title="Reactive Oxygen Species">ROS</abbr> and iron levels. <cite class="reflink">[<a 
             href="#s-tai">s-tai</a></cite>
                </p>
                
                <p>
                    Overexpression of Œ±-synuclein inhibits <abbr title="Adenosine 5‚Ä≤ Monophosphate-Activated Protein Kinase">AMPK</abbr> activity, contributing to the neurodegenerative process in PD. <cite class="reflink">[<a 
             href="#lw-bobela">w-bobela</a>]</cite>
                </p>
                
                <h4>Synergy</h4>
                <h5>Na-r-ALA, Creatine, ALCAR, and Carbohydrates</h5>
                
                <p>
                    ALCAR helps transport fatty acids into the mitochondria, where they can be converted into energy. R-ALA, an antioxidant, helps protect the mitochondria from damage, allowing them to function more efficiently. <cite class="reflink">[<a 
             href="#leite-sampaio">leite-sampaio</a>]</cite>
                </p>
                <p>
                    Combining ALCAR, r-ALA, and creatine together can potentially enhance their update and amplify their effects, making this combination a potent pre-workout mitochondrial activator. <cite class="reflink">[<a href="#h-zhang">h-zhang</a></cite>, <cite class="reflink"><a 
             href="#w-bobela">w-bobela</a>]</cite>
                </p>
                <h4>Side Effects</h4>
                <p>
                    Gastrointestinal upset can occur. Some individuals experience this when taking Na-r-ALA on a full stomach, but not when taking r-ALA in the morning with water and fruit.
                </p>
                
                <h4>Products</h4>
                <ul class="product-list">
                    <li>
                        <figure>
                            <img src="img/mitochondrial-optimizer.jpeg" alt="mitochondrial optimizer">          
                            <figcaption>
                                <p>
                                    <a href="https://www.amazon.com/gp/product/B006L8DWSC/ref=as_li_tl?ie=UTF8&amp;tag=garrettsmit02-20&amp;camp=1789&amp;creative=9325&amp;linkCode=as2&amp;creativeASIN=B006L8DWSC&amp;linkId=c6c8f2664db42d477f10657223837e34"
                                    >Life Extension Mitochondrial Energy Optimizer with PQQ</a>
                                </p>
                            <p>
                                Note: This product contains Taurine, which is
                                <a href="https://journeywithparkinsons.com/2018/04/05/neuroprotection-with-taurine-in-a-parkinsons-model-system/">neuroprotective </a> and
                                <a href="https://pubmed.ncbi.nlm.nih.gov/26004911/">found to be suppressed in PD patients on L-Dopa</a>.
                            </p>
                            </figcaption>
                        </figure>
                    </li>
                    
                    <li>
                        <figure>
                            <img src="img/r-ala.jpeg" alt="r-Alpha Lipoic Acid" height="280">
                            <figcaption>
                            <p>
                                <a
href="https://www.amazon.com/gp/product/B0027YKO1C/ref=as_li_tl?ie=UTF8&amp;tag=garrettsmit02-20&amp;camp=1789&amp;creative=9325&amp;linkCode=as2&amp;creativeASIN=B0027YKO1C&amp;linkId=ebcbfd85708db0064877b27b10629629"
                                >Life Extension Super R-Lipoic Acid, 240mg
                                </a>
                            </p>
                            </figcaption>
                        </figure>
                    </li>
                </ul>
                <h4>References</h4>
                <ol class="reference-list">
                
                	<li id="b-salehi">
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6723188/"
                        title="Insights on the Use of Œ±-Lipoic Acid for Therapeutic Purposes"
                        target="_blank"
                        >Insights on the Use of Œ±-Lipoic Acid for Therapeutic Purposes
</a>, Bahare Salehi, et al.
                        <p>
                            The R enantiomer of ALA shows better pharmacokinetic parameters, including increased bioavailability as compared to its S enantiometer.
                        </p>
                    </li>
                    
					<li id="d-a-carlson">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/18069903/"
                        title="The plasma pharmacokinetics of R-(+)-lipoic acid administered as sodium R-(+)-lipoate to healthy human subjects"
                        target="_blank"
                        >The plasma pharmacokinetics of R-(+)-lipoic acid administered as sodium R-(+)-lipoate to healthy human subjects</a>, David A Carlson, et al.
                        <p>
                            Na-r-ALA is less prone to polymerization, completely soluble in water, and displays significantly higher <dfn title="maximum serum concentration">Cmax</dfn> and <abbr title="Area Under the Curve">AUC</abbr> values and decreased time to maximum concentration (Tmax) and T1/2 values than RLA or rac-LA.
                        </p>
                    </li>
                    <li id="s-tai">
                        <a href="https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2020.00612/full"
                        title="Alpha-Lipoic Acid Mediates Clearance of Iron Accumulation by Regulating Iron Metabolism in a Parkinson‚Äôs Disease Model Induced by 6-OHDA"
                        target="_blank">Alpha-Lipoic Acid Mediates Clearance of Iron Accumulation in PD Model</a>, Shengyan Tai, et al.
                        
                        <p>
                            This PD-induced rodent model showed that ALA could provide significant protection from 6-OHDA-induced cell damage in vitro by decreasing the levels of intracellular reactive oxygen species and iron. 
                        </p>
                    </li>
                    
                    <li id="HOMA-IR">
                        <a href="https://www.parkinson.org/blog/science-news/insulin-resistance"
                        >Parkinson's Disease and Insulin Resistance (HOMA-IR)
</a>, <cite>(anonymous)</cite>
                        <p>
                            A recently published study in the Journal of Parkinson‚Äôs Disease titled, ‚ÄúHigh Prevalence of Undiagnosed Insulin Resistance in Non-Diabetic Subjects with Parkinson‚Äôs Disease‚Äù (Hogg et al., 2018)
                        </p>
                        
                        <p>
                            The study revealed nearly 60% of the non-diabetic study participants may have undiagnosed insulin resistance &mdash; despite having normal blood sugar levels.
                        </p>
                    </li>
					<li id="w-j-lee">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/15913551/"
                        title="Alpha-lipoic acid increases insulin sensitivity by activating AMPK in skeletal muscle"
                        target="_blank"
                        >Alpha-lipoic acid increases insulin sensitivity by activating AMPK in skeletal muscle</a>, Woo Je Lee, et al.
                        <p>
                            This study suggests that ALA-induced improvement of insulin sensitivity is mediated by activation of AMPK and reduced triglyceride accumulation in skeletal muscle.
                        </p>
                    </li>
                    <li id="w-bobela">
                        <a href="https://molecularneurodegeneration.biomedcentral.com/articles/10.1186/s13024-017-0220-x"
                        title="Modulating the catalytic activity of AMPK has neuroprotective effects against Œ±-synuclein toxicity"
                        target="_blank"
                        >AMPK activation mitigates Œ±-synuclein toxicity</a>, Wojciech Bobela, et al.
                        <p>
                            Researches modulated AMPK activity to overexpress AMPK. Overexpression of AMPK mitigated Œ±-synuclein toxicity in nigral dopamine neurons.
                        </p>
                    </li>
                    <li id="p-lingor">
                        <a title="Alpha-synuclein and iron: two keys unlocking Parkinson's disease"
                        target="_blank"
                        href="https://pubmed.ncbi.nlm.nih.gov/28168622/">
                            Alpha-synuclein and iron: two keys unlocking Parkinson's disease</a>, Paul Lingor, et al.
                            
                    	<p>
                    		This short review, focuses on two disease mechanisms: alpha-synuclein pathology and dysfunction of iron homeostasis, as well as their intricate interaction.
                    	</p>
                    </li>
					<li id="f-jia">
                        <a href="https://www.frontiersin.org/articles/10.3389/fnagi.2018.00097/full">
                            High Dietary Iron Supplement Induces the Nigrostriatal Dopaminergic Neurons Lesion in Transgenic Mice Expressing Mutant A53T Human Alpha-Synuclein</a>, Fengju Jia, et al.
                            
                    <p>
                    	These results suggested high dietary iron supplement could induce nigral dopaminergic neurons lesion in A53T mice, which might be due to the vulnerability of SN to accumulate iron.
                    </p>
                    </li>
                    <li id="h-zhang">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/20414966/"
                        title="Combined R-alpha-lipoic acid and acetyl-L-carnitine exerts efficient preventative effects in a cellular model of Parkinson's disease"
                        target="_blank"
                        >Combined R-alpha-lipoic acid and acetyl-L-carnitine exerts efficient preventative effects in a cellular model of Parkinson's disease</a>, Hongyu Zhang, et al.
                        <p>
                            This in vitro study revealed that pretreatment with combined ALA and ALCAR increased mitochondrial biogenesis and decreased production of <abbr title="reactive oxygen species">ROS</abbr> through the up-regulation of <abbr title="Peroxisome Proliferator-activated Receptor-gamma Coactivator 1 alpha">PGC-1a</abbr> as a possible underlying mechanism.
                        </p>
                        <p>
                            <abbr title="the peroxisome proliferator-activated receptor-gamma coactivator 1 alpha">PGC-1a</abbr> is a transcriptional coactivator that regulates various cellular energy metabolism, mitochondrial biogenesis, and cellular stress responses. 
                        </p>
                    </li>
                    <li id="araujo">
                        <a href="https://www.tandfonline.com/doi/abs/10.3109/00207454.2010.535934"
                        title="Acetyl-l-carnitine and Œ±-lipoic acid affect rotenone-induced damage in nigral dopaminergic neurons of rat brain, implication for Parkinson's disease therapy"
                        target="_blank">ALACAR and Œ±-lipoic acid improve motor performance and reduced brain lipid peroxides in rat PD model</a>, Dayane Pessoa De Ara√∫jo, et al.
                        <p>
                            In this rodent model, researchers found treatment with acetyl-l-carnitine or Œ±-lipoic acid improved the motor performance and reduced the level of lipid peroxides in rat brains.
                        </p>
                    </li>
                </ol>
            </section>
            
            <section id="gaba-5-htp-melatonin">
                <h3>GABA, 5-HTP, and Melatonin</h3>
                <p>
                    GABA, 5-HTP, and melatonin can help PD patients through multiple neurological pathways. They're grouped because they all promote sleep and should all be taken at night.
                </p>
                <h4>Dopaminergic, Serotonergic, and GABAergic Systems</h4>
                <p>
                    The dopaminergic, serotonergic, and GABAergic systems are three important and interdependent neurotransmitter systems in the brain that play critical roles in regulating various physiological and psychological processes. All are impacted by PD and all are interrelated. Doctors typically only address the dopaminergic system, leading to imbalances in the other systems, nutrient deficiencies, and progressive neurodegeneration (PN).
                </p>
                <p>
                    Addressing only the dopaminergic system without considering the broader neurochemical landscape results in inadequate management of PD symptoms, exacerbates non-motor symptoms, and leads treatment-related complications. Furthermore, medications used to manage PD symptoms, such as levodopa, modulate only the dopaminergic system. This lopsided approach impacts other neurotransmitter systems and can contribute to nutrient deficiencies or imbalances.
                </p>
                <p>
                    It is crucial to take a comprehensive approach to PD management that considers the interplay between neurotransmitter systems and addresses both motor and non-motor symptoms. This may involve a combination of pharmacological interventions, lifestyle modifications, and nutritional support to optimize patient outcomes and quality of life while minimizing potential side effects and complications associated with treatment.
                </p>
                <p>
                    A comprehensive approach to PD must consider not only the direct effects of medications but also their broader implications for nutritional status and metabolic function.
                </p>
                <p>
                    Unfortunately, most doctors focus disproportionately on the dopaminergic system, a lopsided approach that has negative health consequences.
                </p>

                <p>
                    GABA and 5-HTP modulate the GABAergic and serotonergic pathways, respectively. It's crucial to have everyone on your medical team on board with this to avoid causing depletion of any one nutrient, as depletion can exacerbates PN.
                </p>
                <section id="gaba">
                    <h3>GABA</h3>
                    <ul class="treatment-rating">
                        <li>Mechanisms: Sleep, Dopaminergic side-effects
                        <li>Dose: 1000mg üí§</li>
                        <li>ü©∏üß†BBB: ‚ùå
                        <li>Safety: 7/10 (75% œÉ)
                        <li>Efficacy: 6/10 (70% œÉ)
                    </ul>
                    <p>
                        GABA is an inhibitory neurotransmitter that regulates dopaminergic neuron activity in the brain. 
                    </p>
                    
                    <h4>GABA and Sleep</h4>
                    <p>
                        GABA supplementation improves sleep by interacting with neurotransmitter systems in both the enteric nervous system (ENS) of the gastrointestinal tract and peripheral nervous system (PNS) receptors in the brainstem. This interaction influences the vagus nerve, leading to relaxation and better sleep quality.
                    </p>

                    <h4>GABA and Dopaminergic Side Effects</h4>
                    <p>
                        In Parkinson‚Äôs disease, the loss of GABAergic neurons in the substantia nigra contributes to motor symptoms.
                    </p>

                    <p>
                        Dyskinesia is a common side effect of long-term treatment with levodopa in Parkinson‚Äôs disease. GABA supplementation at 1000mg daily has the potential to help regulate dopamine release and likely ameliorate dyskinesia. 
                    </p>
                    
                    <p>
                        Non-pharmacological approaches, such as physical therapy and deep brain stimulation (DBS) targeting GABAergic circuits, may also help manage motor complications.
                    </p>
                    
                    <ul>
                    
                        <li>
                            <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366437/"
                                title="GABA and l-theanine mixture decreases sleep latency and improves NREM sleep"
                                target="_blank"
                            >GABA and l-theanine mixture decreases sleep latency and improves NREM sleep in rats</a>
                            
                            <p>
                                Researchers demonstrated that GABA and l-theanine together enhance sleep activity more effectively than either alone, likely through changes in GABA and glutamate receptor expression.
                            </p>
                        </li>
                        
                        <li>
                            <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6031986/"
                                title="Safety and Efficacy of Gamma-Aminobutyric Acid from Fermented Rice Germ in Patients with Insomnia Symptoms: A Randomized, Double-Blind Trial"
                                target="_blank"
                            >Safety and Efficacy of Gamma-Aminobutyric Acid from Fermented Rice Germ in Patients with Insomnia Symptoms: A Randomized, Double-Blind Trial</a>
                            
                            <p>
                                This small double-blind RCT shows that treatment with 300mg unpolished-rice-germ-derived GABA improved both subjective sleep quality and objective sleep efficiency in patients with insomnia, with no severe adverse events.
                            </p>
                        </li>
                        <li>
                            <a href=""
                            title="The Role of the GABAergic System in Diseases of the Central Nervous System"
                            target="_blank">GABAergic System in CNS Diseases</a>
                        <p>
                            This review study discusses how the decline in dopamine production impairs neurotransmission in the substantia nigra and reduces GABAergic function, leading to lower GABA+/creatine levels in the occipital cortex of individuals with Parkinson's disease.
                        </p>
                        </li>
                        <li>
                            <a href="https://content.iospress.com/articles/journal-of-alzheimers-disease/jad120535"
                            title="GABA Attenuates Amyloid Toxicity by Downregulating its Endocytosis and Improves Cognitive Impairment"
                            target="_blank"
                            >GABA Attenuates Amyloid Toxicity by Downregulating its Endocytosis and Improves Cognitive Impairment</a>
                            <p>
                                GABA reduces amyloid toxicity by downregulating amyloid-Œ≤ (AŒ≤) endocytosis, improving cognitive impairment. High levels of GABA decrease AŒ≤-induced cytotoxicity in wild-type mice through the receptor for advanced glycation end-products.
                            </p>
                        </li>
                        
                        <li>
                            <a href="https://pubmed.ncbi.nlm.nih.gov/12948617/"
                            title="Correlation between GABA(A) receptor density and vagus nerve stimulation in individuals with drug-resistant partial epilepsy
"
                            target="_blank">GABA(A) receptors correlated to vagus nerve stimulation</a>
                            <p>
                                In this comparative study, researchers concluded that stimulating the vagus nerve increased GABA(A) receptor density. GABAergic activation affects the vagus nerve, contributing to the regulation of sleep and relaxation."
                            </p>
                        </li>
                        
                    </ul>
                </section>
                <section id="5-htp">
                    <h4>5-HTP (5-Hydroxytryptophan)</h4>

                    <p>
                        5-HTP is converted into serotonin in the brain, promoting relaxation and sleep.
                    </p>
                    <p>
                        Changes in serotonin signaling happen in the early stages of Parkinson's. It is imperative to work on this system as early as possible. Do not wait for GI symptoms to develop.
                    </p>
                    <p>
                    	Dopamine Replacement Therapy (DRT) commonly used to treat Parkinson‚Äôs can cause involuntary movements; <dfn>"L-DOPA-induced dyskinesia (LID)"</dfn>. 5-HTP supplementation helps balance and restore serotonin to reduce the severity of these symptoms by modulating serotonin levels and dopamine release.
                    </p>
                    
                    <p>
                        Parkinson's disease affects not only the dopaminergic system but also other neurotransmitter systems, including the serotonergic system, by the same mechanisms (mitochondrial dysfunction, aggregation, etc). This leads to progressive degeneration of serotonergic terminals associated with the ANS (Autonomic Nervous System), the development of non-motor symptoms, and complications like GI dysfunction, a common problem in PD, and may be related to visual hallucinations in some patients.
                    </p>
                    <p>
                        DRT depletes vitamin B6 levels, essential for nerve health and neurotransmitter synthesis. This problem impacts nerves directly and <em>also</em> leads to multiple neurotransmitter systems failure, further damaging nerves (and with the unpleasant symptom of neuropathy) (B-12 causes neuropathy, too).
                    </p>
                    <p>
                        Metabolic pathways involving neurotransmitters are complex. The complexities of these delicate interactions, as shown in the figure "Competitive Neurotransmitter Inhibitors", are well-handled in healthy individuals, but disrupted in PD and disrupted further by DRT.
                    </p>   
                    
                    <p>
                    To elaborate, the aforementioned pathways include Dopamine, norepinephrine, epinephrine, glutathione, S-adenosylmethionine (SAMe), methionine, cysteine, tryptophan, serotonin, and vitamin B6 affect each other and contribute to neurological function, oxidative stress regulation, mood regulation, and overall health. 
                    </p>
                    <p>
                    	Minimizing DRT and supporting other neurotransmitter systems avoids the impossible challenge of micromanaging every neurotransmitter pathway.
                    </p>
                    <p>
                        Diet, supplementation, and regular monitoring must be balanced to slow disease progression.
                    </p>
                    
                    <figure>
	                    <img src="img/5-htp-competitive-inhibitors.jpeg" alt="Diagram of Competitive Neurotransmitter Inhibitors">
	                    <figcaption>
							<p>
								<strong>Competitive Neurotransmitter Inhibitors:</strong> 5-HTP is converted into serotonin in the brain. It inhibits the release of glutamate, mitigates oxidation, and modulates dopamine release.
							</p>
						</figcaption>
					</figure>

                    <p>
                        The effects of PD on the serotonergic system are vastly understated. Several studies have shown serotonergic dysfunction in Parkinson's disease is associated with the development of motor and non-motor symptoms and complications.
                    </p>

                    <p>
                        5-HTP has been shown to have neuroprotective effects in various animal models of neurodegenerative diseases, including PD. It reduces oxidative stress, inflammation, and mitochondrial dysfunction, all of which contribute to PN (Progressive Neurodegeneration).
                    </p>
                    <h5>Serotonin and 5-HTP References</h5>
                    <ol class="reference-list">
						<li>
							<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3201695/"
							title="Serotonergic Dysfunction in Parkinson's Disease and Its Relevance to Disability"
							target="_blank"
							>Serotonergic Dysfunction in Parkinson's Disease and Its Relevance to Disability</a>
							<p>
								This study confirms the lack of any autoregulatory feedback control in serotonergic neurons to regulate L-DOPA-derived dopamine release contributes to L-DOPA-induced dyskinesia (LID).
							</p>
						</li>

                        <li>
							<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7289026/"
							title="Interactions Between the Serotonergic and Other Neurotransmitter Systems in the Basal Ganglia: Role in Parkinson‚Äôs Disease and Adverse Effects of L-DOPA"
							target="_blank"
							>Interactions Between the Serotonergic and Other Neurotransmitter Systems in the Basal Ganglia: Role in Parkinson‚Äôs Disease and Adverse Effects of L-DOPA</a>
							<p>
							Parkinson‚Äôs disease (PD) is characterized by the progressive loss of dopaminergic neurons in the substantia nigra. However, other non-dopaminergic neuronal systems such as the serotonergic system are also involved. Serotonergic dysfunction is associated with non-motor symptoms and complications, including anxiety, depression, dementia, and sleep disturbances. 
							</p>
							<p>
								The lack of any autoregulatory feedback control in serotonergic neurons to regulate L-DOPA-derived dopamine release contributes to the appearance of L-DOPA-induced dyskinesia (LID). 
							</p>
						</li>

                        <li>
							<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4827589/"
							title="Parkinson‚Äôs disease managing reversible neurodegeneration (retracted)"
							target="_blank"
							>Parkinson‚Äôs disease managing reversible neurodegeneration (retracted)</a>
							<p>
								This study explains the interactions between serotonin and dopamine along with their precursors in synthesis, transport, and metabolism. 
							</p>
							<p>
								The study was retracted for conflict of interest, not factual inaccuracies.
							</p>
						</li>
                    </ol>
                </section>
            
                <section id="melatonin">
                    <h4>Melatonin</h4>
                    <ul class="treatment-rating">
                        <li>Mechanisms: Neuroprotective, Antioxidant, Anti-inflammatory, Mitochondrial, Anti-ischemic</li>
                        <li>Dose: 10mg per day üí§ </li>
                        <li>ü©∏üß†BBB: ‚úÖ</li>
                        <li>Safety: 9/10 (90% œÉ)</li>
                        <li>Efficacy: 8/10 (85% œÉ)</li>
                    </ul>
                    <p>
                        Melatonin is a hormone produced by the pineal gland, a small endocrine gland located in the midbrain between the two hemispheres.
                    </p>
                
                    <h5>Neuroprotective</h5>
                    <p>
                        Melatonin protects neurons against oxidative stress, a problem exacerbated by Parkinson's Disease (PD) that leads to progressive neurodegeneration (PN). It interacts with nuclear receptors and signaling pathways to regulate gene transcription. This causes an increase in the production of superoxide dismutase (SOD), glutathione peroxidase, and glutathione reductase.
                    </p>
                	
					<p>
						 Neuroinflammation leads to increased ROS production. Increased ROS production contributes to neuronal damage which perpetuates further neuroinflammation. Melatonin reduces inflammation, thereby reducing oxidative stress.
					</p>
					
					<p>
						Melatonin directly scavenges free radicals, reducing the oxidative burden on cells and allowing antioxidant enzymes to function more efficiently.
					</p>
                    <p>
                        Melatonin receptors MT1 and MT2 in the substantia nigra are reduced in PD patients. Supplementing melatonin helps amend this deficit.
                    </p>

                    <p>
                        Melatonin's neuroprotective effects, bolstered by its anti-inflammatory effects, may contribute to the preservation of MT1 and MT2 receptors and contribute to neuroprotection.
                    </p>

                    <h5>Vasodilation Effects</h5>
                    <p>                
                        Brain ischemia, a common problem in PD, occurs when blood flow and oxygen supply are restricted to various parts of the brain. Worse, ischemia to the substantia nigra exacerbates the problem of decreased dopamine output. This impairs mitochondrial function, leading to energy depletion and cell death.
                    </p>
                
                    <p>
                        Melatonin has vasodilatory effects, relaxing blood vessels, and improving blood flow. This may help improve perfusion to ischemic brain regions, potentially reducing tissue damage and promoting recovery. 
                    </p>
                    
                    <figure>
                        <img src="img/ischemia-pathophysiology.png" alt="Diagram of ischemia pathophysiology in PD" class="block-image">
                        <figcaption>
                            <p>
                                Ischemia pathophysiology at four stages: energy failure, excitotoxicity, oxidative stress, and inflammation. <img src="img/ischemia-mechanism-icon.jpeg" alt="icon for diagram"> Represents the site of melatonin action
                            </p>
                        </figcaption>
                    </figure>

                
                    <h5>Mitoprotective</h5>
                    <p>
                        Melatonin protects mitochondrial function and integrity, mitigating cellular damage caused by ischemia.
                    </p>
                    <h5>Supplementation</h5>
                    <p>
                    	Melatonin is safe to take. Excessive doses over 10-15mg may cause next-day tiredness and headache.


                    <p>
                        Time-released formulations help maintain melatonin levels for a longer period of time. The reduced peak concentration helps maintain sleep throughout the night.
                    </p>
                    
                    <h5>
                        Product
                    </h5>
                    <figure>
                    <img src="img/sleep3.png" alt="Sleep3 &mdash; Nature's Bounty Sleep3 Melatonin 10mg, Maximum Strength 100% Drug Free Sleep Aid, Dietary Supplement, L-Theanine & Nighttime Herbal Blend Time Release Technology, 60 Tri-Layered Tablets">
                    <figcaption>
						<p>
							<a
								href="https://www.amazon.com/gp/product/B07PXT5LYR/ref=ppx_yo_dt_b_search_asin_title?ie=UTF8&psc=1;tag=garrettsmit02-20&amp;camp=1789&amp;creative=9325&amp;linkCode=as2&amp;creativeASIN=B07DJJXPDD&amp;linkId=fcbfe06c3bf2c5b2709c3b7afef8459"
								>Sleep3 &mdash; Nature's Bounty &mdash; Time-released Melatonin &mdash; 10mg</a>
						</p>
                    </figcaption>
                	</figure>
                	
                    <h5>Melatonin References</h5>
                    <ol class="reference-list">
                        <li>
                            <a href="https://pubmed.ncbi.nlm.nih.gov/10668453/"
                    >Melatonin as a pharmacological agent against neuronal loss in experimental models of Huntington's disease, Alzheimer's disease and 
                    parkinsonism</a>
                    
                    		<p>
                    			Melatonin easily crosses the BBB and stimulates a variety of antioxidative enzymes including superoxide dismutase, glutathione peroxidase and glutathione reductase. 
                        </li>

                        <li>
                        	<a href="https://pubmed.ncbi.nlm.nih.gov/16179266/"
                        	title="Role of Melatonin in Neurodegenerative Diseases"
                        	target="_blank">Role of Melatonin in Neurodegenerative Diseases</a>
                        	<p>
                        	This review concluded that melatonin preserves mitochondrial homeostasis, reduces free radical generation, e.g., by enhancing mitochondrial glutathione levels, and safeguards proton potential and ATP synthesis by stimulating complex I and IV activities.
                        	</p>
                        <li>
                        	<a href="https://www.parkinsonalliance.org/grantsgiven/2000-23/"
                        	target="_blank"
                        	title="Superoxide Dismutase Activity in Early and Advanced Parkinson's Disease">Superoxide Dismutase Activity in Early and Advanced Parkinson's Disease</a>
                        	<p>
                        		 A defect in SOD activity develops over time in PD.
                        	</p>
                        </li>
                        <li>
							<a href="https://www.frontiersin.org/articles/10.3389/fnagi.2020.00053/full"
							title="Contra-Directional Expression of Plasma Superoxide Dismutase with Lipoprotein Cholesterol and High-Sensitivity C-reactive Protein as Important Markers of Parkinson‚Äôs Disease Severity"
							target="_blank"
							>[Contra-Directional Expression of Plasma Superoxide Dismutase with Lipoprotein Cholesterol and High-Sensitivity C-reactive Protein as Important Markers of Parkinson‚Äôs Disease Severity</a>
							<p>
								&ldquo;Superoxide dismutase (SOD) is one of the most important antioxidant enzymes both inside and outside cell membranes, and it catalyzes the dismutation of superoxide radicals (O2‚àí) to hydrogen peroxide (H2O2), which is converted to water and oxygen by catalase and glutathione peroxidase.&rdquo;
							</p>
						</li>
                    </ol>
                </section>
            </section>
            <section id="quinones">
                <h3>
                    Mitochondrial Quinones (PQQ, CoQ10, K2) 
                </h3>
                <p>
                    Quinones are a class of compounds that play a crucial role in maintaining mitochondrial function and overall cellular health. 
                </p>
                <p>
                    PQQ, CoQ10, and Menaquinone (MK-4 and MK7 (k2)) are three quinones that have been studied for their potential benefits on mitochondrial function.
                </p>
                <p>
                    All three promote mitochondrial function by supporting biogenesis, energy production, and reducing oxidative stress. Combined supplementation may have synergistic effects on mitochondrial function, leading to improved overall cellular health, reduced fatigue, and better overall health.
                </p>
                <section id="pqq">

                    <h3>Pyrroloquinoline Quinone (PQQ)</h3>
                    <ul class="treatment-rating">
                        <li>Mechanisms: Antifibrillogenic, Anti-aggregant, Anti-ischemic, Mitochondrial, Neuroprotective, Antioxidant, Anti-inflammatory, Neurorestorative</li>
                        <li>Dose: 50-200mg per day üçΩÔ∏è </li>
                        <li>ü©∏üß†BBB: ‚úÖ</li>
                        <li>Safety: 9/10 (90% œÉ)</li>
                        <li>Efficacy: 8/10 (85% œÉ)</li>
                    </ul>

                    <p>
                        PQQ is a naturally occurring coenzyme manufactured by bacteria, found in plants in tiny amounts, and utilized by mammalian cells as an important nutritional growth factor. PQQ is not produced endogenously in humans.
                    </p>
                    <p>
                        PQQ has multiple beneficial effects, including preventing the formation of &alpha;-synuclein fibrils, strengthening mitochondria, promoting mitochondrial biogenesis in brain cells, improving cognitive deficits from oxidative damage, inhibiting senescence, and enhancing memory, attention, cognition, and learning. It also increases blood flow to the cerebral cortex, protects against cell damage from pesticides, prevents neurodegeneration due to oxidative stress, and reduces LDL cholesterol to inhibit osteoporosis.
                    </p>
                    
                    <h4>Supplementation</h4>
                    <p>
                        50mg-200mg per day PQQ is very safe. It is fat-soluble and best taken with other fat-soluble supplements and food.
                    </p>
                    <p>
                        In 2017, the European Food Safety Authority (EFSA) Panel on Dietetic Products determined a No Observed Adverse Effect Level (NOAEL) of 100mg/kg per day for 90 days. For a 50kg woman, this translates to a dose of 5g per day. Other studies have investigated PQQ's benefits and safety using similar dosages.
                    </p>
                    <p>
                        Given the vast multitude of benefits that occur on the cellular level, and especially by reducing alpha-synuclein fibrils relevant to PD sufferers, and the incredibly high safety threshold, a recommended dose of PQQ is 100-200mg per day. There are no known contraindications.
                    </p>
                    
                    <h4>Side Effects</h4>
                    <p>
                        Mild headaches and insomnia when taking PQQ at night. Higher doses (e.g., 100-200 mg per day) are well-tolerated and might offer more pronounced effects. Start with a lower dose 50 mg per day and work your way up.
                    </p>
                    
                    <h5>Product</h5>
                    <a
                href="https://www.amazon.com/gp/product/B07DJJXPDD/ref=as_li_tl?ie=UTF8&amp;tag=garrettsmit02-20&amp;camp=1789&amp;creative=9325&amp;linkCode=as2&amp;creativeASIN=B07DJJXPDD&amp;linkId=fcbfe06c3bf2c5b2709c3b7afef84597"
                    >
                        VED PQQ 50mg
                    </a>
                    <h5>
                        <img src="img/pqq.jpeg" alt="pqq" />
                    </h5>
                    <h5>
                        PQQ References:
                    </h5>
                    <h4>PQQ References</h4>
                    <ol>
                        <li>
                            <a href="https://www.dementia.news/2018-12-13-pqq-combats-neurodegeneration-that-can-affect-the-aging-brain.html" 
                                title="PQQ is effective in combating neurodegeneration"
                                target="_blank">PQQ combats neurodegeneration that can affect the aging brain</a>
                            <p>
                                This article discusses the effectiveness of PQQ in preventing neurodegenerative diseases.
                            </p>
                        </li>
                        <li>
                            <a href="https://www.sciencedirect.com/science/article/abs/pii/S0006291X06019747" 
                                title="Pyrroloquinoline quinone (PQQ) prevents fibril formation of Œ±-synuclein"
                                target="_blank">PQQ prevents fibril formation of alpha-synuclein</a>
                            <p>
                                This study demonstrates that PQQ inhibits the fibril formation of alpha-synuclein, which is significant in neurodegenerative diseases.
                            </p>
                        </li>
                        <li>
                            <a href="https://pubmed.ncbi.nlm.nih.gov/19861415/" 
                                title="Pyrroloquinoline quinone stimulates mitochondrial biogenesis through cAMP response element-binding protein phosphorylation and increased PGC-1alpha expressions"
                                target="_blank">PQQ stimulates mitochondrial biogenesis</a>
                            <p>
                                This study shows that PQQ enhances mitochondrial biogenesis through cAMP response element-binding protein phosphorylation and increased PGC-1alpha expression.
                            </p>
                        </li>
                        <li>
                            <a href="https://pubmed.ncbi.nlm.nih.gov/31860387/" 
                                title="Effects of Pyrroloquinoline Quinone (PQQ) Supplementation on Aerobic Exercise Performance and Indices of Mitochondrial Biogenesis in Untrained Men"
                                target="_blank">PQQ supplementation on aerobic exercise performance</a>
                            <p>
                                The study found PQQ supplementation increases mitochondrial biogenesis by way of significant elevations in PGC-1Œ± protein content. untrained men.
                            </p>
                        </li>
                        <li>
                            <a href="https://pubmed.ncbi.nlm.nih.gov/29714638/" 
                                title="Mechanisms Behind Pyrroloquinoline Quinone Supplementation on Skeletal Muscle Mitochondrial Biogenesis: Possible Synergistic Effects with Exercise"
                                target="_blank">PQQ's effects on skeletal muscle mitochondrial biogenesis</a>
                            <p>
                            This research explores how PQQ supplementation, possibly synergistic with exercise, impacts skeletal muscle mitochondrial biogenesis.
                            </p>
                        </li>
                        <li>
                            <a href="https://pubmed.ncbi.nlm.nih.gov/18231627/" 
                                title="PQQ prevents cognitive deficit in rats"
                                target="_blank">PQQ prevents cognitive deficit caused by oxidative stress in rats</a>
                            <p>
                                This rodent study indicates that PQQ supplementation markedly improved the memory deficit and can prevent cognitive deficits in rats induced by oxidative stress.
                            </p>
                        </li>
                        <li>
                            <a href="https://pubmed.ncbi.nlm.nih.gov/20482893/" 
                                title="The inhibitory effect of pyrroloquinoline quinone on the amyloid formation and cytotoxicity of truncated alpha-synuclein"
                                target="_blank">PQQ inhibits amyloid formation and cytotoxicity</a>
                            <p>
                                This study showed that PQQ dramatically inhibits the fibril formation of C-terminal truncated alpha-synuclein 110119, and 133 as well as the mixtures of full-length alpha-synuclein with these truncated variants. Moreover, PQQ decreases the cytotoxicity of truncated alpha-synuclein.
                            </p>
                        </li>
                        <li>
                            <a href="https://pubmed.ncbi.nlm.nih.gov/26622336/" 
                                title="PBiological effects of pyrroloquinoline quinone on liver damage in Bmi-1 knockout mice"
                                target="_blank">PQQ effects on liver damage in Bmi-1 knockout mice</a>
                            <p>
                                This study found that a moderate dose of PQQ significantly protected the liver from deleterious effects by inhibiting oxidative stress and participating in DNA damage repair
                            </p>
                        </li>
                        <li>
                            <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5666047/" 
                                title="Effect and mechanism of pyrroloquinoline quinone on anti-osteoporosis in Bmi-1 knockout mice-Anti-oxidant effect of pyrroloquinoline quinone"
                                target="_blank">PQQ's anti-osteoporosis effects in Bmi-1 knockout mice</a>
                            <p>
                                The study showed that supplemental PQQ played a role in anti-osteoporosis by up-regulating antioxidant capacity, inhibiting oxidative stress and reducing DNA damage, down-regulating CDKI proteins levels, and decreasing cell apoptosis
                            </p>
                        </li>
                        <li>
                            <a href="https://pubmed.ncbi.nlm.nih.gov/27773733/" 
                                title="Effects of Pyrroloquinoline Quinone Disodium Salt Intake on the Serum Cholesterol Levels of Healthy Japanese Adults"
                                target="_blank">PQQ intake effects on serum cholesterol levels</a>
                            <p>
                                This study showed the effects of PQQ disodium salt (BioPQQ‚Ñ¢) on serum TG and cholesterol levels in humans after 6 and 12 wk of treatment at an oral dosage of 20 mg/d. 
                            </p>
                            <p>
                                PQQ suppressed the LDL-chol level, which is an important finding, because a high level of this lipid is a risk factor for various lifestyle-related diseases.
                            </p>
                        </li>
                    </ol>
                </section>
                <section id="k2">
                    <h4>Vitamin K2</h4>
                    <p>
                        Vitamin K2 has been shown to support the production of ATP and to reduce the production of ROS.
                    </p>
                    <p>
                        Vitamin K2 supports mitochondrial function by activating sirtuin 1 (SIRT1), a longevity gene and protein that regulates mitochondrial biogenesis and function.
                    </p>
                </section>
                <section id="ubiquinol">
                    <h3>Ubiquinol</h3>
                    <ul class="treatment-rating">
                        <li>Mechanisms: Mitochondrial, Antioxidant
                        <li>Dose: [Recommended dose]
                        <li>ü©∏üß†BBB: ‚ùå?
                        <li>Safety: 8/10 (85% œÉ)
                        <li>Efficacy: 7/10 (80% œÉ)
                    </ul>
                    <p>
                        Ubiquinol is the reduced form of CoQ10. Ubiquinol is better absorbed by the body than ubiquinone, the oxidized form of CoQ10.
                    </p>
                    
                    <p>
                     CoQ10 improves mitochondrial function with exercise and improves cognitive function in chronic fatigue syndrome (CFS).
                    <p>
                        In Parkinson&rsquo;s, ubiquinol-10 may significantly improve PD with wearing off, as judged by total UPDRS scores, and is safe and well-tolerated.
                    </p>
                    <p>
                        Previous studies using ubiquinone showed a lack of effect in PD patients. However, unlike ubiquinone, ubiquinol, the reduced form of CoQ10, has shown to be effective.
                    </p>
                
                    <h3>Ubiquinol in Parkinson's Disease</h3>
                        
                    <p>
                        Mitochondrial dysfunction is a problem in the pathogenesis of PD. Impaired mitochondrial function leads to increased oxidative stress and reduced ATP production, exacerbating neuronal damage. This dysfunction compromises cellular energy metabolism and impairs the ability of neurons to maintain their normal functions. Defective mitochondria contribute to the accumulation of toxic protein aggregates, including alpha-synuclein, leading to lewy bodys, leading to senescence, further exacerbating neurodegeneration. 
                    </p>
                    <p>
                        Addressing mitochondrial dysfunction in Parkinson's disease requires a multifaceted approach. High-dose CoQ10 supplementation is one way to improve mitochondrial function.
                    </p>
                    <p>
                        Multiple system atrophy (MSA) is progressive neurodegeneration characterized by autonomic failure in various forms of Parkinsonism.
                    </p>
                    <p>
                        In studies show that CoQ10 supplementation can reduce apoptosis in neurons derived from MSA patients. 
                    </p>
                    <p>
                        CoQ10 plays an essential role in mitochondrial electron transport (<abbr title="electron transport chain">ETC</abbr>), transferring electrons and protons across the mitochondrial inner membrane to generate cellular energy.
                    </p>

                    <h5>Supplementation</h5>
                    <p>
                        Ubiquinol has been demonstrated to be superior to ubiquinone. Phytosome Q10 has been shown to provide even greater absorption, but research shows strong safety and efficacy of ubiquinol, making it a reliable option for CoQ10 supplementation.
                    </p>
                    <p>
                        In a study published in The Lancet, a patient with advanced Multiple System Atrophy (MSA) showed restored brain oxygen consumption after taking 1200 mg of oral ubiquinol. This finding suggests a potential benefit of ubiquinol supplementation in MSA patients, possibly related to its role in supporting mitochondrial function. 
                    </p>
                    <h5>Products</h5>
                    <ul class="product-list">
                        <li>
                            <figure>
                                <img src="img/coq10-pqq.png" alt="Life Extension Super Ubiquinol CoQ10 with PQQ">
                                <figcaption>
                                    <p>
                                        <a href="https://www.amazon.com/Life-Extension-Ubiquinol-Softgels-Bottles/dp/B00MOX1IZC/ref=sr_1_5_pp?sr=8-5" target="_blank">Life Extension Super Ubiquinol CoQ10 with PQQ, 30 Softgels. Pack of 2 Bottles</a>
                                    </p>
                                </figcaption>
                            </figure>
                        </li>
                        <li>
                            <figure>
                                <img src="img/solary-phytosome-q10.png" alt="CoQ 10 ubiquisome">
                                <figcaption>
                                    <p>
                                        <a href="https://www.amazon.com/SOLARAY-CoQ-10-Phytosome-Easy-Digest/dp/B0CD2Z7TFW/ref=sr_1_5?dib=eyJ2IjoiMSJ9.cmtVvwJRdfFnIup8jBAQPfvVyJOLRy8nh2-QFBIp8FRrhaaSERHS7aUruerpkYDNNQLuYcSkt54YPUcPYAm6BK6gTaouilEq7Oba4FdcjHvzQvkLw2K1YeX0pnTSFYvjhwRqOXHnSsl2r0RoMzCilQ.5DYKhoPdVCHt_af3m1ICyUIAviwqKzsCkLSGWbQcUFg&dib_tag=se&keywords=UBIQSOME&qid=1717966723&sr=8-5">SOLARAY CoQ-10 Phytosome</a>
                                    </p>
                                </figcaption>
                            </figure>
                        </li>
                    </ul>

                    <h4>
                        Ubiquinol References:
                    </h4>
                    <ol class="reference-list">
                        <li>
                            <a href="https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00097-4/fulltext"
                            title="High-dose ubiquinol supplementation in multiple-system atrophy: a multicentre, randomised, double-blinded, placebo-controlled phase 2 trial"
                            target="_blank">
                            High-dose ubiquinol supplementation in multiple-system atrophy: a multicentre, randomised, double-blinded, placebo-controlled phase 2 trial</a>
                            <p>
                                This multicenter, randomised, double-blind, placebo-controlled, phase 2 trial showed igh-dose ubiquinol was well-tolerated and improved multiple system atrophy, compared with placebo.
                            </p>
                        </li>
                        <li>
                            <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10632062/"
                            title="[Involvement of Coenzyme Q10 in Various Neurodegenerative and Psychiatric Diseases]"
                            target="_blank"
                            >Involvement of Coenzyme Q10 in Various Neurodegenerative and Psychiatric Diseases</a>
                            <p>
                                Discusses how CoQ10 might protect the nervous system from degeneration and deterioration, mainly due to its antioxidant and energy-regulating role in mitochondria. Specifically, how CoQ10 supplementation can lead to an increment in its levels in the mitochondria.
                            </p>
                        </li>
                        <li>
                            <a href="https://pubmed.ncbi.nlm.nih.gov/27125909/"
                            title="Ubiquinol supplementation improves autonomic nervous function and cognitive function in chronic fatigue syndrome"
                            target="_blank">
                            Ubiquinol supplementation improves ANS and cognitive function in CFS</a>
                            <p>
                                This RCT showed that supplementation with ubiquinol-10 (150 mg/day) for 12 weeks improved many CFS symptoms.
                            </p>
                        </li>
                        <li>
                            <a href="https://www.wjgnet.com/2218-6212/full/v4/i1/1.htm?s=qc"
                            title="Coenzyme Q10 in neurodegenerative disorders: Potential benefit of CoQ10 supplementation for multiple system atrophy"
                            target="_blank"
                            >Coenzyme Q10 in neurodegenerative disorders: Potential benefit of CoQ10 supplementation for multiple system atrophy</a>
                            <p>
                                Discusses how CoQ10 supplementation may be beneficial for MSA, as for other primary CoQ10 deficiencies
                            </p>
                        </li>
                        <li>
                            <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6220380/"
                            title="Combination of Coenzyme Q10 Intake and Moderate Physical Activity Counteracts Mitochondrial Dysfunctions in a SAMP8 Mouse Model"
                            target="_blank">
                            Combination of Coenzyme Q10 Intake and Moderate Physical Activity Counteracts Mitochondrial Dysfunctions in a SAMP8 Mouse Model</a>
                            <p>
                                This rodent study shows that ubiquinol supplementation counteracts the deleterious effects of physical exercise-derived ROS improving mitochondrial functionality in an oxidative stress model, such as SAMP8 in the presarcopenia phase
                            </p>
                        </li>
                        <li>
                            <a href="https://pubmed.ncbi.nlm.nih.gov/26054881/"
                            title="Randomized, double-blind, placebo-controlled pilot trial of reduced coenzyme Q10 for Parkinson's disease"
                            target="_blank">
                            Randomized, double-blind, placebo-controlled pilot trial of reduced coenzyme Q10 for Parkinson's disease</a>
                            <p>
                            This  double-blind, placebo-controlled RCT pilot trial showed improvement in symptoms in PD patients.
                            </p>
                        </li>

                        <li>
                            <a href="https://pubmed.ncbi.nlm.nih.gov/31475897/"
                            title="A New Food-grade Coenzyme Q10 Formulation Improves Bioavailability: Single and Repeated Pharmacokinetic Studies in Healthy Volunteers"
                            target="_blank">Phytosome Q10 Formulation Improves Bioavailability in Healthy Volunteers</a>
                            <p>
                                This study shows that coenzyme Q10 phytosome in simulated intestinal fluids results in an improvement in oral absorption of coenzyme Q10 in healthy volunteers, three times more than the coenzyme Q10 according
                            </p>
                        </li>
                        <li>
                            <a href="https://pubmed.ncbi.nlm.nih.gov/27128225/"
                            title="Comparison study of plasma coenzyme Q10 levels in healthy subjects supplemented with ubiquinol versus ubiquinone"
                            target="_blank"></a>
                            <p>
                                This small study on human volunteers showed both ubiquinol and ubiquinone increased plasma CoQ10, but the increase in CoQ10 /cholesterol ratio were significantly better after ubiquinol than ubiquinone, indicating superior bioavailability. 
                            </p>
                        </li>
                        <li>
                            <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6155102/"
                            title="The pathogenesis linked to coenzyme Q10 insufficiency in iPSC-derived neurons from patients with multiple-system atrophy"
                            target="_blank">Coenzyme Q10 insufficiency in patients with multiple-system atrophy</a>
                            <p>
                                This study shows a causal relationship between neuronal apoptosis and coenzyme Q10 deficiency.
                            </p>
                        </li>
                        <li>
                            <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7278738/"
                            title="Bioavailability of Coenzyme Q10: An Overview of the Absorption Process and Subsequent Metabolism"
                            target="_blank">Bioavailability of Coenzyme Q10</a>
                            <p>
                                This study compares the relative bioavailability and efficacy of ubiquinone and ubiquinol forms of CoQ10.
                            </p>
                        </li>
                    </ol>
                </section>
            </section>
            <section id="gg">
                <h3>
                    Geranylgeraniol (GG)
                </h3>
                <ul class="treatment-rating">
                    <li>Mechanisms: Mitochondrial, Dopaminergic side-effects, Antioxidant
                    <li>Dose: 150 mg per day üçΩÔ∏è
                    <li>ü©∏üß†BBB: ‚úÖ? (probably)
                    <li>Safety: 9/10 (85%)
                    <li>Efficacy: 5/10 (30%)
                </ul>
                <p>
                    Geranylgeraniol (GG) is an essential precursor for CoQ10, vitamin K2, and testosterone biosynthesis. It also plays a role in protein synthesis and modification. 
                </p>
                
                <p>
                    GG is synthesized naturally within the human body through the mevalonate (cholesterol) pathway, but its production decreases with age. This decline in GG synthesis can lead to decreased production of CoQ10, vitamin K2, and testosterone.
                </p>
                                                                                
                <h4>GG and Parkinson‚Äôs Disease</h4>
                <p>
                    GG can <em>probably</em> cross the BBB (molecules with a molecular weight &lt; 400 <abbr title="daltons">Da</abbr> can cross it) and, if it does, this would confer an advantage over supplementation of CoQ10 and K2. 
                </p>
                <p>
                    Dopamine synthesis is energetically demanding, relying on cellular energy. CoQ10 acts as a vital energy substrate for brain mitochondria, supporting their function and facilitating dopamine production. 
                </p>

                <p>
                    Given the uncertainty regarding CoQ10's BBB permeability, supplementing GG may ensure CoQ10 availability in the brain.
                </p>
                <h4>Mechanism of Action</h4>
                <p>
                    GG is used to convert mevalonic acid, the precursor for cholesterol, to CoQ10 and K2, and sex hormones. 
                </p>
                
                <p>
                    CoQ10 and vitamin K2 are primarily synthesized endogenously in the body and the brain. Evidence suggests that some forms of CoQ10 and vitamin K2 can cross the blood-brain barrier (BBB), however, this is not firmly established. 
                </p>

                <h4>Supplementation</h4>
                <p>
                    GG extracted from annatto is used to produce GG, a fat-soluble, orally-bioavailable supplement that probably crosses the BBB and aids in CoQ10 biosynthesis. 
                </p>

                <p>
                    Supplementing geranyl geraniol is considered very safe because the body has a natural regulatory mechanism to keep levels from exceeding a healthy range.
                </p>
                
                <h4>Product</h4>
                <p>
                    
                </p>
                <ul class="product-list">
                    <li>
                        <a href="https://www.amazon.com/Xtendlife-GG-Pure-Contains-lowering/dp/B0988TVJCH/ref=sr_1_8?sr=8-8">Xtendlife GG Pure - Geranylgeraniol</a>
                    </li>
                    <li>
                        <figure>
                            <figcaption>
                                <p>
                                    <a href="https://www.amazon.com/Xtendlife-Xtend-Quinol-Geranylgeraniol-Supplement-Production/dp/B0CCRMH1W6/ref=sr_1_1?rdc=1&s=hpc&sr=1-1">Xtendlife Xtend-Quinol CoQ10 &amp; GG</a>
                                </p>
                            </figcaption>
                        </figure>
                    </li>
                </ul>
                
                <h4>References</h4>
                <ol>
                    <li>
                        <a href="https://pubmed.ncbi.nlm.nih.gov/34352722/"
                        title="Beneficial effect of dietary geranylgeraniol on glucose homeostasis and bone microstructure in obese mice is associated with suppression of proinflammation and modification of gut microbiome"
                        target="_blank">GG improves glucose homeostasis and bone microstructure in obese mice</a>
                        <p>
                            This rodent study concluded that GG improves glucose homeostasis and bone microstructure in obese mice, probably via suppression of pro-inflammation and modification of microbiome composition.
                        </p>
                    </li>
                    
                    <li>
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4813225/"
                        title="Geranylgeraniol and Neurological Impairment: Involvement of Apoptosis and Mitochondrial Morphology"
                        target="_blank"
                        >Geranylgeraniol and Neurological Impairment: Involvement of Apoptosis and Mitochondrial Morphology</a>
                        <p>
                            This in vitro study found co-administration of geranylgeraniol (GGOH) reduced the inflammatory marker and the damage of the mitochondria, maintaining its shape and components. 
                        </p>
                    </li>
                </ol>
            </section>
            <section id="nattokinase">
                <h3>Nattokinase</h3>
                <p>
                    Nattokinase is a proteolytic and fibrinolytic enzyme Nattokinase that reduces inflammation.
                </p>
                <p>
                    Nattokinase has been shown to degrade amyloid fibrils in mice, which may help to slow down the progression of Parkinson‚Äôs disease.
                </p>
                <p>
                    Nattokinase has been shown to promote the non-amyloidogenic processing of AŒ≤, which may help to reduce the accumulation of amyloid plaques in the brain.
                </p>
            </section>
            <section id="dha">
                <h3>
                    Docosahexaenoic Acid (DHA)
                </h3>
                <p>
                    DHA is neuroprotective and prevents ROS production in dopaminergic neurons via enhancement of glutathione homeostasis. With DHA, higher doses are not only safe, they are more effective in lipid oxidation. 2000mg DHA per
                    day is effective and safe, and, in DHA/EPA combinations, DHA in greater proportion to EPA is more effective.
                </p>
                <p>
                    In PD, Unilateral oxidopamine lesions of the nigrostriatal pathway produce side-biased motor impairments that reflect motor deficits.
                </p>
                <p>
                    <strong>
                        DHA Dosage:
                    </strong>
                    2 &ndash; 6g/day.
                </p>
                <p>
                    DHA exhibits a dose-dependent response. Gastric tolerance between individuals vary. Start at 2 grams and work upwards from there. Spread consumption over a period of time.
                </p>
                <p>
                    <strong>
                        DHA + Uridine
                    </strong>
                </p>
                <p>
                    DHA has been shown to restore unilateral dopaminergic neurotransmission loss in this model of Parkinson's disease, and the effect was augmented when combined with Uridine (uridine-5&rsquo;-monophosphate).
                </p>
                <p>
                    In a 2006 dual university study, Brain phosphatidylcholine rose by 13&ndash;22% with uridine and choline alone, or DHA alone, or by 45% with the combination. Oral administration of uridine or DHA alone was shown to
                    increases synaptic proteins and phospholipids, and in combination, a synergistic effect was noticed.
                </p>
                <h4>
                    DHA Product:
                </h4>
                <a href="https://www.amazon.com/gp/product/B004T7DYOO/ref=as_li_tl?ie=UTF8&amp;tag=garrettsmit02-20&amp;camp=1789&amp;creative=9325&amp;linkCode=as2&amp;creativeASIN=B004T7DYOO&amp;linkId=03df93bc6eab5eeabecf94de7e16e7e4">
                    Nordic Naturals Children&rsquo;s DHA, Strawberry
                </a>
                <div>
                    <img src="img/childrens-dha.jpeg" title="children's DHA" />
                </div>
                <h4>
                    DHA + Uridine References:
                </h4>
                <ol>
                    <li>
                        <a href="https://pubmed.ncbi.nlm.nih.gov/32001239/">
                            Docosahexaenoic acid protects motor function and increases dopamine synthesis in a rat model of Parkinson's disease via mechanisms associated with increased protein kinase activity in the striatum
                        </a>
                    </li>

                    <li>
                        <a href="https://pubmed.ncbi.nlm.nih.gov/25545062/"> Docosahexaenoic acid prevents paraquat-induced reactive oxygen species production in dopaminergic neurons via enhancement of glutathione homeostasis</a>
                    </li>

                    <li>
                        <a href="https://pubmed.ncbi.nlm.nih.gov/29846653/"> High-Dose DHA Has More Profound Effects on LDL-Related Features Than High-Dose EPA: The ComparED Study</a>
                    </li>
                    <li>
                        <a href="https://pubmed.ncbi.nlm.nih.gov/28778752/"> DHA, EPA, and their combination at various ratios differently modulated A&beta; 25-35-induced neurotoxicity in SH-SY5Y cells</a>
                    </li>

                    <li>
                        <a href="https://pubmed.ncbi.nlm.nih.gov/18761383/"> Restorative effects of uridine plus docosahexaenoic acid in a rat model of Parkinson's disease</a>
                    </li>

                    <li>
                        <a href="http://wurtmanlab.mit.edu/static/pdf/1016.pdf">Synaptic proteins and phospholipids are increased in gerbil brain by administering uridine plus docosahexaenoic acid orally</a>
                    </li>

                    <li>
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2478743/">
                            Chronic Administration of DHA and UMP Improves the Impaired Memory of Environmentally Impoverished Rats
                        </a>
                    </li>

                    <li>
                        <a href="https://www.tandfonline.com/doi/full/10.1080/10408398.2018.1425978">
                            How does high DHA fish oil affect health? A systematic review of evidence
                        </a>
                    </li>
                </ol>
            </section>
            <section id="uridine">
                <h4>
                    Uridine Monophoshate (uridine-5&rsquo;-monophosphate, UMP)
                </h4>
                <p>
                    Uridine is a type of nucleoside, a fundamental component of nucleic acids. Nucleic acids are the building blocks of life, and they play a crucial role in the storage and transmission of genetic information.
                </p>
                <h5>How it Works</h5>
                <p>
                    Uridine increases CDP choline. As explained under the section DHA &amp; Uridine, Uridine restores unilateral dopaminergic neurotransmission caused by oxidopamine lesions.
                </p>
                <p>
                    UMP is a precursor to the synthesis of brain phospholipids, which are important for cell membrane structure and function. It has been shown to support memory, learning, and overall cognitive function.
                </p>

                <p>
                    <strong>‚ùå CAUTION </strong>
                </p>
                <p>
                    Contrary to dying myth, acetylcholine does not cause the tremors of PD. The drugs given to reduce CDP choline in PD, such as Trihexyphenidyl and Benztropine, not only don't help PD, they cause confusion, memory issues, hallucinations, dry mouth, blurry vision, and urinary retention problems &mdash; serious side effects.
                </p>
                <p><em>Increasing</em> choline by 1,200 mg of supplemental citicoline improved tremors in PD and allowed patients to halve their L-dopa + dopa decarboxylase inhibitor dose. Uridine increases CDP.</p>
                <p>
                    It's important to have a healthcare provider that understands and accounts for this as part of a holistic plan.
                </p>

                <h5>
                    Uridine Monophosphate Product
                </h5>
                <a
                    href="https://www.amazon.com/Monophosphate-Disodium-Supports-Cognitive-Mitochondrial/dp/B01BYY0QY0/ref=sr_1_4_pp?s=hpc&sr=1-4&amp;tag=garrettsmit02-20&amp;camp=1789&amp;creative=9325&amp;linkCode=as2&amp;creativeASIN=B086KMB9YN&amp;linkId=e758783750e802b48ff75aa147f0afa9"
                >Uridine Monophosphate Powder
                </a>
                <h5>Uridine and CDP Choline References</h5>
                <ol>
                    <li>
                        <a href="https://pubmed.ncbi.nlm.nih.gov/18761383/"> Restorative effects of uridine plus docosahexaenoic acid in a rat model of Parkinson's disease</a>
                    </li>
                </ol>
            </section>
            <section id="citicoline">
                <h4>
                    Citicoline (CDP Choline)
                </h4>
                <p>
                    As mentioned in the uridine discussion, citicoline supplementation halves L-Dopa / dopa decarboxylase dosage. Citicoline is neuroprotective.
                </p>
                <p>
                    In patients with chronic cerebral ischemia, citicoline improves scores in cognitive rating scales. 
                </p>
           
                <p>     
                    Citicoline neuroprotectives effects through multiple pathways. It reduces glutamate excitotoxicity and oxidative stress, reduces glutamate excitotoxicity and oxidative stress, increases neurotrophin levels, enhances neurotransmitter release (such as norepinephrine and dopamine), promotes mitochondrial function, and modulates insulin signaling. 
                </p>
                
                <p>
                    Neurotrophins BDNF and NT-3 are reduced in PD. This is problematic, as neurotrophins increase neuronal survival and growth. Their depletion in PD likely contributes to progressive neurodegeneration (PN). Strategies aimed at increasing neurotrophin expression or activity, such as by supplementation do not hurt, are neuroprotective, and are reported to have noticeable positive effects.
                </p>
                
                
                <h4>Ischemic Mitigation</h4>
                <p>
                Citicoline prevents ischemia-induced tissue accumulation of free fatty acids and reduces infarct volume (a direct measurement of the extent of tissue death or necrosis caused by an ischemic stroke), and brain edema, thus resulting in an antiapoptotic effect that is related to the mitochondrial-dependent cell death mechanism.
                </p>
                
                
                <p>
                    Citicoline improves axonal transport deficits and supports axon regeneration. Axon regeneration is limited in adults, partly due to the reduced growth potential of mature neurons.
                </p>

                <h5>Uridine and CDP Choline</h5>
                <p>
                    CDP choline is involved in the synthesis of phosphatidylcholine and also serves as a precursor to both choline and uridine in the brain.
                </p>
                <p>
                    Uridine, a nucleotide base, can convert back to CDP-choline (Citicoline) and back again through a natural metabolic pathway.
                </p>
                <p>
                    The combination of uridine and CDP choline has been shown to have numerous benefits for brain health and cognitive function.
                </p>
                <p>
                    Uridine and CDP choline have been shown to enhance memory and learning by increasing the production of acetylcholine, a neurotransmitter involved in memory formation.
                </p>
                <p>
                    Uridine and CDP choline are each neuroprotective. Both increase phosphatidylcholine and improves the integrity of cell membranes. When combined, these effects are synergistic, leading to enhanced neuroprotection.
                </p>
                <p>
                   Uridine and CDP choline have been shown to improve cognitive function, including attention, focus, and processing speed.
                </p>
                <p>
                    Because Uridine increases CDP levels, it is necessary balance their co-supplemention.
                </p>
                <p>
                    Striking a balance between supplemental uridine and CDP choline is especially important for individuals taking carbidopa/levodopa.
                </p>
                <p>
                    Since uridine is a precursor to CDP choline, increasing uridine levels can potentially affect the balance of these two compounds in the body.
                </p>
                
                <p>
                    UMP and CDP choline may have slightly different mechanisms of action and potential benefits. Some research suggests that CDP-choline may have more direct effects on acetylcholine levels in the brain, while UMP more directly effects dopamine levels.
                </p>
                <p>
                   No serious side effects have occurred in any series of patients treated with citicoline, which attests to the safety of treatment with citicoline.  Normally, the body tightly regulates these pathways but excessive supplementation is unnecessary and may lead to imbalances, especially in the later stages of the disease.
                </p>
                <h5>CDP Choline Supplementation</h5>
                <p>
                    500-1000mg CDP choline is generally very safe and well tolerated.
                </P>
                <p>
                    The effects of CDP choline vary on individual bases and are affected by other supplements and medications being used, so the dose will need to be custom-tailored.
                </p>
                <h5>
                    Product:
                </h5>
                <a href="https://www.amazon.com/gp/product/B001ESE21K/ref=as_li_tl?ie=UTF8&amp;tag=garrettsmit02-20&amp;camp=1789&amp;creative=9325&amp;linkCode=as2&amp;creativeASIN=B001ESE21K&amp;linkId=1a2fefa4dbb6e04cc9613e95c02b9867">
                    Healthy Origins Cognizin Citicoline 250 MG, 150 Count
                </a>
                <h5>
                    <img src="img/cdp-choline.jpeg" alt="Healthy Origins Cognizin Citicoline 250 MG, 150 Count" />
                </h5>
                <h5>
                    Citicoline References:
                </h5>
                <ol>
                    <li>
                        <a href="https://examine.com/supplements/cdp-choline/"
                        >CDP-Choline: Examine</a>
                    </li>
                    <li>
                        <a href="https://pubmed.ncbi.nlm.nih.gov/2289218/">
                            Citicoline in the treatment of Parkinson's disease
                        </a>
                    </li>

                    <li>
                        <a href="https://pubmed.ncbi.nlm.nih.gov/7162583/"> New strategies in the management of Parkinson's disease: a biological approach using a phospholipid precursor (CDP-choline)</a>
                    </li>

                    <li>
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003774/">
                            Citicoline in Ophthalmological Neurodegenerative Disease: A Comprehensive Review
                        </a>
                    </li>

                    <li>
                        <a href="https://pubmed.ncbi.nlm.nih.gov/29450391/">
                            Citicoline - a neuroprotector with proven effects on glaucomatous disease
                        </a>
                    </li>
                    <li>
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3823450/#sec-a.i.g"
                        >Basic mechanisms of neurodegeneration: Dysfunction of neurotrophins</a>
                    </li>
                </ol>
            </section>
            <section id="magnesium-threonate">
                <h5>
                    Magnesium Threonate
                </h5>
                <p>
                    Magnesium Threonate Crosses the Blood-brain barrier (BBB), inhibits oxidative stress, attenuates motor deficits, and slows the progression of neurodegeneration.
                </p>
                <h5>
                    Product:
                </h5>
                <a href="https://www.amazon.com/gp/product/B07KWM4C5L/ref=as_li_tl?ie=UTF8&amp;tag=garrettsmit02-20&amp;camp=1789&amp;creative=9325&amp;linkCode=as2&amp;creativeASIN=B07KWM4C5L&amp;linkId=8f6f3f54762aeaec83a6e9014c89c8fe">
                    Life Extension Neuro-Mag Magnesium L-Threonate
                </a>
                <h5>
                    <img src="img/neuromag.jpeg" alt="neuromag" />
                </h5>
                <p>
                    Magnesium relaxes blood vessels and causes overall relaxation. Therefore, it&rsquo;s best to take this at night.
                </p>
                <h5>
                    Magnesium Threonate References:
                </h5>
                <ol>
                    <li>
                        <a href="https://parkinsonsnewstoday.com/2019/11/12/magnesium-compound-reaching-brain-slows-motor-decline-neuronal-loss-parkinsons-mouse-study/">
                            Oral Magnesium Compound Able to Reach Brain Seen to Slow Motor Decline, Neuronal Loss in Early Study
                        </a>
                    </li>

                    <li>
                        <a href="https://pubmed.ncbi.nlm.nih.gov/31806980/">
                            Treatment Of Magnesium-L-Threonate Elevates The Magnesium Level In The Cerebrospinal Fluid And Attenuates Motor Deficits And Dopamine Neuron Loss In A Mouse Model Of Parkinson's disease
                        </a>
                    </li>
                </ol>
            </section>
            <section id="vitamin-d">
                <h4 class="neuroprotective">
                    Vitamin D
                </h4>
                <p>
                    A study on Parkinson‚Äôs Disease Research, Education, and Clinical Center at the Portland and Puget Sound Veteran Affairs (VA) Clinics performed an add-on study to a longitudinal study following neuropsychiatric function in persons with PD.
                </p>
                <p>
                    Researchers found higher plasma vitamin D was associated with better cognition and better mood in their sample of PD patients without dementia.
                </p>
                <p>
                    More is not always better! Too much vitamin D3 can disturb calcium levels. Ask your team to optimize your vitamin D3 levels with regular bloodwork and supplement accordingly. 4,000 IU per day is safe. The body stores D3 so if you miss a day, you can double up the next day.
                </p>
                <h4>
                    Vitamin D References
                </h4>
                <ol>
                    <li>
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3966187/">Memory, Mood, and Vitamin D in Persons with Parkinson‚Äôs Disease</a>
                    </li>
                </ol>
            </section>
            <section id="vitamin-b6">
                <h4 class="neuroprotective dopaminergic">
                    Vitamin B-6 (pyridoxine)
                </h4>
                
                <p>
                    Vitamin B6, also known as pyridoxine, is neuroprotective, playing a crucial role in the synthesis of neurotransmitters, regulation of the glutamatergic and system, and maintenance of the nervous system‚Äôs health.
                </p>
                <p>
                    Vitamin B6 is necessary for dopamine biosynthesis and antioxidant properties. However, high doses of vitamin B6 can cause peripheral neuropathy, and it is essential to consume it as part of a balanced diet and consult with a healthcare professional before taking supplements.
                </p>

                <p>
                    Vitamin B6 helps in reducing the side effects of dopaminergic treatments,
                </p>
            </section>
            <section id="vitamin-b12">
                <h4>
                    Vitamin B-12
                </h4>
                <h5>How B-12 helps Parkinson's Disease</h5>
                <p>
                    Vitamin B-12 reduces <abbr title="Reactive Oxygen Species">ROS</abbr> and improves mitochondrial biogenesis regulator <abbr title="Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1 Alpha">PGC-1Œ±</abbr>.
                </p>
                <p>
                    Vitamin B-12 has multiple mechanisms related to <abbr title="Leucine Rich Repeat Kinase 2">LRRK2</abbr> expressions that protect dopaminergic neurons. B12 inhibits LRRK2 kinase activity. This protects dopaminergic neurons from toxicity induced by LRRK2 and its mutant form, LRRK2-G2019S.
                </p>
                <p>
                    Vitamin B12 prevents LRRK2-G2019S-potentiated &alpha;-synuclein accumulation in dopaminergic neurons.
                </p>
                <ol>
                    <li>
                        <a href="https://pubmed.ncbi.nlm.nih.gov/30858560/"
                        title="Vitamin B12 modulates Parkinson‚Äôs disease LRRK2 kinase activity through allosteric regulation and confers neuroprotection"
                        target="_blank">Vitamin B12 modulates Parkinson‚Äôs disease LRRK2 kinase activity through allosteric regulation and confers neuroprotection</a>
                        <p>
                        	Vitamin B-12 protected dopaminergic neurons from toxicity induced by LRRK2 and its mutant form, LRRK2-G2019S. The effect was shown to improve deficits in dopamine transmission in LRRK2-PD mouse models.
                        </p>
                    </li>
                     <li>
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9854476/"
                        title="Vitamin B12 Ameliorates the Pathological Phenotypes of Multiple Parkinson‚Äôs Disease Models by Alleviating Oxidative Stress"
                        target="_blank"
                        >Vitamin B12 Ameliorates the Pathological Phenotypes of Multiple Parkinson‚Äôs Disease Models by Alleviating Oxidative Stress</a>
                        <p>
                        	This multiple model study demonstrated that Vitamin B12 significantly ameliorated oxidative stress by reducing ROS and alleviating reductants in a cellular PD model. In vivo, VB12 rescued the movement deficit of C. elegans and the mouse PD model. Mechanistically, VB12 reduced JNK phosphorylation and improved the mitochondrial biogenesis regulator PGC-1Œ±. 
                        </p>
                    </li>
                </ol>
            </section>
            <section id="tocotrienols">
                <h4>
                    Tocotrienols + Tocopherols
                </h4>
                <ul>
                    <li>Mechanisms: Antioxidant, Anti-inflammatory, Mitochondrial, Neuroprotective, Neurorestorative, Anti-aggregant, Cholesterol-Lowering
                    <li>Dose: 150 IU ED/EOD üçΩÔ∏è
                    <li>Fat-soluble: ‚úÖ
                    <li>BBB: ‚úÖ
                    <li>Safety: 6/10 (80% œÉ)
                    <li>Efficacy: 7/10 (70% œÉ)
                </ul>
                <p>
                    Tocotrienols cross the BBB and exert neuroprotective effects.
                </p>
                
                <p>
                    Vitamin E is fat-soluble, so it‚Äôs best taken with other fats, like DHA or coconut oil, and with other fat-soluble supplements. More is not better! Excessive intake can be harmful and it's OK to miss a dose.
                </p>
                
                <h5>Neuroprotective Effects</h5>
                
                <p>
                    Tocotrienols have been shown to improve learning impairment in elderly subjects. Tocotrienols have shown cytoprotective, neuroprotective, and improved behavior effects in murine PD models.
                </p>
                <p>
                    Tocotrienols reduce BBB permeability by modulating tight junction proteins and reducing oxidative and inflammatory damage to the BBB. This helps maintain its integrity, which is essential for protecting the brain.
                </p>
                
                <p>
                    Tocotrienols protect mitochondrial function by preserving mitochondrial membrane potential, enhancing ATP production, and reducing mitochondrial-generated <abbr title="Reactive Oxygen Species">ROS</abbr>. 
               </p>
               
               <p>
                    Tocotrienols inhibit lipid peroxidation more effectively than tocopherols due to their better incorporation into cell membranes.
                </p>
                <p>
                    They also prevent mitochondrial dysfunction, which is a common feature in many neurodegenerative diseases.
                </p>
                
                <h5>Supplementation and Safety</h5>
                <p>
                    High doses of vitamin E, particularly alpha-tocopherol, and especially the synthetic form, dl-alpha-tocopherol, are toxic.
                </p>
                <p>
                    Vitamin E can thin the blood. Individuals taking blood thinners with a history of stroke, hemorrhagic stroke, or bleeding in the brain should be cautious when taking vitamin E supplements.
                </p>
                <p>
                    Light supplementation of a blend of the four tocotrienols and four tocopherols provides benefits while avoiding these risks. Do not exceed the recommended dose. Overdosing is harmful, and it is better to err on the side of caution.
                </p>
                <h5>
                    Product
                </h5>
                <ul class="product-list">
                    <li>
                        <figure>
                            <img src="img/tocotrienols.jpeg" alt="mixed tocotrienols">
                            <figcaption>
                                <p>
                                    <a href="https://www.amazon.com/Kala-Health-Vitamin-softgels-tocotrienols/dp/B07S52CF4L/ref=pd_ci_mcx_mh_mcx_views_0?pd_rd_i=B07S52CF4L"
                                    title="Doctor's Best Tocotrienols contains EVNol SupraBio Full Spectrum Vitamin E Complex"
                    target="_blank"
                >Doctor's Best Tocotrienols contains EVNol SupraBio Full Spectrum Vitamin E Complex</a>
                                </p>
                            </figcaption>
                        </figure>
                    </li>
                    <li>
                        <a href="https://www.amazon.com/gp/product/B00AZQXO3E/ref=as_li_tl?ie=UTF8&amp;tag=garrettsmit02-20&amp;camp=1789&amp;creative=9325&amp;linkCode=as2&amp;creativeASIN=B00AZQXO3E&amp;linkId=3ba360ffd9243d4be9db93ad7adaf534"
                        title="Kala Health Unique Formula with All 8 Tocopherols and Tocotrienols Vitamin E‚Äì Contains no PAH‚Äôs, Heavy Metals, Contaminants or Preservatives - Certified Sustainable - Hair, Scars and Skin"
                        target="_blank"
                    >Kala Health Unique Formula with All 8 Tocopherols and Tocotrienols</a>
                    </li>
                </ul>
                <h5>
                    Tocotrienol References
                </h5>
                <ol class="reference-list">
                    <li>
                        <a href="https://pubmed.ncbi.nlm.nih.gov/31619646/"
                        >Protective Effect of Tocotrienol on In Vitro and In Vivo Models of Parkinson's Disease</a>
                        <p>
                            This rodent model study demonstrated that tocotrienols bind to the estrogen receptor in vitro, resulting in relieved PD-related symptoms. The result was explained by the observed cellular signalling that led to cytoprotective effects.
                        </p>
                    </li>
                    <li>
                        <a href="https://pubmed.ncbi.nlm.nih.gov/34068460/"
                        title="Tocotrienols Ameliorate Neurodegeneration and Motor Deficits in the 6-OHDA-Induced Rat Model of Parkinsonism: Behavioural and Immunohistochemistry Analysis"
                        target="_blank"
                        >Tocotrienols Ameliorate Neurodegeneration and Motor Deficits in the 6-OHDA-Induced Rat Model of Parkinsonism: Behavioural and Immunohistochemistry Analysis</a>
                        <p>
                            &ldquo;&hellip;this study revealed that supplementation of Œ±- and Œ≥-T3 was able to ameliorate the motor deficits induced by 6-OHDA and improve the neuronal functions by reducing inflammation, reversing the neuronal degradation, and preventing further reduction of dopaminergic neurons in the SN and striatum (STR) fibre density.&rdquo;
                        </p>
                    </li>
                </ol>
            </section>
            <section id="nicotinamides">
                <h3>NAD+ and its precursors NMN, NR, and Niacin</h3>

                <h3>Nicotinamide Adenine Dinucleotide (NAD+)</h3>
                <p>
                    NAD+ is a coenzyme involved in energy metabolism, DNA repair, and cell signaling.
                </p>

                <p>
                     NAD+ reduces oxidative stress (including in the brain). This promotes recovery on a cellular level and leads to better energy metabolism, neuroprotection, mitochondrial function, and DNA repair. 
                </p>
                
                <p>
                    NAD+ affects macrophages to reduce the production of pro-inflammatory cytokines and increases the production of anti-inflammatory cytokines.
                </p>

                <p>
                    NAD+ promotes mitophogy, leading to mitogenesis. This promotes neuronal survival and function and decreases ROS. Lower ROS levels reduce oxidative stress, which can prevent the misfolding and aggregation Œ±-synuclein.
                </p>
                
                <h4>Declining NAD+ Levels</h4>
                <p>
                    Declining NAD+ levels contribute to reduced mitochondrial function and impaired cellular energy metabolism in neurons, making them more susceptible to oxidative damage and degeneration, particularly in PD, necessitating intervention.
                </p>

                <p>
                    Raising NAD levels (through injection, precursor supplementation, and upregulation via exercise) improves mitochondrial function and count in neuronal cells. This explains how it improves neurotransmission, synaptic plasticity, and improved motor symptoms.
                </p>
                <p>
                    NAD+ is essential for mitochondrial function which is significant in the pathogenesis of Parkinson's disease.
                </p>
                <h4>NAD Precursors</h4>
                <p>
                    Supplementation with NAD precursors NMN, NR, and niacin, increases cellular levels of NAD+ (nicotinamide adenine dinucleotide). Among these, NMN appears to be the safest, best-tolerated, and most effective in increasing NAD+ production. This is because NMN converts to NAD+ more directly than the other precursors.
                </p>

                <p>
                    Niacin increases NAD+ levels, but through a different metabolic pathway than NMN and NR.
                </p>
                <section id="nmn">
                    <h3>NMN</h3>
                    <ul>
                        <li>Mechanisms: Antioxidant, Anti-inflammatory, Mitochondrial, Neuroprotective, Neurorestorative, Anti-aggregant
                        <li>Dose: 1000mg ED
                        <li>Fat-soluble: ‚ùå
                        <li>BBB: ‚úÖ
                        <li>Safety: 8/10 (80% œÉ)
                        <li>Efficacy: 7/10 (70% œÉ)
                    </ul>
                    
                    <p>
                        NMN is directly converted to NAD+ and its supplementation increases NAD+ levels.
                    </p>
                     
                    <p>
                        Preclinical studies and some clinical trials have shown promising results regarding the potential benefits of NMN supplementation in Parkinson's disease.
                    </p>
                
                    <h4>Supplementation</h4>
                    <p>
                        A typical dose of NMN is about 1g per day. It's safe and effective at much higher levels, as shown in human studies and rodent models. The only downside with higher doses is the cost. 
                    </p>

                    <p>
                        Long-term NMN supplementation at lower doses has shown increased NAD+ levels, improved insulin sensitivity, enhanced mitochondrial function, anti-aging effects, and cardiovascular health.
                    </p>
                    
                    
                    <h4>NMN Bulk Powder</h4>
                    <p>
                        <a href="https://www.prohealth.com/products/prohealth-nmn-pro-powder-1-kilo-ph537?selling_plan=3992027236">NMN Bulk &mdash; Prohealth Longevity</a>
                    </p>
                    <p>
                        ProHealth Longevity is a well-established company that provides GMP compliance and third-party testing for purity and potency.
                    </p>
                    
                    <h4>NMN References</h4>
                    <ol>
                    
                        <li>
                            <a href="https://pubmed.ncbi.nlm.nih.gov/27130898/"
                            >Nicotinamide mononucleotide protects against Œ≤-amyloid oligomer-induced cognitive impairment and neuronal death</a> by Wang et al.
                            <p>
                                This rodent found monumental 500mg/kg dosages of NMN injected caused sustained improvement in cognitive function as assessed by the Morris
water maze. 
                            </p>
                        </li>
                        
                        <li>
                            <a href="https://pubmed.ncbi.nlm.nih.gov/33373320/"
                            >Neuroprotective effects and mechanisms of action of nicotinamide mononucleotide (NMN) in a photoreceptor degenerative model of retinal detachment</a>              <p>
                                This rodent model study found 250mg/kg and 500mg/kg NMN inhibited cell death at the acute phase of photoreceptor injury, with the more protective results achieved at the dose of 500 mg/kg.
                            </p>
                        </li>
                        <li>
                            <a href="https://jissn.biomedcentral.com/articles/10.1186/s12970-021-00442-4"
                            >Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study</a>
                            <p>
                                This double-blind RCT showed 6 weeks NMN increased the aerobic capacity of humans during exercise training in groups taking 300mg, 600mg, and 1200mg twice per day.
                            </p>
                        </li>
                    </ol>
                </section>
                
                <section id="nr">
                    <h3>Nicotinamide Riboside (NR)</h3>
                    <h3>Nicotinamide Riboside (NR)</h3>
                    <ul class="treatment-rating">
                        <li>Mechanisms: Antioxidant, Anti-inflammatory, Mitochondrial health promoter, Neuroprotective, Neurorestorative, Anti-aggregant
                        <li>Dose: 300-500mg ED
                        <li>ü©∏üß†BBB: ‚úÖ
                        <li>Safety: 8/10 (85% œÉ)
                        <li>Efficacy: 6/10 (70% œÉ)
                    </ul>
                    <p>
                    NR is phosphorylated to NMN by the enzyme nicotinamide riboside kinase.
                    </p>
                    
                    <h4>Supplementation</h4>
                
                    <p>
                        The recommended dose is 300-500mg ED, taken along with NMN and niacin and occasional NAD+ injections. Oral supplementation of NR at 3000mg daily for 30 days was safe and well-tolerated.
                    </p>
                    
                    <h4>NR References</h4>
                    <ol>
                        <li>
                            <a href="https://pubmed.ncbi.nlm.nih.gov/29599478/7"
                            title="Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults"
                            target="_blank"
                            >Chronic NR supplementation in older adults</a>
                            <p>
                                This small-scale RCT (Randomized Controlled Clinical Trial) found that chronic oral supplementation with 1000mg of NR daily increased NAD+ levels in healthy middle-aged and older adults. 
                            </p>
                        </li>                   
                        <li>
                            <a href="https://pubmed.ncbi.nlm.nih.gov/38016950/"
                            target="_blank"
                            title="NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson's disease"
                        >NR-SAFE trial</a>, a Phase I clinical trial published in 2023 found that high-dose NR supplementation (3,000 mg/day) was well-tolerated and associated with improved motor symptoms in patients with PD.
                        </li>
                        <li>
                            <a href="https://pubmed.ncbi.nlm.nih.gov/35235774/"
                            title="The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson‚Äôs disease"
                            target="_blank"
                            >NADPARK</a>
                            <p>
                                A phase I clinical trial published in 2022 found that NR supplementation increased whole blood NAD+ levels and expanded the NAD+ metabolome in patients with PD.
                            </p>
                        </li>
                    </ol>
                </section>
                
                <section id="niacin">
                    <h3>Niacin</h3>
                    <ul class="treatment-rating">
                        <li>Mechanisms: Antioxidant, Anti-inflammatory, Mitochondrial health promoter, Neuroprotective, Neurorestorative, Anti-aggregant
                        <li>Dose: 100-300mg BID
                        <li>ü©∏üß†BBB: ‚úÖ
                        <li>Safety: 7/10 (75% œÉ)
                        <li>Efficacy: 5/10 (60% œÉ)
                    </ul>
                    <p>
                        Niacin increases NAD+ levels through a longer metabolic pathway than that of NMN however, NMN and NR are considered superior due to their more direct conversion pathways and higher efficiency, supported by various studies and research.
                    </p>
                    
                    <h4>Safety</h4>
                    <p>
                    Niacin causes a flushing at higher doses. This is harmless, but may be uncomfortable. 
                    </p>

                    <h4>Niacin References</h4>
                    <ol>
                        <li>
                            <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8245760/"
                        >Niacin Enhancement for Parkinson‚Äôs Disease: An Effectiveness Trial</a>
                        </li>
                    </ol>
                </section>
                
                <section id="nad-injection">
                    <h4>NAD+ Injection &amp; IV Drip</h4>
                    <ul class="treatment-rating">
                        <li>Mechanisms: Antioxidant, Anti-inflammatory, Mitochondrial health promoter, Neuroprotective, Neurorestorative, Anti-aggregant
                        <li>Dose: Varies (injections or infusions)
                        <li>ü©∏üß†BBB: ‚úÖ
                        <li>Safety: 8/10 (85% œÉ)
                        <li>Efficacy: 7/10 (75% œÉ)
                    </ul>
                    <p>
                        NAD can be injected intramuscularly, subcutaneously, or intravenously via a drip. It is popular, safe, and generally enjoyed and very well-tolerated. 
                    </p>
                         
                    <p>
                        <a href="https://www.peptidesciences.com/nad-100mg">NAD+ 750mg &mdash; Peptide Sciences</a> (wait for 15% off sale) Peptide Sciences is the place for peptides. Compared to others, only PS sells lyophilized peptides.
                    </p>
                    <figure>
                        <img src="./img/nad__750mg.png" alt="peptide sciences NAD+" height="280">
                    </figure>
                <h4>NAD+ Injection References</h4>
                <ol>
                    <li>
                        <a href="https://www.frontiersin.org/articles/10.3389/fnagi.2019.00257/full"
                        title="A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+"
                        target="_blank">A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+</a>
                    
                        <p>
                            Eleven (Test n = 8, Control n = 3) male participants aged 30&ndash;55 years received 750 mg NAD+ in normal saline over a 6 h period. This resulted in a significant and quick elevation of intracellular NAD+.
                        </p>
                    </li>
                </ol>
                </section>
                
                <h4>NAD+ References</h4>
                <ol>
                    <li>
                        <a href="https://pubmed.ncbi.nlm.nih.gov/8101414/">Nicotinamide adenine dinucleotide (NADH)&mdash;a new therapeutic approach to Parkinson's disease.</a>
                    </li>
                    <li>
                        <a href="https://pubmed.ncbi.nlm.nih.gov/27798264/">NAD+ repletion reverses age-related behavioral and synaptic deficits in mice</a>
                        <p>
                            This study demonstrates supplementation with NAD+ precursors, including NMN, improves mitochondrial function, synaptic plasticity, and cognitive function in aged mice. The findings suggest that NAD+ repletion may have potential therapeutic benefits for age-related neurological disorders.
                        </p>
                    </li>
                    <li>
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7963035/">NAD+ metabolism and its roles in cellular processes during ageing</a>
                        <p>
                            NAD+ metabolism in cellular processes associated with aging and age-related diseases, including neurodegenerative disorders like PD. It highlights the potential therapeutic implications of NAD+ precursors in
                            mitigating age-related declines in cellular function and promoting healthy aging.
                        </p>
                    </li>
                    <li>
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518566/">Nicotinamide mononucleotide requires SIRT3 to improve cardiac function and bioenergetics in a Friedreich's ataxia cardiomyopathy model</a>
                        <p>
                            Although this study focuses on a cardiomyopathy model in Friedrich's ataxia, it provides insights into the potential benefits of NMN supplementation in a disease characterized by mitochondrial dysfunction.
                            The findings suggest that NMN administration improves cardiac function and bioenergetics through SIRT3-mediated mechanisms, highlighting the importance of NAD+ metabolism in mitochondrial health.
                        </p>
                    </li>
                    <li>
                        <a href="https://www.heraldopenaccess.us/openaccess/intravenous-administration-of-nicotinamide-adenine-dinucleotide-alleviates-tremors-associated-with-parkinson-s-disease-a-case-report"
                        >A Case Report</a>
                        <p>
                            This single case study used BR+NAD ("Brain Restoration Plus" NAD) comprised of multiple IV infusions of NAD+ over six days, as well as added oral supplementation of Vitamin C, B6, Folate, Selenium, N-acetyl-L-cysteine, N-acetyl-L-tyrosine and electrolytes. Following Day 6, he received sublingual NAD+ tablets (300mg, twice per day) for 14 days.
                        </p>
                        <p>
                            The patient initially presented with bilateral hand tremors (significantly more pronounced in right hand), shuffling gate/gait rigidity and impairments in movements of the hands and fingers
                        <p>
                            Over the course of the six NAD+ treatment days, the patient‚Äôs showed significant decline in hand tremors, development of a steady gate, increased sociability, increased cognitive functioning and improved sleep.
                        </p>
                    </li>
                </ol>
            </section>
            <section id="senolytics">
                <h4>Senolytics</h4>
                <p>
                    Senolytics are used to selectively induce the death of senescent cells. Senolytic means "senescent cell destruction".
                </p>

				<h5>Senolytics in Parkinson's Disease</h5>
                <p>
                    Senolytics inhibit and help degrade &alpha;-synuclein aggregation.
                </p>
                <p>
                    In PD, &alpha;-synuclein and especially its mutant forms damage mitochondria, causing a leak of sirtuins from the inner membrane of the mitochondria leading to mitochondrial failure and eventual cell failure.
                </p>
                <p>
                    Aggregates of &alpha;-synuclein form Lewy bodies inside the cell and block T-cells from activating the lysosome of non-functioning "zombie" cells.
                </p>
                <p>
                    Senolytics help prevent the formation of &alpha;-synuclein aggregates. This has numerous benefits, including neuroprotection, decreased neuroinflammation, improved mitochondrial function, neurogenesis, and autophagy.
                </p>
                <p>
                    Senolytics reduce the formation of Lewy bodies and facilitate T-cell activation of the lysosome in senescent cells by preventing obstruction by  &alpha;-synuclein aggregates
                </p>


                <section id="urolithin-a" class="mitochondrial senolytic neuroprotective">
                    <h4>Urolithin-A</h4>
                    <ul>
                        <li>Mechanisms: Antioxidant, Anti-inflammatory, Mitochondrial, Neuroprotective, Neurorestorative, Anti-aggregant
                        <li>Dose: 1000mg ED
                        <li>Fat-soluble: ‚úÖ
                        <li>ü©∏üß† BBB: ‚úÖ
                        <li>Safety: 8/10 (80% œÉ)
                        <li>Efficacy: 6/10 (70% œÉ)
                    </ul>
                    
                    <h5>Overview</h5>
                    <p>
                        Urolithin-A is a naturally occurring compound produced by gut bacteria through the transformation of polyphenols, such as ellagitannins and ellagic acid, found in small amounts of some foods like wild berries (pomegranates, etc), walnuts, and tea. Urolithin-A supplementation stimulates mitophagy and mitochondrial function in several tissues.
                    </p>
                    
                    <h5>Benefits</h5>
                    <p>
                        Urolithin-A-induced mitophagy leads to mitogenesis. This promotes neuronal survival and function, making Urolithin-A strongly neuroprotective.
                    </p>
                    
                    <h5>Mitophagy</h5>
                    <p>
                        Mitophagy is a cellular process that recycles and removes damaged or unhealthy mitochondria, leading to their replacement with new, healthy mitochondria. Urolithin-A modulates the PINK1-Parkin pathway, autophagosome formation, and AMPK-SIRT1 activation.
                    </p>
                    <p>
                        When PINK1 enters healthy mitochondria, the mitochondria removes it. However, when the mitochondria is damaged, PINK1 accumulates on the outer membrane. This signals the recruitment of Parkin to the outer membrane, which marks the damaged mitochondria for recognition by autophagosomes. The autophagosomes engulf the damaged mitochondria and transport them to the cell's lysosome for degradation. This process, known as <dfn>mitophagy</dfn>, signals the cell to initiate  <dfn>mitochondrial biogenesis</dfn>, restoring cellular energy and function.
                    </p>
                    
                    <h5>Mitophagy in Parkinson's Disease</h5>
                    <p>
                        In PD, there is an abnormally higher number of damaged mitochondria. Damaged mitochondria accumulate alpha-synuclein and contribute to the formation of Lewy bodies. Inducing mitophagy helps clear these harmful mitochondria and restore cellular energy production. This process protects against dopaminergic neurodegeneration.
                    </p>
                    <figure>
                        <img src="img/urolithin-a-activity.png">
                    
                        <figcaption>
                            <p>
                                Urolithin-A benefits include reduced neuroinflammation, reduced &alpha;-synuclein aggregation, decreased apoptosis, protection of dopaminergic neurons, improved mitochondrial function, and improved motor and cognitive function.
                            </p>
                            <p>
                                <cite>Urolithin A in Health and Diseases: Prospects for Parkinson‚Äôs Disease Management</cite>, B Smolinska, et al.
                            </p>
                        </figcaption>
                    </figure>
                    
                    <h5>Supplementation</h5>
                    
                    <p>
                        1000mg per day of Urolithin-A is safe and well-tolerated in humans.
                    </p>
                    
                    <p>
                        Urolithin-A is fat-soluble and can cross the BBB. Taking with food or other fat-soluble vitamins may improve absorption. 
                    </p>
                    
                    <h6>Food Sources</h6>
                        Pomegranates contain ellagitannins, convertible to urolithin A by gut bacteria in 30% to 50% of people. Optimistically, eating 1 pomegranate might yield a negligible 2 milligrams of Urolithin-A &mdash; <em>not enough</em>!             
                    
                    <h5>Side Effects</h5>
                    <p>
                        Potential unknown side effects might include gastric upset or potential interactions with certain medications that also undergo hepatic metabolism.  Taking with food may help.
                    </p>
    
                    <h5>References</h5>
                    <ol class="reference-list">
                        <li>
                            <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9133463/" title="Urolithin-A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults"
                            target="_blank"
                            >Urolithin-A on exercise performance in middle-aged adults</a>
                            <p>
                                This randomized, placebo-controlled trial in middle-aged adults found Urolithin-A improved muscle strength, exercise performance, inflammation, and biomarkers of mitochondrial health.
                            </p>
                        </li>
                        <li>
                            <a href="https://pubmed.ncbi.nlm.nih.gov/32694802/"
                            title="The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans
"
                            target="_blank"
                            >Regular oral Urolithin-A improves mitochondrial and cellular health in humans.</a>
                            <p>
                                This clinical trail found Urolithin-A induces a molecular signature of improved mitochondrial and cellular health following regular oral consumption in humans.
                            </p>
                        </li>
                        <li>
                            <a href="https://pubmed.ncbi.nlm.nih.gov/34905594/"
                            title="Urolithin-A protects dopaminergic neurons in experimental models of Parkinson's disease by promoting mitochondrial biogenesis through the SIRT1/PGC-1Œ± signaling pathway"
                            target="_blank"
                            > Urolithin-A is neuroprotective in rodents</a>
                            <p>
                                This rodent study found Urolithin-A demonstrated neuroprotective effects by promoting mitochondrial biogenesis via SIRT1-PGC-1Œ± signaling.
                            </p>
                        </li>
                        <li>
                            <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10376282/"
                            title="Urolithin-A in Health and Diseases: Prospects for Parkinson‚Äôs Disease Management"
                            target="_blank"
                            >Urolithin-A in Health and Diseases: Prospects for Parkinson‚Äôs Disease Management</a>
                            <p>
                                This review study found Urolithin-A reduced cognitive decline, increased mitochondrial quality and content, and protected against neurodegeneration.
                            </p>
                        </li>
                        <li>
                            <a href="https://pubmed.ncbi.nlm.nih.gov/30871577/"
                            title="Urolithin A attenuates memory impairment and neuroinflammation in APP/PS1 mice"
                            target="_blank"
                            >Urolithin-A attenuates memory impairment and neuroinflammation</a>
                            <p>
                                 Urolithin-A significantly improved spatial learning and memory, protected neurons from death, reduced neuroinflammation, and triggered neurogenesis.
                            </p>
                        </li>
                    </ol>
                </section>

                <section id="resveratrol">
                    <h4>
                        Resveratrol
                    </h4>            

                    <p>
                        Resveratrol has displayed potent neuroprotective efficacy in several PD animal models.
                    </p>
                    <h5>
                        How it works:
                    </h5>
                    <p>
                        Resveratrol inhibits &alpha;-synuclein aggregation and cytotoxicity, lowering the levels of total &alpha;-synuclein and oligomers, and reducing neuroinflammation and oxidative stress in a dose-dependent manner.
                    </p>
                    <h5>
                        Product:
                    </h5>
                    <p>
                        <a
                            href="https://www.amazon.com/gp/product/B00IM21FBG/ref=as_li_tl?ie=UTF8&amp;tag=garrettsmit02-20&amp;camp=1789&amp;creative=9325&amp;linkCode=as2&amp;creativeASIN=B00IM21FBG&amp;linkId=ec9df367e733c718d4c8ac89e53e5bdf"
                            target="_blank"
                        >Purity Labs Organic Trans-Resveratrol 1,500MG Enhanced with Quercetin</a>
                    </p>
                    <img src="img/trans-resveratrol.jpeg" alt="trans-resveratrol">
                    <p>
                        Purity Labs Trans-Resveratrol is a high dose, 2 pills per day formula. It might be better to take just one
                    </p>
                    
                    <h4>Resveratrol References</h4>
                    <ol>
                        <li>
                            <a href="https://scienceofparkinsons.com/tag/resveratrol/"
                            target="_blank"
                            >Brain. On. Fire | The Science of Parkinson&rsquo;s.
                            </a>
                            (this article covers other published research on compounds with inhibitory activities on components of the NLRP3 inflammosome pathway, including EGCG, Curcumin, Sulforaphane, and Quercetin)
                        </li>

                        <li>
                            <a href="https://pubmed.ncbi.nlm.nih.gov/33967780/"
                            target="_blank"
                            >Resveratrol in Rodent Models of Parkinson's Disease: A Systematic Review of Experimental Studies
                            </a>
                        </li>
                    </ol>
                </section>
                <section id="fisetin">
                    <h3>Fisetin</h3>
                    <p>
                        Fisetin is a fat-soluble polyphenol capable of crossing the BBB. Fisetin is found in many fruits and vegetables, such as strawberries, apples, persimmons, onions, and cucumbers.
                    </p>
                    <h4>Fisetin References</h4>
                    <ol>
                        <li>
                            <a href="https://pubmed.ncbi.nlm.nih.gov/34199487/">Small Molecule Fisetin Modulates Alpha-Synuclein Aggregation</a>
                        </li>
                        <li>
                            Fisetin <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5527824/">helps to maintain glutathione (GSH) levels</a>.</li>
                        <li>
                            <a href="https://link.springer.com/article/10.1007/s11626-013-9681-6">Fisetin reduces ROS production</a>
                        </li>
                    </ol>
                </section>
                <section id="quercetin">
                    <h3>Quercetin</h3>
                    <p>
                        Quercetin is a fat-soluble flavonoid capable of crossing the BBB. Quercetin is naturally found in many plant foods like fruits and vegetables, especially apples, onions, and capers.
                    </p>
                    
                    <p>
                        Quercetin inhibits Œ±-synuclein aggregation, protects mitochondria, and modulates various cell-signalling pathways to promote neuronal survival and function.
                    </p>
                    
                    <h4>Quercetin References</h4>
                    <ol>
                        <li>
                            <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7014205/">Animal Study by Zhang et al. (2017)</a> 
                            <p>
                                Investigated the effects of quercetin on mice models of Parkinson's disease, showing reduced Œ±-synuclein aggregation and improved motor function.
                            </p>
                        </li>
                        <li>
                            <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10472805/">Neuroprotective Role of Quercetin against Alpha-Synuclein-Associated Hallmarks in Parkinson‚Äôs Disease</a>
                            <p>
                                This cell culture study demonstrated quercetin's ability to reduce alpha-synuclein aggregation and protect dopaminergic neurons from oxidative stress in vitro.
                            </p>
                        </li>
                        <li>
                            <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10094159/">The Potential Benefits of Quercetin for Brain Health: A Review of Anti-Inflammatory and Neuroprotective Mechanisms</a>
                            <p>
                                This review article synthesizes existing research on the mechanisms by which quercetin may benefit brain health, including anti-inflammatory and neuroprotective effects. It provides a comprehensive overview of both preclinical and some clinical studies, making it a valuable resource for understanding the potential applications of quercetin.
                            </p>
                        </li>
                        <li>
                            <a href="https://pubmed.ncbi.nlm.nih.gov/31654381/"
                            >Neuroprotective Effect of Quercetin in Combination with Piperine Against Rotenone- and Iron Supplement-Induced Parkinson's Disease in Experimental Rats</a>
                            <p>
                                This preclinical study conducted on rats found the combination of quercetin and piperine provided substantial neuroprotection in the rat model of Parkinson's disease, suggesting potential for therapeutic use.
                            </p>
                        </li>
                    </ol>
                </section>
                <section id="sulforaphane">
                	<h3>Sulforaphane ‚Äî TODO</h3>
                </section>
                <section id="apigenin">
                	<h3>Apigenin ‚Äî TODO</h3>
                </section>
                
                
                <section id="sulforaphane">
                	<h3>Piperlongumin ‚Äî TODO</h3>
                	<!-- 
                	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6087492/
                	>
                </section>
                
                <section id="theaflavin">
                    <h4>Theaflavin</h4>
                    <p>
                        Theaflavin, from black tea, is senolytic.
                    </p>
                </section>
                <!-- section id="blueberry">
                    <h4>Blueberry</h4>
                
                Blueberry juice augments exercise-induced neuroprotection in a Parkinson‚Äôs disease model through modulation of GDNF levels
                https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8935512/
                </section -->
            </section>
        </section>
    </section>
	<section id="summary">
        <h2>Summary</h2>

        <p>
            Ultimately, your health is your responsibility. Parkinson's Disease is your problem. This guide is an outline designed to assist with with the best possible knowledge to address this problem, to maximize their health span, and do so based on the latest scientific research, not healthcare dogma; not lies designed to make you feel good about yourself.
        </p>
        
        <p>
        Lies designed to you to make you feel good about yourself provide a false sense of reality, create dependence on external validation, impact relationships, and lead to missed opportunities for improvement. This guide lays solid foundation for cutting through the bullshit. The responsibility now rests with you to take proactive steps forward.
        </p>
        
    </section>
</body>
</html>
